```
 * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *
FILE 'HOME' ENTERED AT 08:12:56 ON 11 AUG 2003
=> file biosis,caba,caplus,embase,japio,lifesci,medline,scisearch,uspatfull
=> e class reiner/au
E1        1   CLASS RAINER/AU
E2        1   CLASS RANDY/AU
E3       32 --> CLASS REINER/AU
E4        1   CLASS REINER J W/AU
E5        1   CLASS REINER JOSEPH/AU
E6        2   CLASS ROBERT/AU
E7        1   CLASS ROBERT N/AU
E8       12   CLASS S/AU
E9        1   CLASS S M/AU
E10       5   CLASS STEVEN/AU
E11       1   CLASS STEVEN J/AU
E12       1   CLASS STUDY GROUP/AU
=> s e3-e5
L1       34 ("CLASS REINER"/AU OR "CLASS REINER J W"/AU OR "CLASS REINER
         JOSEPH"/AU)
=> dup rem l1
PROCESSING COMPLETED FOR L1
L2       25 DUP REM L1 (9 DUPLICATES REMOVED)
=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 25 ANSWERS - CONTINUE? Y/(N):y

L2  ANSWER 1 OF 25  USPATFULL on STN
AN    2003:24144  USPATFULL
TI    Therapeutic, prophylactic, and diagnostic agent for cancer, useful for
      characterizing cancer cells with individual properties
IN    Zeppezauer, Michael, Scheidt, GERMANY, FEDERAL REPUBLIC OF
      Leinenbach, Hans-Peter, Tholey, GERMANY, FEDERAL REPUBLIC OF
        ***Class, Reiner*** , Drexel Hill, PA, UNITED STATES
      Fassbender, Cordula, Koln, GERMANY, FEDERAL REPUBLIC OF
PI    US 2003017987     A1   20030123
AI    US 2002-238726    A1   20020911 (10)
RLI   Continuation of Ser. No. US 1999-402468, filed on 12 Oct 1999, PENDING A
      371 of International Ser. No. WO 1998-EP2112, filed on 9 Apr 1998,
      UNKNOWN
PRAI  DE 1997-19715149    19970411
DT    Utility
FS    APPLICATION
LREP  BACON & THOMAS, PLLC, 625 SLATERS LANE, FOURTH FLOOR, ALEXANDRIA, VA,
      22314
CLMN  Number of Claims: 44
ECL   Exemplary Claim: 1
DRWN  5 Drawing Page(s)
LN.CNT 579
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB    A therapeutic or prophylactic agent for cancer is disclosed which
      damages the membrane and kills cancer cells, in particular of the
      blood-forming system, having membrane protein aggregates which contain
      several core histones or largely core-like histones and/or their parts.
      The therapeutic or prophylactic agent contains at least one pure histone
      or its active sequence section selected from the group composed of
      histone H1, H1 subtypes, H2A, H2B, H2A:H2B dimer, H3 and H4, covalent
```

modified histones of the above-mentioned type and/or their active sections and functionally and structurally similar proteins (protamines, histone-like proteins of prokaryotic and archae bacteria).

L2 ANSWER 2 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 1
AN 2003:151458 BIOSIS
DN PREV200300151458
TI Radiation enhancement by gemcitabine-mediated cell cycle modulations.
AU Mose, Stephan (1); ***Class, Reiner*** ; Weber, Hans-Walter; Rahn, Angelika; Brady, Luther W.; Boettcher, Heinz D.
CS (1) Department of Radiation Oncology, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, D-60590, Frankfurt/Main, Germany Germany
SO American Journal of Clinical Oncology, (February 2003, 2003) Vol. 26, No. 1, pp. 60-69. print.
ISSN: 0277-3732.
DT Article
LA English
AB The purpose of this study was to investigate the exact dose dependency and time dependency of the radiation-enhancing effect of gemcitabine (2',2'difluoro desoxycytidine (dFdC)) in in vitro experiments (HeLa cells: cancer of the uterine cervix, 4197 cells: oropharyngeal squamous cell carcinoma), and to correlate this effect with the underlying changes in cell cycle distribution. Cell viability was determined fluorometrically after exposure to dFdC (0-20.0 mumol/l), irradiation (0-37.5 Gy), and both modalities. Combining both therapies, cells were exposed to dFdC (0-10.0 mumol/l) for 24 hours before further treatment and irradiated (0-30 Gy) immediately afterwards with or without removal of dFdC. For cell cycle analysis by flow cytometry, cells were irradiated (0-40 Gy) or treated with dFdC (0.012-1.0 mumol/l, 24-48 hours). Additionally, cells were exposed to dFdC (2.0 mumol/l, 0-4 hours). Cell cycle kinetics were evaluated using bromodeoxyuridine (BrdU) (10 mumol/l) S-phase labeling, given either 30 minutes before or in the last hour of dFdC treatment (2.0 mumol/l, 0-6 hours). The fluorometric assay revealed that dFdC enhances radiation-induced cytotoxicity at marginally toxic or nontoxic concentrations (<37 nmol/l). Radiation resulted in the anticipated G2/M arrest already at 2 Gy. DFdC induced concentration and exposure time-dependent cell cycle changes that were better resolved using BrdU, demonstrating a pronounced S-phase arrest already at 12 nmol/l. BrdU-pulse labeling revealed that the cell cycle block occurred at the G1/S boundary. Our data reconfirm the already known radiation enhancement, the S-phase specific activities of dFdC, and the relevance of the synchronized progression of cells through the S-phase with regard to the radiosensitizing properties of low-dose dFdC. However, we could demonstrate that before progressing in the S-phase, cells were blocked and partially synchronized at the more radiosensitive G1/S boundary. Furthermore, cells progressing past the block might accumulate proapoptotic signals caused by both radiation and dFdC, which will also results in cell death.

L2 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:675811 CAPLUS
DN 137:195614
TI Compositions and methods for preventing platelet aggregation comprising histones

IN ***Class, Reiner*** ; Soslau, Gerald; Zeppezauer, Michael
PA Philadelphia, Health and Education Corporation, USA; Symbiotec G.m.b.H.
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002067907	A1	20020906	WO 2002-US5157	20020222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-270759P P 20010222
AB Compns. and methods for preventing platelet aggregation and treating cardiovascular disease via histone compds. are provided. An assay for platelet aggregation using angonist and antagonist is described.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 2
AN 2003:73618 BIOSIS
DN PREV200300073618
TI Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: Ten-year synopsis of a novel treatment.
AU Emrich, Jacqueline G. (1); Brady, Luther W.; Quang, Tony S.; ***Class,*** *** Reiner*** ; Miyamoto, Curtis; Black, Perry; Rodeck, Ulrich
CS (1) Department of Radiation Oncology, College of Medicine, Drexel University, 245 North 15th Street, Mail Stop 200, Philadelphia, PA, 19102-1192, USA USA
SO American Journal of Clinical Oncology, (December 2002, 2002) Vol. 25, No. 6, pp. 541-546. print.
ISSN: 0277-3732.
DT Article
LA English
AB The present report is the follow-up of patients enrolled in a phase II clinical trial using 125I-MAb 425 as an adjuvant treatment for high grade gliomas. Patient median survivals support published data from an earlier preliminary report. From January 29, 1987 to January 25, 1997, 180 patients diagnosed with astrocytoma with anaplastic foci (AAF) and glioblastoma multiforme (GBM) were treated as outpatients with an average of three weekly intravenous or intraarterial injections of radiolabeled MAb 425. The mean dose was 140 mCi (5.2 GBq). Only one patient who received a single dose of more than 60 mCi (2.2 GBq) experienced acute toxicity. Patients received prior surgery and radiation therapy, with and without chemotherapy. Overall median survival for patients with GBM and AAF was 13.4 and 50.9 months, respectively, with Karnofsky Performance

Status (KPS) ranging from 40 to 100 and age ranging from 11 to 75 years. Prognostic factors (KPS and age) correlated positively with increased survival, with KPS the most important determinant of median survival. Data analysis was performed on patients followed 5 years or longer. We conclude that the administration of 125I-MAb 425 with intensive medical management demonstrates a significant increase in median survival and should be considered a therapeutic regimen for the management of patients with high grade gliomas.

L2 ANSWER 5 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 3
AN 2002:230496 BIOSIS
DN PREV200200230496
TI [Combination of radiotherapy and Gemcitabine: Evaluation of clinical data based on experimental results.
Original Title: Kombination von Radiotherapie und Gemcitabine: Bewertung der klinischen Daten auf der Basis experimenteller Erkenntnisse..
AU Mose, Stephan (1); ***Class, Reiner*** ; Weber, Hans-Walter; Oszvald, Agi; Rahn, Angelika; Brady, Luther W.; Boettcher, Heinz-D.
CS (1) Klinik fuer Strahlentherapie, Johann-Wolfgang-Goethe-Universitaet, Theodor-Stern-Kai 7, 60590, Frankfurt/Main: S.Mose@vff.uni-frankfurt.de Germany
SO Strahlentherapie und Onkologie, (Februar, 2002) Vol. 178, No. 2, pp. 59-70. print.
ISSN: 0179-7158.
DT Article
LA German
AB Background: In experimental studies that nucleoside analog Gemcitabine (2',2' difluorodesoxycytidine) clearly demonstrates radiation enhancing properties. After describing the pharmacological Gemcitabine-related data and the clinical studies regarding combined radiochemotherapy and taking under consideration the in-vitro data and the results provided by animal models, this overview is aimed to draw clinically relevant conclusions, resulting in the improvement of treatment approaches. Materials and Methods: The available literature data regarding the metabolism and the mechanism of action, the evaluation of possible schedules of administration, and combined radiochemotherapy including Gemcitabine has been reviewed. Publications reporting experimental data in vitro and in vivo as well as our own experimental results have been incorporated. Results: In clinical phase I and II studies, the favorable tumor response is accompanied by a high incidence of grade III-IV toxicities whereby the maximum-tolerated dose (MTD) of the various schedules of administration used is always lower compared to the MTD of single-agent treatment. In in-vitro and in-vivo data addressing the description and the evaluation of the radiation enhancing mechanism (especially influence on cell cycle, depletion of the dATP pool, induction of apoptosis, inhibition of DNA synthesis, reduction of DNA repair) this effect is already observed with non and moderately toxic Gemcitabine concentrations and depends on drug concentration and exposure time. Independent of the fractionation effect of radiotherapy, the radiation enhancement is persistent for at most 72 hours after the end of drug exposure. Taking under consideration the single dose per day and the target volume, a prolonged infusion and/or a twice-weekly administration of Gemcitabine at low concentration each and simultaneous radiotherapy are presumably considered to resemble the experimental data. Conclusion: It is without doubt that data provided by

clinical studies are of highest relevance for the evaluation of an optimized radiochemotherapy with Gemcitabine. However, although it is often difficult to transfer experimental data into the clinical situation, these data offer the possibility to develop an improved schedule of administration in patient treatment based on rational evidence in tumor biology.

L2 ANSWER 6 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:335570 BIOSIS
DN PREV200300335570
TI Differential Activation and Inhibition of Human Platelet Thrombin Receptors by Structurally Distinct Alpha-, Beta- and Gamma-Thrombins.
AU Soslau, Gerald (1); Goldenberg, Seth J. (1); ***Class, Reiner (1)*** ; Jameson, Bradford (1)
CS (1) Biochemistry, Drexel Univ Coll of Medicine, Phila, PA, USA USA
SO Blood, (November 16 2002) Vol. 100, No. 11 , pp. Abstract No. 970. print. Meeting Info.: 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA December 06-10, 2002 American Society of Hematology . ISSN: 0006-4971.
DT Conference
LA English
AB The development of drugs to neutralize the action of thrombin has to date focused on the alpha form of the protease. It is generally agreed that inactive prothrombin is proteolytically converted to active alpha-thrombin which may be further hydrolyzed to beta- and gamma-thrombin. While all three forms of the enzyme retain catalytic activities only alpha-thrombin is presumed to be physiologically important. The beta- and gamma-thrombin are presumed to be degradation products of no physiological significance. Our demonstration that beta- and gamma-thrombin selectively activate PAR-4 in this and a previous report (J. Biol. Chem. 276, 21173-21183, 2001) necessitates a reevaluation of how we view their physiological role and how we approach the pharmacological regulation of their actions. beta-Thombin, like gamma-thrombin, at nM levels selectively activates PAR-4. This was demonstrated by full retention of aggregatory activity with platelets whose PAR-1 and GP Ib receptors were inactivated. Furthermore, the beta-thombin response was abrogated by desensitizing platelets with suboptimal levels of the thrombin receptor activating peptide for PAR-4 (TRAP-4). alpha-Thrombin is rapidly converted to beta- and gamma-thrombin by activated factor X at physiological pH, in vitro. This implies that the same may hold true in vivo in the proper microenvironment. The differential activation of the three platelet thrombin receptors by alpha-, beta- and gamma-thrombin implies selective structural variations between these thrombin species. This would also account for the marked differential response to the antithrombotics, heparin and hirudin, which are found to be poor inhibitors of beta- and gamma-thrombin-induced platelet aggregation. Histone-1 selectively inhibits beta- and gamma-thrombin with no effect on alpha-thrombin. However, histone-1 appears to function primarily at the receptor level of PAR-4 rather than on the thrombin molecule. Since trypsin, like beta- and gamma-thrombin, activates PAR-4 and is also inactive with TRAP-4 desensitized platelets it was hypothesized that the crystalline structure of gamma-thrombin would be more like that of trypsin than alpha-thrombin. The analysis of the crystalline structures of alpha-, gamma-thrombin and trypsin confirm that this is the case. It is further postulated that the physiologic activator of PAR-2 may be beta- and gamma-thrombin since it,

like PAR-4, can be activated by trypsin. These findings should help to elucidate structure-function relationships of the different thrombins and may aid in the development of new antithrombotic drugs.

L2 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:115183 CAPLUS
DN 134:168376
TI Antimicrobial histone H1 compositions, kits, and methods of use thereof
IN ***Class, Reiner*** ; Zeppezauer, Michael
PA Symbiotec Gm.b.H., Germany; Philadelphia Health and Education Corp.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001010901	A2	20010215	WO 2000-US21747	20000809
WO 2001010901	A3	20010809		
WO 2001010901	C2	20020912		
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 2001046976	A1	20011129	US 1999-372500	19990811
US 6565854	B2	20030520		
EP 1200463	A2	20020502	EP 2000-957347	20000809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

PRAI US 1999-372500 A 19990811
US 1998-96382P P 19980813
WO 2000-US21747 W 20000809
AB The invention includes antibiotic pharmaceutical compns. comprising eukaryotic histone H1 protein and methods of using eukaryotic histone H1 protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a eukaryotic histone H1-contg. animal feed and methods of improving growth of an animal by supplying the feed to the animal. The invention still further includes a kit comprising a eukaryotic histone H1-contg. antibiotic pharmaceutical compn. and an instructional material which describes the use of the compn. In addn., the invention includes a vaccine comprising a eukaryotic histone H1 protein and a method of vaccinating an animal using the vaccine.

L2 ANSWER 8 OF 25 USPATFULL on STN
AN 2001:218486 USPATFULL
TI ANTIMICROBIAL HISTONE H1 COMPOSITIONS, KITS, AND METHODS OF USE THEREOF
IN ***CLASS, REINER J. W.*** , DREXEL HILL, PA, United States
HAND, CHRISTOPHER M., WAYNE, PA, United States
PI US 2001046976 A1 20011129
US 6565854 B2 20030520
AI US 1999-372500 A1 19990811 (9)
PRAI US 1998-96382P 19980813 (60)
DT Utility
FS APPLICATION
LREP AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005

MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes antibiotic pharmaceutical compositions comprising eukaryotic histone H1 protein and methods of using eukaryotic histone H1 protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a eukaryotic histone H1-containing animal feed and methods of improving growth of an animal by supplying the feed to the animal. The invention still further includes a kit comprising a eukaryotic histone H1-containing antibiotic pharmaceutical composition and an instructional material which describes the use of the composition. In addition, the invention includes a vaccine comprising a eukaryotic histone H1 protein and a method of vaccinating an animal using the vaccine.

L2 ANSWER 9 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 4
AN 2001:406252 BIOSIS
DN PREV200100406252
TI Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib.
AU Soslau, Gerald (1); ***Class, Reiner*** ; Morgan, Doris A.; Foster, Carolyn; Lord, Susan T.; Marchese, Patrizia; Ruggeri, Zaverio M.
CS (1) Biochemistry, IMS, MCP Hahnemann University, 245 N. 15th St., Philadelphia, PA, 19102 USA
SO Journal of Biological Chemistry, (June 15, 2001) Vol. 276, No. 24, pp. 21173-21183. print.
ISSN: 0021-9258.
DT Article
LA English
SL English
AB Thrombin plays a central role in normal and abnormal hemostatic processes. It is assumed that alpha-thrombin activates platelets by hydrolyzing the protease-activated receptor (PAR)-1, thereby exposing a new N-terminal sequence, a tethered ligand, which initiates a cascade of molecular reactions leading to thrombus formation. This process involves cross-linking of adjacent platelets mediated by the interaction of activated glycoprotein (GP) IIb/IIIa with distinct amino acid sequences, LGGAKQAGDV and/or RGD, at each end of dimeric fibrinogen molecules. We demonstrate here the existence of a second alpha-thrombin-induced platelet-activating pathway, dependent on GP Ib, which does not require hydrolysis of a substrate receptor, utilizes polymerizing fibrin instead of fibrinogen, and can be inhibited by the Fab fragment of the monoclonal antibody LJIb-10 bound to the GP Ib thrombin-binding site or by the cobra venom metalloproteinase, mocarhagin, that hydrolyzes the extracellular portion of GP Ib. This alternative alpha-thrombin pathway is observed when PAR-1 or GP IIb/IIIa is inhibited. The recognition sites involved in the cross-linking of polymerizing fibrin and surface integrins via the GP Ib pathway are different from those associated with fibrinogen. This pathway is insensitive to RGDS and anti-GP IIb/IIIa antibodies but reactive with a mutant fibrinogen, gamma407, with a deletion of the gamma-chain sequence, AGDV. The reaction is not due to simple trapping of platelets by the

fibrin clot, since ligand binding, signal transduction, and second messenger formation are required. The GP Ib pathway is accompanied by mobilization of internal calcium and the platelet release reaction. This latter aspect is not observed with ristocetin-induced GP Ib-von Willebrand factor agglutination nor with GP Ib-von Willebrand factor-polymerizing fibrin trapping of platelets. Human platelets also respond to gamma-thrombin, an autoproteolytic product of alpha-thrombin, through PAR-4. Co-activation of the GP Ib, PAR-1, and PAR-4 pathways elicit synergistic responses. The presence of the GP Ib pathway may explain why anti-alpha-thrombin/anti-platelet regimens fail to completely abrogate thrombosis/restenosis in the cardiac patient.

L2 ANSWER 10 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:255186 BIOSIS
DN PREV200100255186
TI The three thrombin receptors on human platelets respond differentially to alpha-, beta-, and gamma-thrombin.
AU Soslau, Gerald (1); Goldenberg, Seth J. (1); ***Class, Reiner (1)***
CS (1) MCPHahnemann Univ, 245 N 15th Street, Philadelphia, PA, 19102-1192 USA
SO FASEB Journal, (March 8, 2001) Vol. 15, No. 5, pp. A896. print.
Meeting Info.: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001
ISSN: 0892-6638.
DT Conference
LA English
SL English
AB Cardiovascular diseases remain the leading cause of death in the USA despite the availability of clinically employed anti-thrombotic and anti-platelet drugs. The presumption that alpha-thrombin and the platelet fibrinogen receptor, GP IIb/IIIa, are the two targets in coagulation and platelet aggregation pathways that need to be inhibited to fully regulate hemostasis and thrombosis needs to be revisited. We have found that the controversially defined thrombin receptor, GP Ib, is activated by alpha-thrombin via a pathway that is insensitive to GP IIb/IIIa inhibitors. The GP Ib pathway is readily detected when PAR-1 is blocked. Aggregation under these conditions is inhibited by the anti-GP Ib antibody, LJ Ib-10, or by the cobra venom metalloproteinase, mocarhagin, that hydrolyzes off the extracellular portion of GP Ib. Furthermore, three active forms of thrombin exist with alpha-thrombin being the major player, however, the two actoproteolytic products, beta- and gamma-thrombin are potentially significant contributors to hemostasis as well. These three thrombins function differentially at the three platelet thrombin receptors, GP Ib, PAR-1 and PAR-4, and also respond differently to thrombin inhibitors. At 0.1-10nM levels of thrombins, PAR-4 can only be activated by gamma-thrombin while GP Ib and PAR-1 are insensitive to gamma-thrombin, but both respond to alpha-thrombin. Beta-thrombin appears to be more selective for PAR-1. Gamma-thrombin/PAR-4 is inhibited stoichiometrically by histone-1 while alpha- and beta-thrombins and their receptors are insensitive. The three thrombin species display different sensitivities to heparin. Gamma-thrombin is totally insensitive to hirudin while alpha- and beta-thrombins are completely inhibited. These thrombin species can function synergistically and some individuals also appear to possess varying levels of the three thrombin receptors. It is likely that these disparate properties along with differential responses to drugs

could account for continued coronary disease processes even in the light of aggressive therapy regimens.

L2 ANSWER 11 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 5
AN 2000:200404 BIOSIS
DN PREV200000200404
TI Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow.
AU Colter, David C.; ***Class, Reiner*** ; DiGirolamo, Carla M.; Prockop, Darwin J. (1)
CS (1) Center for Gene Therapy, MCP Hahnemann University, 245 North 15 Street, 10118 New College Building, Philadelphia, PA, 19102-1192 USA
SO Proceedings of the National Academy of Sciences of the United States of America, (March 28, 2000) Vol. 97, No. 7, pp. 3213-3218.
ISSN: 0027-8424.
DT Article
LA English
SL English
AB Cultures of plastic-adherent cells from bone marrow have attracted interest because of their ability to support growth of hematopoietic stem cells, their multipotentiality for differentiation, and their possible use for cell and gene therapy. Here we found that the cells grew most rapidly when they were initially plated at low densities (1.5 or 3.0 cells/cm2) to generate single-cell derived colonies. The cultures displayed a lag phase of about 5 days, a log phase of rapid growth of about 5 days, and then a stationary phase. FACS analysis demonstrated that stationary cultures contained a major population of large and moderately granular cells and a minor population of small and agranular cells here referred to as recycling stem cells or RS-1 cells. During the lag phase, the RS-1 cells gave rise to a new population of small and densely granular cells (RS-2 cells). During the late log phase, the RS-2 cells decreased in number and regenerated the pool of RS-1 cells found in stationary cultures, In repeated passages in which the cells were plated at low density, they were amplified about 109-fold in 6 wk. The cells retained their ability to generate single-cell derived colonies and therefore apparently retained their multipotentiality for differentiation.

L2 ANSWER 12 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:275520 BIOSIS
DN PREV200000275520
TI Formation of a lethal membrane complex caused by selective binding of histone H1 to leukemia cells membranes.
AU ***Class, Reiner Joseph (1)*** ; Zeppezauer, Michael; Weber, Hans-Walter Albert; Brady, Luther W.
CS (1) MCP Hahnemann Univ, Philadelphia, PA USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2000) No. 41, pp. 755-756. print..
Meeting Info.: 91st Annual Meeting of the American Association for Cancer Research. San Francisco, California, USA April 01-05, 2000
ISSN: 0197-016X.
DT Conference
LA English
SL English

L2 ANSWER 13 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:128305 BIOSIS
DN PREV200000128305
TI Influence of vortex speed on fresh versus stored platelet aggregation in the absence and presence of extracellular ATP.
AU Soslau, Gerald (1); Schechner, Adam J.; Alcasid, Patrick J.; ***Class,*** *** Reiner***
CS (1) MCP Hahnemann School of Medicine, 245 North 15th Street, Philadelphia, PA, 19102-1192 USA
SO Thrombosis Research, (Jan. 15, 2000) Vol. 97, No. 2, pp. 15-27. ISSN: 0049-3848.
DT Article
LA English
SL English
AB Platelets are subjected to vastly differing shear forces under laminar and nonlaminar flow patterns throughout the tortuous cardiovascular system. Different activation pathways appear to be associated with platelet adhesion and aggregation under high shear rates vs. low shear rates. We found that platelets continue to aggregate at very low stirring rates (100 RPM) and low shear forces although significantly less than at high stirring rates (1000 RPM). These conditions may model vortices encountered in vivo, such as downstream of partially occluded blood vessels. The extent of agonist-induced platelet aggregation, at varying stir rates, remained essentially unchanged between 1200 and 600 RPM. This was true for both freshly prepared and stored platelets even though the extent of aggregation was significantly reduced with stored platelets. Agonists used were thrombin, thrombin receptor activating peptide (TRAP), SFLLRNP, the thromboxane A2 mimetic, U46619, plus epinephrine and ADP+epinephrine. At lower stir rates (100-400 RPM), little or no difference in aggregation levels was observed between fresh and stored platelets, depending upon agonist used. This may indicate that old and young platelets, in vivo, would be equally active at vessel walls exposed to blood flowing through a slow vortex at low shear rates. ATP, released from activated platelets, may act as a potent regulator of platelet aggregation within a vortex where the resident time of platelets and bioactive molecules is greater than in laminar flow regions. High levels of extracellular ATP (100 muM) inhibited agonist-induced aggregation of fresh platelets to a greater extent than stored platelets, except with ADP+epinephrine where the converse was observed. Inhibition, in general, appeared to be inversely related to stir rates. Low levels of extracellular ATP (10 nM, 1 muM) generally stimulated agonist-induced aggregations independent of stir rates and to a greater extent with stored platelets than fresh platelets. Unraveling how hemostasis functions within microenvironments may facilitate ways to further regulate this process.

L2 ANSWER 14 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN DUPLICATE 6
AN 1999:228049 BIOSIS
DN PREV199900228049
TI A central role of Bcl-xL in the regulation of keratinocyte survival by autocrine EGFR ligands.
AU Jost, Monika; ***Class, Reiner*** ; Kari, Csaba; Jensen, Pamela J.; Rodeck, Ulrich (1)
CS (1) Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, 233 S 10th Street, BLSB Room 319, Philadelphia, PA, 19107 USA

SO Journal of Investigative Dermatology, (April, 1999) Vol. 112, No. 4, pp. 443-449.
ISSN: 0022-202X.
DT Article
LA English
SL English
AB The epidermal growth factor receptor has multiple roles in epidermal biology relating to growth, migration, and, as shown recently, survival of keratinocytes. In cultured keratinocytes activation of the epidermal growth factor receptor upregulates expression of Bcl-xL, an anti-apoptotic Bcl-2 homolog. The functional contribution of epidermal growth factor receptor-dependent Bcl-xL expression to keratinocyte survival is poorly understood. Here we demonstrate that inhibition of the epidermal growth factor receptor tyrosine kinase activity with either an epidermal growth factor receptor antagonistic monoclonal antibody (MoAb 425) or an epidermal growth factor receptor-selective tyrosine kinase inhibitor (AG 1478) downregulated Bcl-xL expression in normal human keratinocytes but had no effect on expression of the pro-apoptotic Bcl-2 homologs Bad, Bak, and Bax. Bovine pituitary extract and insulin partially alleviated both, downregulation of Bcl-xL expression and cell death upon epidermal growth factor receptor inhibition. Forced expression of Bcl-xL attenuated cell death of immortalized keratinocytes (HaCaT) induced by either forced suspension (anoikis) or by epidermal growth factor receptor blockade. These results demonstrate that epidermal growth factor receptor-dependent signaling pathways control the balance of pro-apoptotic and anti-apoptotic Bcl-2 family members expressed in normal keratinocytes. Inappropriate survival supported by aberrant signaling through the epidermal growth factor receptor may contribute to the pathogenesis of psoriasis and of squamous cell carcinomas.

L2 ANSWER 15 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:41540 BIOSIS
DN PREV200000041540
TI Propagation and senescence of human marrow stromal cells in culture: A simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate.
AU DiGirolamo, Carla M.; Stokes, David; Colter, David; Phinney, Donald G.; ***Class, Reiner*** ; Prockop, Darwin J. (1)
CS (1) Center for Gene Therapy, MCP Hahnemann University, 245 North 15 Street, 10118 NCB, Philadelphia, PA, 19102-1192 USA
SO British Journal of Haematology, (Nov., 1999) Vol. 107, No. 2, pp. 275-281.
ISSN: 0007-1048.
DT Article
LA English
SL English
AB Marrow stromal cells (MSCs) were isolated from bone marrow obtained by aspirates of the iliac crest of normal volunteers. The cells were isolated by their adherence to plastic and then passed in culture. Some of the samples expanded through over 15 cell doublings from the time frozen stocks were prepared. Others ceased replicating after about four cell doublings. The replicative potential of the cells in culture was best predicted by a simple colony-forming assay in which samples from early passages were plated at low densities of about 10 cells per cm2. Samples with high colony-forming efficiency exhibited the greatest replicative potential. The colonies obtained by plating early passage cells at low

density varied in size and morphology. The large colonies readily differentiated into osteoblasts and adipocytes when incubated in the appropriate medium. As samples were expanded in culture and approached senescence, they retained their ability to differentiate into osteoblasts. However, the cells failed to differentiate into adipocytes. The loss of multipotentiality following serial passage in culture may have important implications for the use of expanded MSCs for cell and gene therapy.

L2 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 7
AN 1998:487847 CAPLUS
DN 129:90476
TI Therapeutic method using synergistic combination of cytostatic agent and histone for treatment of carcinoma or autoimmune diseases
IN Zeppezauer, Michael; ***Class, Reiner***
PA Allegheny University of the Health Sciences, USA
SO U.S., 26 pp., Cont.-in-part of U.S. 5,578,571.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5780432	A	19980714	US 1996-755147	19961122
US 5578571	A	19961126	US 1994-310378	19940922

PRAI US 1990-635709 19901228
US 1994-310378 19940922
DE 1990-4000154 19900104
AB A therapeutic method for treatment of carcinoma or autoimmune diseases of a patient is provided which includes administering a biol. active compn. comprising a therapeutically acceptable carrier and, in a quantity having a therapeutic effect, two active substances comprising a pure cytostatic drug as the first active substance and a biol. active pure histone selected from the group consisting of H1, H2A, H2B, H2A:H2B, and H3 as the second active substance, providing a synergistic action of both of said active substances at a site of pathogenic process.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:701017 CAPLUS
DN 129:298380
TI Histones for use as targeted antitumor agents in leukemia
IN Zeppezauer, Michael; Leinenbach, Hans-Peter; ***Class, Reiner*** ; Fassbender, Cordula
PA Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biot, Germany
SO Ger. Offen., 10 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 19715149	A1	19981015	DE 1997-19715149	19970411
WO 9846252	A1	19981022	WO 1998-EP2112	19980409

W: AU, BG, BR, CA, CN, CZ, EE, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SK, TR, UA, US, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9883110 A1 19981111 AU 1998-83110 19980409
EP 973541 A1 20000126 EP 1998-919254 19980409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO
JP 2000512311 T2 20000919 JP 1998-542074 19980409
US 2003017987 A1 20030123 US 2002-238726 20020911
PRAI DE 1997-19715149 A 19970411
WO 1998-EP2112 W 19980409
US 1999-402468 A1 19991012
AB An antitumor agent is disclosed for damaging cell membranes and killing cancer cells, esp. leukemia cells, by targeting of membrane-fixed receptors consisting of protein aggregates contg. several core histones or core-like histones and/or their parts. The agent comprises at least a pure histone or its active segment sequence, i.e., histone H1, the pure H1 subtypes, histones H2A, H2B, and H2A:H2B dimer, and histones H3 and H4, which can cross-link the protein aggregates into larger superstructures.

L2 ANSWER 18 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 8
AN 1998:132318 BIOSIS
DN PREV199800132318
TI Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta.
AU Pereira, Ruth F.; O'Hara, Michael D.; Laptev, Alexey V.; Halford, Kenneth W.; Pollard, Marea D.; ***Class, Reiner*** ; Simon, Daniela; Livezey, Kristin; Prockop, Darwin J. (1)
CS (1) Cent. Gene Therapy, Allegheny Univ. Health Sci., 245 N. 15 St., 10118 NCB, Mail Stop 421, Philadelphia, PA 19102-1192 USA
SO Proceedings of the National Academy of Sciences of the United States of America, (Feb. 3, 1998) Vol. 95, No. 3, pp. 1142-1147.
ISSN: 0027-8424.
DT Article
LA English
AB Marrow stromal cells from wild-type mice were infused into transgenic mice that had a phenotype of fragile bones resembling osteogenesis imperfecta because they expressed a human minigene for type I collagen. In mice that were irradiated with potentially lethal levels (700 cGy) or sublethal levels (350 cGy), DNA from the donor marrow stromal cells was detected consistently in marrow, bone, cartilage, and lung either 1 or 2.5 mo after the infusions. The DNA also was detected but less frequently in the spleen, brain, and skin. There was a small but statistically significant increase in both collagen content and mineral content of bone 1 mo after the infusion. Similar results were obtained with infusion of relatively large amounts of wild-type whole marrow cells into the transgenic mice. In experiments in which male marrow stromal cells were infused into a female osteogenesis imperfecta-transgenic mouse, fluorescense in situ hybridization assays for the Y chromosome indicated that, after 2.5 mo, donor male cells accounted for 4-19% of the fibroblasts or fibroblast-like cells obtained in primary cultures of the lung, calvaria, cartilage, long bone, tail, and skin. In a parallel experiment in which whole marrow cells from a male mouse were infused into a female immunodeficient rag-2 mouse,

donor male cells accounted for 4-6% of the fibroblasts or fibroblast-like cells in primary cultures. The results support previous suggestions that marrow stromal cells or related cells in marrow serve as a source for continula renewal of cellls or related cells in marrow serve as a source for continual renewal of cells in a number of nonhematopoietic tissues.

L2 ANSWER 19 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1998:61209 BIOSIS
DN PREV199800061209
TI Thrombopoietin (Tpo) recruits a subpopulation of cord blood progenitors into megakaryocytopoiesis.
AU Morgan, Doris Anne (1); ***Class, Reiner*** ; Ross, Douglas
CS (1) Dep. Med., Allegheny Univ. Health Sci., Philadelphia, PA USA
SO Blood, (Nov. 15, 1997) Vol. 90, No. 10 SUPPL. 1 PART 2, pp. 149B. Meeting Info.: Thirty-ninth Annual Meeting of the American Society of Hematology San Diego, California, USA December 5-9, 1997 The American Society of Hematology
. ISSN: 0006-4971.
DT Conference
LA English

L2 ANSWER 20 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 9
AN 1997:208806 BIOSIS
DN PREV199799508009
TI Biodistribution of 125I-MAb 425 in a human glioma xenograft model: Effect of chloroquine.
AU Emrich, Jacqueline G. (1); Hand, Christopher M.; Dilling, Thomas J.; ***Class, Reiner*** ; Bender, Hans; Brady, Luther W.
CS (1) Allegheny Univ. Health Sci., Mail Stop 102, Broad and Vine Sts., Philadelphia, PA 19102-1192 USA
SO Hybridoma, (1997) Vol. 16, No. 1, pp. 93-100.
ISSN: 0272-457X.
DT Article
LA English
AB Chloroquine has been shown to increase the cellular retention and nuclear incorporation of 125I-labeled monoclonal antibody (MAb) 425, a murine anti-epidermal growth factor receptor monoclonal antibody, in human high-grade glioma cells in vitro. The objective of this study was to examine the effect of chloroquine on the biodistribution of 125I-MAb 425 in an intracerebral xenogeneic transplant of glioma cells. Nude rats were stereotaxically implanted in the right hemisphere with A1207 human high-grade glioma cells. After 14 days, animals were injected i.v. with chloroquine (40 mg/kg) followed 2 h later by an 125I-MAb 425 (9 MEBq) infusion. Tissue distributions were performed up to 168 h post 125I-MAb 425 injection. From 24 to 168 h, tumor-to-contralateral left brain ratios increased from 9 to 15 for 125I-MAb 425 alone, and 7 to 13 for the 125I-MAb 425/chloroquine combination, respectively. A single administration of chloroquine did not result in any significant difference in radiolabeled MAb accumulation in either the tumor site or other tissues. We conclude that chloroquine did not increase the amount of 125I-MAb 425 into the tumor; however, it is safe to administer i.v. at the 40 mg/kg dose. Under these experimental conditions, the increased radioactive accumulation observed for in vitro data did not translate into similar in vivo results.

concentrations. Furthermore, 250 mu-g H1 injected into a Burkitt's lymphoma (Daudi), xenotransplanted into nude mice, arrested tumor growth. As shown by electron microscopy and flow cytometry, incubation of leukemia cells with H1 resulted in severe plasma membrane damage and ultimately cytolysis. This report characterizes a 33-kd protein that binds H1 and is responsible for the cell death via destruction of the cell membrane integrity. New extranuclear functions of histones are presented.

L2 ANSWER 23 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1997:47009 BIOSIS
DN PREV199799346212
TI Leukemia-derived cell lines display surface protein ligand for histone H1: Histone H1 suppresses tumor growth of leukemia cells in vitro, ex vivo and in an animal model suggesting extracellular functions of histones.
AU ***Class, Reiner (1)*** ; Lindman, Sissel; Fassbender, Cordula (1); Leinenbach, Hans-Peter (1); Rawer, Stefan (1); Emrich, Jacqueline G.; Brady, Luther W.; Zeppezauer, Michael (1)
CS (1) Dep. Biochem., Univ. Saarland, D-66041 Saarbruecken Germany
SO Cellular and Molecular Biology (Noisy-Le-Grand), (1996) Vol. 42, No. CONGRESS SUPPL., pp. S25-S26.
Meeting Info.: 2nd World Congress of Cellular and Molecular Biology Ottawa, Ontario, Canada September 3-7, 1996
DT Conference; Abstract
LA English

L2 ANSWER 24 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1996:3628 BIOSIS
DN PREV199698575763
TI Chloroquine improves targeted delivery of 125I-MAb 425 in a human glioma animal model.
AU Emrich, Jacqueline G. (1); Hand, Christopher M.; ***Class, Reiner*** ; Dilling, Thomas; Brady, Luther W.
CS (1) Dep. Radiation Oncology Nuclear Med., Med. Coll. Pa., Hahnemann Univ., Center City Campus, Philadelphia, PA 19102 USA
SO Pharmaceutical Research (New York), (1995) Vol. 12, No. 9 SUPPL., pp. S267.
Meeting Info.: Annual Meeting of the American Association of Pharmaceutical Scientists Miami Beach, Florida, USA November 5-9, 1995
ISSN: 0724-8741.
DT Conference
LA English

L2 ANSWER 25 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1995:348516 BIOSIS
DN PREV199598362816
TI Epidermal Growth Factor Receptor 425 Monoclonal Antibodies Radiolabeled with Iodine-125 in the Adjuvant Treatment of High-Grade Astrocytomas.
AU Snelling, Lesley; Miyamoto, Curtis T.; Bender, Hans; Brady, Luther W. (1); Steplewski, Zenon; ***Class, Reiner*** ; Emrich, Jacqueline; Rackover, Michael A.
CS (1) Dep. Radiation Oncol., Hahnemann Univ., Philadelphia, PA 19102 USA
SO Hybridoma, (1995) Vol. 14, No. 2, pp. 111-114.
ISSN: 0272-457X.
DT Article
LA English

AB Fifty-nine patients with primary presentation of high-grade gliomas of the brain, 13 with astrocytomas with anaplastic foci and 46 with glioblastoma multiforme, were treated with surgical intervention and definitive postoperative radiation therapy followed by multiple intravenous administration of iodine-125-labeled monoclonal antibody-425, which binds specifically to human epidermal growth factor receptor. The total cumulative labeled antibody doses ranged from 40 to 296 mCi. The administration of the radiolabeled antibody was performed in most instances within 3 months following completion of the primary surgery and radiation therapy. No significant life-threatening toxicities were observed during the trial. At one year, 34 (58 %) of the 59 patients in the trial were alive. The median overall survival for both groups was 13.5 months.

=> e zeppezauer michael/au
E1 387 ZEPPEZAUER M/AU
E2 7 ZEPPEZAUER M M/AU
E3 138 --> ZEPPEZAUER MICHAEL/AU
E4 2 ZEPPEZAUER MICHAEL M/AU
E5 1 ZEPPEZUER M/AU
E6 3 ZEPPI C/AU
E7 4 ZEPPI CLAUDIO/AU
E8 2 ZEPPI R/AU
E9 1 ZEPPIE C R/AU
E10 7 ZEPPIERI A/AU
E11 1 ZEPPIERI ANNA/AU
E12 1 ZEPPIERI D J/AU

=> s e1-e5 and (histone? or h1)
L3 69 ("ZEPPEZAUER M"/AU OR "ZEPPEZAUER M M"/AU OR "ZEPPEZAUER MICHAEL "/AU OR "ZEPPEZAUER MICHAEL M"/AU OR "ZEPPEZUER M"/AU) AND (HIST ONE? OR H1)

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 38 DUP REM L3 (31 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 38 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1
AN 2003:590868 CAPLUS
TI Peptides for the production of preparations for the diagnosis and therapyof autoimmun diseases
IN ***Zeppezauer, Michael*** ; Schonberger, Arno; Cebecauer, Ladislav
PA Germany
SO U.S. Pat. Appl. Publ., 7 pp., Cont.-in-part of U.S. Ser. No. 946,180.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003144473	A1	20030731	US 2001-988165	20011119
US 6369203	B1	20020409	US 1992-946180	19920916
WO 2003044054	A2	20030530	WO 2002-EP12955	20021119

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 1992-946180 A2 19920916
US 2001-988165 A 20011119

AB Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from autoimmun diseases, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis. In the case of the peptides it is preferably a question of the C terminus of bovine ***histone*** ***H1*** with the sequence section 187-211 or corresponding human histon- ***H1*** -peptides of the sub-types ***H1*** .1, ***H1*** .2, ***H1*** .3, ***H1*** .4, ***H1*** .5 and ***H1*** .a and the N termini of ***histone*** H2B with the sequence sections 1-35 and 36-76, which are capable of cross reactions with the autoantibodies (anti- ***histone*** -antibodies). The invention furthermore provides ways of forming monoclonal antibodies and antiidiotypical antibodies, which are directed against autoantibodies. The diagnosis of autoimmun diseases is possible in accordance with the invention with a high degree of certainty and the monoclonal antibodies directed against the autoantibodies are suitable for the production of medicaments for the therapy of said diseases.

L4 ANSWER 2 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:417777 CAPLUS
DN 139:5653
TI ***Histone*** -derived peptides for diagnosis and therapy of autoimmune disease
IN ***Zeppezauer, Michael*** ; Schoenberger, Arno; Cebecauer, Ladislav
PA Symbiotec Gesellschaft zur Erforschung und Entwicklung auf dem Gebiete der Biotechnology M.b.h., Germany
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003044054	A2	20030530	WO 2002-EP12955	20021119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003144473	A1	20030731	US 2001-988165	20011119
PRAI US 2001-988165	A	20011119		
US 1992-946180	A2	19920916		

AB The authors disclose peptides which react with autoantibodies in the body fluids of patients, who are suffering from autoimmune diseases, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis. The antigenic peptides are derived from the C-terminus of ***histone*** ***H1*** (bovine or human sub-types ***H1*** .1, ***H1*** .2, ***H1*** .3, ***H1*** .4, ***H1*** .5 and ***H1*** .a) and the N-termini of

histone H2B with the sequence section 1-35 and 36-76 and are capable of cross-reactions with the autoantibodies (anti- ***histone*** -antibodies). The invention furthermore provides ways of forming monoclonal antibodies and anti-idiotypic antibodies, which are directed against autoantibodies. The diagnosis of autoimmune peptides and diseases is possible in accordance with the invention with a high degree of certainty and the monoclonal antibodies directed against the autoantibodies are suitable for the prodn. of medicaments for the therapy of said diseases.

L4 ANSWER 3 OF 38 USPATFULL on STN
AN 2003:24144 USPATFULL
TI Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties
IN ***Zeppezauer, Michael*** , Scheidt, GERMANY, FEDERAL REPUBLIC OF
Leinenbach, Hans-Peter, Tholey, GERMANY, FEDERAL REPUBLIC OF
Class, Reiner, Drexel Hill, PA, UNITED STATES
Fassbender, Cordula, Koln, GERMANY, FEDERAL REPUBLIC OF
PI US 2003017987 A1 20030123
AI US 2002-238726 A1 20020911 (10)
RLI Continuation of Ser. No. US 1999-402468, filed on 12 Oct 1999, PENDING A 371 of International Ser. No. WO 1998-EP2112, filed on 9 Apr 1998, UNKNOWN
PRAI DE 1997-19715149 19970411
DT Utility
FS APPLICATION
LREP BACON & THOMAS, PLLC, 625 SLATERS LANE, FOURTH FLOOR, ALEXANDRIA, VA, 22314
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 579
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A therapeutic or prophylactic agent for cancer is disclosed which damages the membrane and kills cancer cells, in particular of the blood-forming system, having membrane protein aggregates which contain several core ***histones*** or largely core-like ***histones*** and/or their parts. The therapeutic or prophylactic agent contains at least one pure ***histone*** or its active sequence section selected from the group composed of ***histone*** ***H1*** , ***H1*** subtypes, H2A, H2B, H2A:H2B dimer, H3 and H4, covalent modified ***histones*** of the above-mentioned type and/or their active sections and functionally and structurally similar proteins (protamines, ***histone*** -like proteins of prokaryotic and archae bacteria).

L4 ANSWER 4 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN DUPLICATE 2
AN 2002:282968 BIOSIS
DN PREV200200282968
TI Peptides for the production of preparations for the diagnosis and therapy of systemic lupus.
AU ***Zeppezauer, Michael (1)*** ; Schonberger, Arno; Cebecauer, Ladislav
CS (1) Scheidt Germany
ASSIGNEE: Symbiotec Gesellschaft zur Erforschung und Entwicklung auf dem Gebiet der Biotechnologic mbH, Herborn, Germany

PI US 6369203 April 09, 2002
SO Official Gazette of the United States Patent and Trademark Office Patents, (Apr. 9, 2002) Vol. 1257, No. 2, pp. No Pagination. http://www.uspto.gov/web/menu/patdata.html. e-file. ISSN: 0098-1133.
DT Patent
LA English
AB Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from systemic lupus erythematosus (SLE). In the case of the peptides it is preferably a question of the C terminus of ***H1*** with the sequence section 187-211 and the N termini of H2B with the sequence sections 1-35 and 36-76, which are capable of cross reactions with the autoantibodies (anti- ***histone*** -antibodies). The invention furthermore provides ways of forming monoclonal antibodies and antiidiotypical antibodies, which are directed against autoantibodies. The diagnosis of SLE is possible in accordance with the invention with a high degree of certainty and the monoclonal antibodies directed against the autoantibodies are suitable for the production of medicaments for the therapy of SLE.

L4 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:675811 CAPLUS
DN 137:195614
TI Compositions and methods for preventing platelet aggregation comprising ***histones***
IN Class, Reiner; Soslau, Gerald; ***Zeppezauer, Michael***
PA Philadelphia, Health and Education Corporation, USA; Symbiotec G.m.b.H.
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002067907	A1	20020906	WO 2002-US5157	20020222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-270759P P 20010222
AB Compns. and methods for preventing platelet aggregation and treating cardiovascular disease via ***histone*** compds. are provided. An assay for platelet aggregation using angonist and antagonist is described.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:944200 CAPLUS

DN 138:219211
TI Quo vadis protein? ***histone*** ***H1*** as an example of a multifunctional protein
AU Class, R.; Jost, M.; Weber, H. W.; Brady, L. W.; ***Zeppezauer, M.***
CS SymbioTec GmbH, Saarbruecken, Germany
SO Progress in Radio-Oncology VII, Proceedings of the International Meeting on Progress in Radio-Oncology, 7th, Salzburg, Austria, May 15-19, 2002 (2002), 587-595. Editor(s): Kogelnik, H. D.; Lukas, P.; Sedlmayer, F. Publisher: Monduzzi Editore, Bologna, Italy.
CODEN: 69DIQO; ISBN: 88-323-2515-2
DT Conference
LA English
AB ***Histone*** ***H1*** (***H1***) belongs to a family of small cationic and well-conserved nuclear proteins. In recent years, sufficient evidence was accumulated strongly suggesting that ***histones*** might have pivotal biol. activities in compartments other than the nucleus. Here, the authors show that ***H1*** is capable of recognizing leukemia cells and subsequently lysing them. PHA-stimulated normal peripheral blood mononuclear cells (PBMC) and hematopoietic stem cells remained largely unaffected by ***H1*** . These data strongly suggest, that ***H1*** binds to leukemia cells with high affinity. The binding seems to be followed by the assembly of larger protein complexes within the membrane, resulting in formation of a channel-like structure that causes severe disturbances in the membrane integrity, eventually resulting in cell death.
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:115183 CAPLUS
DN 134:168376
TI Antimicrobial ***histone*** ***H1*** compositions, kits, and methods of use thereof
IN Class, Reiner; ***Zeppezauer, Michael***
PA Symbiotec Gm.b.H., Germany; Philadelphia Health and Education Corp.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001010901	A2	20010215	WO 2000-US21747	20000809
WO 2001010901	A3	20010809		
WO 2001010901	C2	20020912		
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 2001046976	A1	20011129	US 1999-372500	19990811
US 6565854	B2	20030520		
EP 1200463	A2	20020502	EP 2000-957347	20000809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRAI US 1999-372500	A	19990811		
US 1998-96382P	P	19980813		

WO 2000-US21747 W 20000809

AB The invention includes antibiotic pharmaceutical compns. comprising eukaryotic ***histone*** ***H1*** protein and methods of using eukaryotic ***histone*** ***H1*** protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a eukaryotic ***histone*** ***H1*** -contg. animal feed and methods of improving growth of an animal by supplying the feed to the animal. The invention still further includes a kit comprising a eukaryotic ***histone*** ***H1*** -contg. antibiotic pharmaceutical compn. and an instructional material which describes the use of the compn. In addn., the invention includes a vaccine comprising a eukaryotic ***histone*** ***H1*** protein and a method of vaccinating an animal using the vaccine.

L4 ANSWER 8 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:275520 BIOSIS
DN PREV200000275520
TI Formation of a lethal membrane complex caused by selective binding of ***histone*** ***H1*** to leukemia cells membranes.
AU Class, Reiner Joseph (1); ***Zeppezauer, Michael*** ; Weber, Hans-Walter Albert; Brady, Luther W.
CS (1) MCP Hahnemann Univ, Philadelphia, PA USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2000) No. 41, pp. 755-756. print..
Meeting Info.: 91st Annual Meeting of the American Association for Cancer Research. San Francisco, California, USA April 01-05, 2000
ISSN: 0197-016X.
DT Conference
LA English
SL English

L4 ANSWER 9 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 3
AN 1998:487847 CAPLUS
DN 129:90476
TI Therapeutic method using synergistic combination of cytostatic agent and ***histone*** for treatment of carcinoma or autoimmune diseases
IN ***Zeppezauer, Michael*** ; Class, Reiner
PA Allegheny University of the Health Sciences, USA
SO U.S., 26 pp., Cont.-in-part of U.S. 5,578,571.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5780432	A	19980714	US 1996-755147	19961122
US 5578571	A	19961126	US 1994-310378	19940922
PRAI US 1990-635709		19901228		
US 1994-310378		19940922		
DE 1990-4000154		19900104		

AB A therapeutic method for treatment of carcinoma or autoimmune diseases of a patient is provided which includes administering a biol. active compn. comprising a therapeutically acceptable carrier and, in a quantity having a therapeutic effect, two active substances comprising a pure cytostatic drug as the first active substance and a biol. active pure ***histone***

selected from the group consisting of ***H1*** , H2A, H2B, H2A:H2B, and H3 as the second active substance, providing a synergistic action of both of said active substances at a site of pathogenic process.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:701017 CAPLUS
DN 129:298380
TI ***Histones*** for use as targeted antitumor agents in leukemia
IN ***Zeppezauer, Michael*** ; Leinenbach, Hans-Peter; Class, Reiner; Fassbender, Cordula
PA Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biot, Germany
SO Ger. Offen., 10 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 19715149	A1	19981015	DE 1997-19715149	19970411
WO 9846252	A1	19981022	WO 1998-EP2112	19980409
W: AU, BG, BR, CA, CN, CZ, EE, GE, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SK, TR, UA, US, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9883110	A1	19981111	AU 1998-83110	19980409
EP 973541	A1	20000126	EP 1998-919254	19980409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2000512311	T2	20000919	JP 1998-542074	19980409
US 2003017987	A1	20030123	US 2002-238726	20020911
PRAI DE 1997-19715149	A	19970411		
WO 1998-EP2112	W	19980409		
US 1999-402468	A1	19991012		

AB An antitumor agent is disclosed for damaging cell membranes and killing cancer cells, esp. leukemia cells, by targeting of membrane-fixed receptors consisting of protein aggregates contg. several core ***histones*** or core-like ***histones*** and/or their parts. The agent comprises at least a pure ***histone*** or its active segment sequence, i.e., ***histone*** ***H1*** , the pure ***H1*** subtypes, ***histones*** H2A, H2B, and H2A:H2B dimer, and ***histones*** H3 and H4, which can cross-link the protein aggregates into larger superstructures.

L4 ANSWER 11 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1997:231756 BIOSIS
DN PREV199799530959
TI Characterization of a novel membrane-protein found in leukemia cells that causes rapid cell death upon binding to ***histone*** ***H1*** .
AU Class, R. (1); ***Zeppezauer, M.*** ; Strupat, K.
CS (1) Allegheny Univ. Health Sci., Dep. Radiation Oncol., Philadelphia, PA 19102 USA
SO Proceedings of the American Association for Cancer Research Annual

Meeting, (1997) Vol. 38, No. 0, pp. 231.
Meeting Info.: Eighty-eighth Annual Meeting of the American Association for Cancer Research San Diego, California, USA April 12-16, 1997
ISSN: 0197-016X.
DT Conference; Abstract
LA English

L4 ANSWER 12 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 4
AN 2002:52460 BIOSIS
DN PREV200200052460
TI Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures.
AU ***Zeppezauer, M.*** ; Leinenbach, H. P.
CS Scheidt Germany
ASSIGNEE: SYMBIOTEC GESELLSCHAFT ZUR FORSCHUNG UND ENTWICKLUNG AUF DEM GEBIET DER BIOTECHNOLOGIE MBH
PI US 5578571 Nov. 26, 1996
SO Official Gazette of the United States Patent and Trademark Office Patents, (Nov. 26, 1996) Vol. 1192, No. 4, pp. 2875-2876.
ISSN: 0098-1133.
DT Patent
LA English

L4 ANSWER 13 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 5
AN 1996:511269 BIOSIS
DN PREV199699233625
TI ***Histone*** ***H1*** suppress tumor growth of leukemia cells in vitro, ex vivo and in an animal model suggesting extracellular functions of ***histones*** .
AU Class, Reiner (1); Lindman, Sissel; Fassbender, Cordula; Leinenbach, Hans-Peter; Rawer, Stefan; Emrich, Jacqueline G.; Brady, Luther W.; ***Zeppezauer, Michael***
CS (1) Allegheny Univ. Health Sci., Cent. City, Broad and Vine Streets, MS 102, Philadelphia, PA 19102 USA
SO American Journal of Clinical Oncology, (1996) Vol. 19, No. 5, pp. 522-531.
ISSN: 0277-3732.
DT Article
LA English
AB Purified ***histone*** ***H1*** exerts growth inhibition of leukemia cells independent of lineage, stage, and maturation. At 200 mu-g/ml, ***H1*** proved cytotoxic in 19 of 21 of the tested leukemia-derived cell lines and for 11 of 16 of the fresh tumor samples from leukemia patients. In all cases, normal peripheral blood mononuclear cells and bone marrow cells remained unaffected. Multicellular spheroids from the Burkitt's lymphoma cell line IM-9 were growth arrested at 500 mu-g ***H1*** /ml. The clonogenic growth of the Burkitt's lymphoma cell line Daudi was arrested at 160 mu-g ***H1*** /ml. Synthetic ***H1*** -peptides as well as peptides and proteins with biochemical properties similar to ***H1*** had no inhibitory growth effect at equimolar concentrations. Furthermore, 250 mu-g ***H1*** injected into a Burkitt's lymphoma (Daudi), xenotransplanted into nude mice, arrested tumor growth. As shown by electron microscopy and flow cytometry, incubation of leukemia cells with ***H1*** resulted in severe plasma

membrane damage and ultimately cytolysis. This report characterizes a 33-kd protein that binds ***H1*** and is responsible for the cell death via destruction of the cell membrane integrity. New extranuclear functions of ***histones*** are presented.

L4 ANSWER 14 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1997:47009 BIOSIS
DN PREV199799346212
TI Leukemia-derived cell lines display surface protein ligand for ***histone*** ***H1*** : ***Histone*** ***H1*** suppresses tumor growth of leukemia cells in vitro, ex vivo and in an animal model suggesting extracellular functions of ***histones*** .
AU Class, Reiner (1); Lindman, Sissel; Fassbender, Cordula (1); Leinenbach, Hans-Peter (1); Rawer, Stefan (1); Emrich, Jacqueline G.; Brady, Luther W.; ***Zeppezauer, Michael (1)***
CS (1) Dep. Biochem., Univ. Saarland, D-66041 Saarbruecken Germany
SO Cellular and Molecular Biology (Noisy-Le-Grand), (1996) Vol. 42, No. CONGRESS SUPPL., pp. S25-S26.
Meeting Info.: 2nd World Congress of Cellular and Molecular Biology Ottawa, Ontario, Canada September 3-7, 1996
DT Conference; Abstract
LA English

L4 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:639444 CAPLUS
DN 125:301582
TI C-terminal peptides of human ***histone*** ***H1*** subtypes: A synthetic problem
AU Hoffmann, R.; Rawer, S.; Berger, R. G.; ***Zeppezauer, M.***
CS Biochemie, Universitat des Saarlandes, Saarbruecken, D-66041, Germany
SO Peptides 1994, Proceedings of the European Peptide Symposium, 23rd, Braga, Port., Sept. 4-10, 1994 (1995), Meeting Date 1994, 389-390. Editor(s): Maia, Hernani L. S. Publisher: ESCOM, Leiden, Neth.
CODEN: 63MBAO
DT Conference
LA English
AB A report from a symposium on the observation of secondary structure formation by UV and conductometric monitoring in the solid-phase prepn. of C-terminal ***histone*** ***H1*** fragments. The repeating Lys-Pro-Lys-Xaa-Xaa sequences induce structure formation.

L4 ANSWER 16 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 6
AN 1995:504452 BIOSIS
DN PREV199598509502
TI Separation and characterisation of bovine ***histone*** ***H1*** subtypes by combined ion-exchange and reversed-phase chromatography and mass spectrometry.
AU Berger, Renate G.; Hoffmann, Ralf; ***Zeppezauer, Michael (1)*** ; Wagner-Redeker, Winfried; Maljers, Louis; Ingendoh, Arndt; Hillenkamp, Franz
CS (1) FR 12.4 Biochemie, Univ. Saarlandes, Postfach 151150, D-66041 Saarbruecken Germany
SO Journal of Chromatography A, (1995) Vol. 711, No. 1, pp. 159-165.
ISSN: 0021-9673.

DT Article
LA English

L4 ANSWER 17 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 7
AN 1996:55789 BIOSIS
DN PREV199698627924
TI Effect of ***histones*** on hematopoietic stem cell-precursors in normal and irradiated organisms.
AU Semina, O. V.; Semenets, T. N.; ***Zeppezauer, M.*** ; Cebecauer, L.; Poverennyi, A. M.
CS Med. Radiol. Res. Cent., Russ. Acad. Med. Sci., Obninsk Russia
SO Radiatsionnaya Biologiya Radioekologiya, (1994) Vol. 34, No. 4-5, pp. 544-549.
DT Article
LA Russian
SL Russian; English
AB Radiotherapeutic activity of ***histone*** fractions H-1 and H-2A/H-2B were studied. It was demonstrated that both fractions are able to reduce the damaging effect of ionizing radiation on spleen colony forming unit (CFU-S) population. ***Histone*** preparations stimulated colony-forming activity of bone marrow cells exposed to dose of 0.5-3.0 Gy both in the case of incubation with preparations and intravenous or intraperitoneal administration into recipients of irradiated cells. The effect of ***histones*** and accessory thymocytes on CFU-S population is compared.

L4 ANSWER 18 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:675684 CAPLUS
DN 121:275684
TI Separation and determination of molecular masses of ***histone*** ***H1*** subtypes from calf thymus
AU Berger, R. G.; Hoffmann, R.; Waidelich, D.; Bayer, E.; Ingendoh, A.; Hillenkamp, F.; ***Zeppezauer, M.***
CS Univ. Saarlandes, Saarbruecken, D-66041, Germany
SO Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp., 13th (1994), Meeting Date 1993, 228-9. Editor(s): Hodges, Robert S.; Smith, John A. Publisher: ESCOM, Leiden, Neth.
CODEN: 60LXAW
DT Conference
LA English
AB A combination of reversed-phase liq. chromatog. and hydrophilic interaction chromatog. is introduced to sep. the subtypes of ***histone*** ***H1*** of calf thymus. Purified subtypes were characterized by SDS-PAGE and mass spectrometry. Four fractions were obtained from ***histone*** ***H1*** , including 1 pure subtype.

L4 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:67096 CAPLUS
DN 122:31948
TI Synthesis of acetylated and phosphorylated peptide fragments of ***histone*** H2A
AU Wachs, W. O.; Hoffmann, R.; ***Zeppezauer, M.*** ; Schmeer, K.; Bayer, E.
CS Dep. Biochem., Univ. Saarland, Saarbruecken, D-66041, Germany

SO Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp., 13th (1994), Meeting Date 1993, 202-3. Editor(s): Hodges, Robert S.; Smith, John A. Publisher: ESCOM, Leiden, Neth.
CODEN: 60LXAW
DT Conference
LA English
AB A symposium report on the synthesis of acetylated and phosphorylated derivs. of peptide SGRGKQGGKARAKA, which is the 1-14 fragment of ***histone*** H2A.

L4 ANSWER 20 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:447344 CAPLUS
DN 119:47344
TI Peptides for diagnosis and therapy of systemic lupus erythematosus (SLE)
IN ***Zeppezauer, Michael*** ; Schoenberger, Arno; Cebecauer, Ladislav
PA Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie mbH, Germany
SO Ger. Offen., 7 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 4130786	A1	19930318	DE 1991-4130786	19910916
EP 532979	A2	19930324	EP 1992-114992	19920902
EP 532979	A3	19940824		
EP 532979	B1	19970716		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
AT 155487	E	19970815	AT 1992-114992	19920902
CZ 284114	B6	19980812	CZ 1992-2816	19920914
SK 280176	B6	19990910	SK 1992-2816	19920914
JP 05271281	A2	19931019	JP 1992-272266	19920916
CA 2078373	C	19990105	CA 1992-2078373	19920916
PRAI DE 1991-4130786		19910916		

AB Peptides for use in immunoassays to detect autoantibodies in body fluids of patients with SLE contain antigenic determinants of ***histones*** ***H1*** and H2B which cross-react with these autoantibodies. The peptides may contain modified peptide bonds, e.g. C(:O)NMe, CH2CH2, or C(:O)CH2, or may contain amino acid insertions, deletions, or substitutions. Monoclonal antibodies to the peptides, and anti-idiotypic antibodies against the monoclonal antibodies or the autoantibodies, may also be useful in diagnosis and/or therapy. Thus, 80% of sera from SLE patients contained autoantibodies reacting with both the C-terminus of ***histone*** ***H1*** and the N-terminus of ***histone*** H2B.

L4 ANSWER 21 OF 38 USPATFULL on STN
AN 93:7089 USPATFULL
TI Use of pure ***histones*** ***H1*** and H2A:H2B dimers in therapeutic methods
IN ***Zeppezauer, Michael*** , Saarbrucken-Scheidt, Germany, Federal Republic of
Reichhart, Robert, Homburg/Saar, Germany, Federal Republic of
PA Rusch, Volker, Germany, Federal Republic of (non-U.S. individual)
PI US 5182257 19930126

AI US 1989-332658 19890403 (7)
RLI Continuation-in-part of Ser. No. US 1985-777783, filed on 12 Sep 1985, now patented, Pat. No. US 4818763, issued on 4 Apr 1989
PRAI DE 1984-3405620 19840216
DE 1984-3400928 19841201
DT Utility
FS Granted
EXNAM Primary Examiner: Cashion, Jr., Merrell C.; Assistant Examiner: Davenport, A. M.
LREP Rosenman & Colin
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 500
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of pure ***histones*** ***H1*** , H2A, H2B, H2A:H2B, H3 as hormonal or hormon-like active substance for the preparation of pharmaceuticals for the immuno-therapy, for the therapy of endocrine disturbance and for cancer therapy. Instead of the ***histones*** also their evolutionary variable sections or at least one partial section of at least five aminoacid residues of at least one evolutionary variable histon section can be used.

L4 ANSWER 22 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1994:190414 BIOSIS
DN PREV199497203414
TI Detection of proteins associated with the Epstein-Barr virus nuclear antigen 2: EBNA-2A binds to ***histone*** ***H1*** and unknown cellular proteins of 130, 110, 105 and 95 kDa.
AU Graesser, Friedrich A. (1); Sauder, Christian (1); Haiss, Peter (1); Hille, Annette (1); Koenig, Sigrid (1); Goette, Suzanne (1); Kremmer, Elisabeth; Leinenbach, Hans Peter; ***Zeppezauer, Michael*** ; Mueller-Lantzsch, Nikolaus (1)
CS (1) Abt. Virol., Universitaetsklin. des Saarlandes, Gebaude 47, 6650 Homburg Germany
SO Tursz, T. [Editor]; Pagano, J. S. [Editor]; Ablashi, D. V. [Editor]; de The, G. [Editor]; Lenoir, G. [Editor]; Pearson, G. R. [Editor]. Colloque INSERM, (1993) Vol. 225, pp. 69-75. INSERM Colloquium; The Epstein-Barr virus and associated diseases. Colloque INSERM; Le virus d'Epstein-Barr et les maladies associees.
Publisher: INSERM (Institut National de la Sante et de la Recherche Medicale) 101, rue de Tolbiac, 75654 Paris Cedex 13, France.
Meeting Info.: Vth International Symposium Annecy, France September 13-19, 1992
ISSN: 0768-3154. ISBN: 2-85598-513-7, 2-7420-0008-9.
DT Book; Conference
LA English

L4 ANSWER 23 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 8
AN 1994:131550 CAPLUS
DN 120:131550
TI Hydrophilic polystyrene-polyoxyethylene graft polymer beads as carrier of antigenic peptides for in vivo and in vitro immunization techniques: applications to the non-catalytic zinc loop of HLADH isoenzymes and to ***histone*** fragments

AU ***Zeppezauer, Michael*** ; Hoffmann, Ralf; Schoenberger, Arno; Rawer, Stephan; Rapp, Wolfgang; Bayer, Ernst
CS Dep. Biochem., Univ. Saarland, Saarbruecken, D-66123, Germany
SO Zeitschrift fuer Naturforschung, B: Chemical Sciences (1993), 48(12), 1801-6
CODEN: ZNBSEN; ISSN: 0932-0776
DT Journal
LA English
AB Immunogenic materials were obtained by synthesizing on tentacle polymer-bound amino derivs. as a solid support the following haptens: the C-terminal sequence 187-211 KPKAA KPKAA KPKAA KPKAA KPKKA APKKK and the N-terminal sequence 3-31 APAAP AAAPP AEKTP VKKKA AKKPA GA of ***histone*** ***H1*** (calf thymus), as well as the sequences 93-116 of the horse liver alc. dehydrogenase EE (FTPQC GKCRV CKHPE GNFCL KNDL) and SS (FIPQC GKCSV CKHPE GNLCL KNSL) isoenzymes (Joernvall, H., 1970), resp. These materials proved to be efficient immunogens both in vivo and in vitro, showing excellent biocompatibility compared to other solid hapten carriers. Tentacle-based immunogens are generally available by std. synthetic procedures either by in situ synthesis of hapten mols. on or by covalent attachment of available antigens or haptens to the beads. Advantageous is the possibility to synthesize the peptide on the tentacle polymer, and to use the solid phase bound peptide directly as hapten. The beads serve as carriers, and no sep. splitting off the peptide and binding to another carrier is necessary.

L4 ANSWER 24 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1994:2598 BIOSIS
DN PREV199497015598
TI Separation of ***histone*** ***H1*** subtypes from calf thymus by reversed phase chromatography.
AU Hoffmann, Ralf; Berger, Renate G.; ***Zeppezauer, Michael***
CS Univ. Saarlandes, Biochemie, Postfach 1150, 66041 Saarbruecken Germany
SO Biological Chemistry Hoppe-Seyler, (1993) Vol. 374, No. 9, pp. 768-769.
Meeting Info.: Annual Autumn Meeting of the Gesellschaft fuer Biologische Chemie (Society for Biological Chemistry) Duesseldorf, Germany September 12-15, 1993
ISSN: 0177-3593.
DT Conference
LA English

L4 ANSWER 25 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1994:2451 BIOSIS
DN PREV199497015451
TI Predicted and experimentally screened epitopes in anti- ***histone*** autoantibodies from systemic lupus erythematosus.
AU Hoffman, Ralf (1); Schoenberg, Arno; Cebecauer, Ladislav; ***Zeppezauer,*** *** Michael (1)***
CS (1) Univ. Saarlandes, Biochemie, Postfach 1150, 66041 Saarbruecken Germany
SO Biological Chemistry Hoppe-Seyler, (1993) Vol. 374, No. 9, pp. 715-716.
Meeting Info.: Annual Autumn Meeting of the Gesellschaft fuer Biologische Chemie (Society for Biological Chemistry) Duesseldorf, Germany September 12-15, 1993
ISSN: 0177-3593.
DT Conference
LA English

L4 ANSWER 26 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 9
AN 1993:411569 BIOSIS
DN PREV199396077294
TI Immunological detection of proteins associated with the Epstein-Barr virus nuclear antigen 2A.
AU Grasser, Friedrich A. (1); Sauder, Christian; Haiss, Peter; Hille, Annette; Koenig, Sigrid; Goettel, Susanne; Kremmer, Elisabeth; Leinenbach, Hans Peter; ***Zeppezauer, Michael*** ; Mueller-Lantzsch, Nikolaus
CS (1) Abt. Virologie, Institut Med. Mikrobiologie Hyg., Universitaetskliniken Saarlandes, Gebaeude 47, 6650 Homburg Germany
SO Virology, (1993) Vol. 195, No. 2, pp. 550-560.
ISSN: 0042-6822.
DT Article
LA English
AB The Epstein-Barr virus nuclear antigen 2A (EBNA-2A) has been strongly implicated in the EBV-mediated B-cell transformation process. Since EBNA-2A might exert this function through interaction with proteins of the infected cell, we studied the association of EBNA-2A with cellular proteins. Immunoprecipitation of EBNA-2A from 32P-labeled cell extracts separated by sucrose gradient centrifugation revealed the presence of phosphoproteins complexed with the two forms of the EBNA-2A sedimenting at 13 S and 34 S. Prominent bands were observed at 250, 170, 120, 110, 105, and 95 kDa with minor species at 78, 52, 45, 31, 26, 22 and 18 kDa. By "West-Western" or "Far-Western" blotting using EBNA-2A protein from insect cells as a probe we detected binding to proteins migrating with apparent molecular masses of about 200, 130, 110, 105, 95, and 31 kDa with minor species detectable at 90, 68, 50-55, 40, and 17 kDa. The protein with an apparent molecular mass of 31 kDa was identified by competition experiments as ***histone*** ***H1*** . Some of the EBNA-2A-complexed phosphoproteins, notably the proteins of 110 and 95 kDa, comigrated with the proteins detectable by "West-Western" analysis. The binding of EBNA-2A to the 130-kDa protein was stable against up to 1.5 M NaCl and could not be competed with ***histone*** ***H1*** . In a similar experiment, the less transforming EBNA-2B which is encoded by the subtype 2 virus bound to most of the proteins detected with EBNA-2A but with strongly reduced efficiency to the protein of 130 kDa indicating that this protein might be a target for EBNA-2 during EBV-mediated transformation.

L4 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:319283 CAPLUS
DN 120:319283
TI Detection of proteins associated with the Epstein-Barr virus nuclear antigen 2: EBNA-2A binds to ***histone*** ***H1*** and unknown cellular proteins of 130, 110, 105 and 95 kDa
AU Graesser, Friedrich A.; Sauder, Christian; Haiss, Peter; Hille, Annette; Konig, Sigrid; Goette, Suzanne; Kremmer, Elisabeth; Leinenbach, Hans Peter; ***Zeppezauer, Michael*** ; Mueller-Lantzsch, Nikolaus
CS Abte. Virol., Universitaetsklin. Saarlandes, Homburg, 6650, Germany
SO Colloque INSERM (1993), 225(Epstein-Barr Virus and Associated Diseases), 69-75
CODEN: CINMDE; ISSN: 0768-3154
DT Journal

LA English
AB The assocn. of EBNA-2A with cellular proteins was studied. Immunopptn. of EBNA-2A from 32P-labeled cell exts. sepd. by sucrose gradient centrifugation revealed the presence of phosphoproteins complexed with the two forms of the EBNA-2A sedimenting at 13S and 34S. Prominent bands were obsd. at 250, 170, 120, 110, 105 and 95 kDa with minor species at 78, 52, 45, 31, 26, 22 and 18 kDa. By "West-Western"- or "Far-Western"- blotting using EBNA-2A protein from insect cells as a probe, the authors detected binding to proteins migrating with apparent mol. masses of about 200, 130, 110, 105, 95 and 31 kDa with minor species detectable at 90, 68, 50-55, 40 and 17 kDa. The protein with an apparent mol. mass of 31 kDa was identified by competition expts. as ***histone*** ***H1*** . The 110 kDa and 95 kDa phosphoproteins comigrated with the proteins detectable by "West-Western"-anal. The binding of EBNA-2A to the 130 kDa protein was stable against up to 1.5 M NaCl and could not be competed with ***histone*** ***H1*** . In a similar expt., EBNA-2B which is encoded by the less transforming subtype 2 virus bound to most of the proteins detected with EBNA-2A but failed to bind to the 130 kDa protein, indicating that this protein might be a target for EBNA-2A during EBV-mediated transformation.

L4 ANSWER 28 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1992:539651 BIOSIS
DN BR43:125351
TI PURIFICATION AND DETERMINATION OF MOLECULAR WEIGHTS OF ***HISTONE*** ***H1*** SUBTYPES FROM CALF THYMUS.
AU BERGER R G; HOFFMANN R; ***ZEPPEZAUER M*** ; WAIDELICH D; BAYER E
CS UNIVERSITAET DES SAARLANDES, FR 12.4 BIOCHEMIE, IM STADTWALD, W-6600 SAARBRUECKEN, GER.
SO 100TH CONFERENCE OF THE GESELLSCHAFT FUER BIOLOGISCHE CHEMIE (SOCIETY FOR BIOLOGICAL CHEMISTRY) ON STRUCTURAL AND FUNCTIONAL ANALYSIS OF PROTEINS, ROSTOCK, GERMANY, SEPTEMBER 25, 1992. BIOL CHEM HOPPE-SEYLER. (1992) 373 (9), 885-886.
CODEN: BCHSEI. ISSN: 0177-3593.
DT Conference
FS BR; OLD
LA English

L4 ANSWER 29 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1993:44644 BIOSIS
DN PREV199344021494
TI Synthesis of branched peptides with sequences taken from ubiquitinated ***histones*** H2A and H2B from calf thymus.
AU Wachs, W. O. (1); Hoffmann, R. (1); Berger, R. G. (1); Kuhn, S. (1); ***Zeppezauer, M. (1)*** ; Waidelich, D.; Bayer, E.
CS (1) Univ. Saarlandes, FB 12.4. Biochem., W-6600 Saarbruecken 11 Germany
SO Biological Chemistry Hoppe-Seyler, (1992) Vol. 373, No. 9, pp. 834-835.
Meeting Info.: Autumn Meeting of the Gesellschaft fuer Biologische Chemie (German Society for Biological Chemistry), Rostock, Germany, September 24-26, 1992. BIOL CHEM HOPPE-SEYLER
ISSN: 0177-3593.
DT Conference
LA English

L4 ANSWER 30 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1991:485413 CAPLUS
DN 115:85413
TI Synergistic neoplasm inhibitors comprising cytostatics and ***histones***
IN ***Zeppezauer, Michael*** ; Leinenbach, Hans Peter
PA SYMBIOTEC Gesellschaft fuer Forschung und Entwicklung auf dem Gebiet der Biotechnologie G.m.b.H., Germany
SO Ger. Offen., 8 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 4000154	A1	19910711	DE 1990-4000154	19900104
EP 438756	A1	19910731	EP 1990-125093	19901221
EP 438756	B1	19940420		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 104553	E	19940515	AT 1990-125093	19901221
CA 2033249	AA	19910705	CA 1990-2033249	19901227
CA 2033249	C	19970127		
JP 04305535	A2	19921028	JP 1990-417523	19901228
JP 08013756	B4	19960214		
CZ 283924	B6	19980715	CZ 1990-6849	19901228
SK 279960	B6	19990611	SK 1990-6849	19901228
US 5578571	A	19961126	US 1994-310378	19940922
PRAI DE 1990-4000154		19900104		
EP 1990-125093		19901221		
US 1990-635709		19901228		

AB Compns. comprising known cytostatic agents (vincristine, methotrexate, cisplatin) and ***histone*** (s) are synergistic neoplasm inhibitors. ***Histones*** ***H1*** , H2A, H2B, H3, and their fragments may be used. Vincristine + ***histones*** H2A:H2B (5 + 100 .mu.g/mL) synergistically inhibited the growth of OH 77 lymphoma cells3in vitro.

L4 ANSWER 31 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:67017 CAPLUS
DN 116:67017
TI Hydrophilic polystyrene-polyoxyethylene graft polymer beads as carriers of antigenic structures for in vivo and in vitro immunization techniques: application to the noncatalytic zinc loop of LADH isozymes and to ***histone*** fragments
AU ***Zeppezauer, M.*** ; Rawer, S.; Hoffmann, R.; Schoenberger, A.; Rapp, W.; Bayer, E.
CS Fr. 14.4 Biochem., Univ. Saarbruecken, Saarbruecken, D-6600, Germany
SO Pept. 1990, Proc. Eur. Pept. Symp., 21st (1991), Meeting Date 1990, 847-8. Editor(s): Giralt, Ernest; Andreu, David. Publisher: ESCOM Sci. Publ., Leiden, Neth.
CODEN: 57HNAI
DT Conference
LA English
AB A novel type of spherical particles, i.e. polystyrene-polyoxyethylene graft polymer beads Tentagel were used as carriers for antigenic peptides. The use of Tentagel showed several advantages for immunization techniques.

L4 ANSWER 32 OF 38 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN
AN 91050518 EMBASE
DN 1991050518
TI Growth inhibition of human lymphatic cancer cells by the homeostatic thymic hormone in vitro.
AU Lindman S.; Leinenbach H.P.; Korsgaard R.; Class R.; Hollemeyer K.; Reichhart R.; ***Zeppezauer M.***
CS Fachrichtung 12.4 Biochemie, Universitat des Saarlandes,D-6600 Saarbrucken, Germany
SO Medical Science Research, (1991) 19/1 (27-28).
ISSN: 0269-8951 CODEN: MSCREJ
CY United Kingdom
DT Journal; Article
FS 003 Endocrinology
005 General Pathology and Pathological Anatomy
016 Cancer
025 Hematology
LA English

L4 ANSWER 33 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:199669 CAPLUS
DN 114:199669
TI Thymus ***histones*** as drugs for the treatment of cancer, endocrine malfunctions, and immune disturbances
IN ***Zeppezauer, Michael*** ; Reichhart, Robert
PA SYMBIOTEC Gesellschaft fuer Forschung und Entwicklung auf dem Gebiet der Biotechnologie G.m.b.H., Germany
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 392315	A1	19901017	EP 1990-106311	19900402
EP 392315	B1	19940921		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5182257	A	19930126	US 1989-332658	19890403
PRAI US 1989-332658		19890413		
DE 1984-3405620		19840216		
DE 1984-3400928		19841201		
US 1985-777783		19850912		

AB ***Histone*** ***H1*** , its active segments, and the ***histone*** dimer H2A:H2B or its segments, with hormonelike activity, esp. thymic hormonelike activity, are drugs for the treatment of immune and endocrine disturbances, and neoplasm inhibitors. ***Histone*** ***H1*** was obtained from calf thymus. ***Histone*** ***H1*** (250 .mu.g/mL) caused 96% decay of DAUDI Burkitt lymphoma cells in vitro after 2 days of exposure.

L4 ANSWER 34 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 10
AN 1989:232345 BIOSIS
DN BR36:110829
TI BIOLOGICALLY ACTIVE SUBSTANCE WITH HORMONAL PROPERTIES PRODUCTION PROCESS

THEREOF AND UTILIZATION OF ***HISTONES*** FOR MEDICAL PURPOSES.
AU RUSCH V; REICHHART R; ***ZEPPEZAUER M*** ; JORNVALL H
CS SCHWALBENWEG 6, 6348 HERBORN, WEST GERMANY.
ASSIGNEE: RUSCH, VOLKER
PI US 4818763 04 Apr 1989
SO Off. Gaz. U. S. Pat. Trademark Off., Pat., (1989) 1101 (1), 532-533.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
FS BR; OLD
LA English

L4 ANSWER 35 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1990:151860 CAPLUS
DN 112:151860
TI ***Histones*** H2A and H2B as immunomodulators and drugs for the treatment of cancer and endocrine disorders
IN ***Zeppezauer, Michael*** ; Reichhart, Robert
PA Rusch, Volker, Fed. Rep. Ger.
SO Ger. Offen., 8 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 3737274	A1	19890601	DE 1987-3737274	19871103
PRAI DE 1987-3737274		19871103		

AB ***Histones*** H2A and/or H2B are drugs for immunotherapy, treatment of hormonal disturbances, cancer, AIDS, and irradn.-induced leukemia. Other therapeutic indications include hypophyseal stimulation and alleviation of the neg. effect of thymectomy. A mixt. of ***histones*** H2A and H2B (200 .mu.g/mL) decreased the vitality of the myeloma cell line P3Ag8.653 in vitro.

L4 ANSWER 36 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:573011 CAPLUS
DN 103:173011
TI Biologically active substance with hormonal properties, and utilization of ***histones*** for medical purposes
IN Rusch, Volker; Reichhart, Robert; ***Zeppezauer, Michael*** ; Joernvall, Hans
PA Fed. Rep. Ger.
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 8503003	A1	19850718	WO 1985-DE4	19850110
W: JP, US				
DE 3400928	A1	19850919	DE 1984-3400928	19840112
DE 3405620	A1	19850905	DE 1984-3405620	19840216
EP 149468	A2	19850724	EP 1985-100179	19850110
EP 149468	A3	19850814		

EP 149468 B1 19901031
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE
JP 61500913 T2 19860508 JP 1985-500453 19850110
AT 57835 E 19901115 AT 1985-100179 19850110
CA 1251134 A1 19890314 CA 1985-471963 19850111
US 4818763 A 19890404 US 1985-777783 19850912
PRAI DE 1984-3400928 19840112
DE 1984-3405620 19840216
EP 1985-100179 19850110
WO 1985-DE4 19850110
AB ***Histones*** H2A and H2B have the immunol. and endocrinol. properties of the thymus hormone. The ***histones*** can be extd. from the calf thymus. Active prepns. may also contain only the variable evolution segments or part of .gtoreq.1 H2 ***histone*** . The findings are based on the identity of the active HTH.alpha. (HTH = homogeneous thymic hormone) and HTH.beta. prepns. with the 2 ***histones*** .

L4 ANSWER 37 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 11
AN 1985:415420 BIOSIS
DN BA80:85412
TI PREPARATIONS OF HOMEOSTATIC THYMUS HORMONE CONSIST PREDOMINANTLY OF ***HISTONES*** H-2A AND H-2B AND SUGGEST ADDITIONAL ***HISTONE*** FUNCTIONS.
AU REICHHART R; ***ZEPPEZAUER M*** ; JORNVALL H
CS DEPARTMENT CHEMISTRY I, KAROLINSKA INSTITUTE, S-104 01 STOCKHOLM, SWEDEN.
SO PROC NATL ACAD SCI U S A, (1985) 82 (15), 4871-4875.
CODEN: PNASA6. ISSN: 0027-8424.
FS BA; OLD
LA English
AB The 2 major constituents in preparations of the homeostatic [calf] thymus hormone (HTH) were purified. Amino acid sequence analysis showed that the components (HTH.alpha. and HTH.beta.) are identical to ***histones*** H2A and H2B, suggesting the possibility that ***histones*** might have hitherto unrecognized occurrence and functions. If the HTH activities are not ascribed to the 2 ***histones*** in the preparation, they could only be derived from minor constituents present in minimal amounts. The ***histone*** structures were scrutinized for properties or relevance in relation to hormone activities and for similarities with thymic hormones. Similarities between COOH-terminal regions of ***histones*** H2A, H2B and H3 were noticed, as well as some similarities between NH2-terminal regions of ***histones*** and parts of recognized thymus hormones and related proteins. Potential signals, resembling cleavage sites in prohormones, are present in the ***histone*** structures, and further correlations with recently discovered ubiquitin functions may explain molecular mechanisms for actions of the HTH preparations. None of the observations is significant by itself, but the combined results suggest the hypothesis of different relationships and functions, including hormone-like activities, for some ***histones*** .

L4 ANSWER 38 OF 38 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 12
AN 1985:212384 BIOSIS
DN BR29:102380

TI THE PRIMARY STRUCTURE OF 2 POLYPEPTIDE CHAINS FROM PREPARATIONS OF HOMEOSTATIC THYMUS HORMONES ALPHA AND BETA ENTIRE-CHAIN IDENTITIES TO 2 ***HISTONES*** .

AU REICHHART R; JORNVALL H; CARLQUIST M; ***ZEPPEZAUER M***

CS FACHBEREICH 15.2, ANALYTISCHE BIOL. CHEM., UNIV. SAARLANDES, D-6600 SAARBRUEKEN, FRG.

SO FEBS Lett., (1985) 188 (1), 63-67.
CODEN: FEBLAL. ISSN: 0014-5793.

FS BR; OLD

LA English

=> s histone? and h1
L5 22069 HISTONE? AND H1
=> s l5 and (eukaryot? or eucaryot?)
L6 2033 L5 AND (EUKARYOT? OR EUCARYOT?)
=> dup rem l6
PROCESSING IS APPROXIMATELY 45% COMPLETE FOR L6
PROCESSING IS APPROXIMATELY 69% COMPLETE FOR L6
PROCESSING COMPLETED FOR L6
L7 1104 DUP REM L6 (929 DUPLICATES REMOVED)
=> s l7 and (antimicrobi? or antibacter?)
L8 132 L7 AND (ANTIMICROBI? OR ANTIBACTER?)
=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 132 ANSWERS - CONTINUE? Y/(N):y
L8 ANSWER 1 OF 132 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:115183 CAPLUS
DN 134:168376
TI ***Antimicrobial*** ***histone*** ***H1*** compositions, kits, and methods of use thereof
IN Class, Reiner; Zeppezauer, Michael
PA Symbiotec Gm.b.H., Germany; Philadelphia Health and Education Corp.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001010901	A2	20010215	WO 2000-US21747	20000809
WO 2001010901	A3	20010809		
WO 2001010901	C2	20020912		
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 2001046976	A1	20011129	US 1999-372500	19990811
US 6565854	B2	20030520		
EP 1200463	A2	20020502	EP 2000-957347	20000809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

PRAI US 1999-372500 A 19990811
US 1998-96382P P 19980813
WO 2000-US21747 W 20000809
AB The invention includes antibiotic pharmaceutical compns. comprising ***eukaryotic*** ***histone*** ***H1*** protein and methods of using ***eukaryotic*** ***histone*** ***H1*** protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a ***eukaryotic*** ***histone*** ***H1*** -contg. animal feed and methods of improving growth of an animal by supplying the feed to the animal. The invention still further includes a kit comprising a ***eukaryotic*** ***histone*** ***H1*** -contg. antibiotic pharmaceutical compn. and an instructional material which describes the use of the compn. In addn., the invention includes a vaccine comprising a ***eukaryotic*** ***histone*** ***H1*** protein and a method of vaccinating an animal using the vaccine.

L8 ANSWER 2 OF 132 USPATFULL on STN
AN 2003:215360 USPATFULL
TI Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
IN Kaelin, William G., JR., Boston, MA, UNITED STATES
Livingston, David M., Brookline, MA, UNITED STATES
Kim, Tae-You, Seoul, KOREA, REPUBLIC OF
PI US 2003150005 A1 20030807
AI US 2002-287670 A1 20021104 (10)
RLI Continuation-in-part of Ser. No. US 2002-101662, filed on 19 Mar 2002, PENDING
PRAI US 2001-277425P 20010320 (60)
US 2001-277431P 20010320 (60)
US 2001-277440P 20010320 (60)
US 2001-332493P 20011109 (60)
US 2001-332334P 20011109 (60)
US 2001-345200P 20011109 (60)
US 2001-345131P 20011220 (60)
US 2001-342598P 20011220 (60)
US 2001-345132P 20011220 (60)
DT Utility
FS APPLICATION
LREP MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 3741
AB Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is "turned on" only under such conditions.

L8 ANSWER 3 OF 132 USPATFULL on STN
AN 2003:213734 USPATFULL
TI Method to screen phage display libraries with different ligands
IN Tomlinson, Ian, Cambridge, UNITED KINGDOM
Winter, Greg, London, UNITED KINGDOM
PI US 2003148372 A1 20030807
AI US 2001-968744 A1 20011001 (9)
RLI Division of Ser. No. US 2000-511939, filed on 24 Feb 2000, PENDING
PRAI GB 1997-22131 19971020
DT Utility
FS APPLICATION
LREP PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS / STR, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2176

AB The present invention relates to methods for selecting repertoires of polypeptides using generic and target ligands. In particular, the invention relates to a library wherein the folded members have binding sites for both generic and target ligands.

L8 ANSWER 4 OF 132 USPATFULL on STN
AN 2003:207869 USPATFULL
TI Peptide-enhanced transfections
IN Hawley-Nelson, Pamela, Silver Spring, MD, UNITED STATES
Lan, Jianqing, Germantown, MD, UNITED STATES
Shih, PoJen, Columbia, MD, UNITED STATES
Jessee, Joel A., Mt. Airy, MD, UNITED STATES
Schifferli, Kevin P., Germantown, MD, UNITED STATES
Gebeyehu, Gulilat, Silver Spring, MD, UNITED STATES
Ciccarone, Valentina C., Gaithersburg, MD, UNITED STATES
Evans, Krista L., Germantown, MD, UNITED STATES
PI US 2003144230 A1 20030731
AI US 2002-200879 A1 20020723 (10)
RLI Continuation of Ser. No. US 2001-911569, filed on 23 Jul 2001, PENDING Continuation of Ser. No. US 1998-39780, filed on 16 Mar 1998, GRANTED, Pat. No. US 6376248 Continuation-in-part of Ser. No. US 1997-818200, filed on 14 Mar 1997, GRANTED, Pat. No. US 6051429 Continuation-in-part of Ser. No. US 1996-658130, filed on 4 Jun 1996, GRANTED, Pat. No. US 5736392 Continuation-in-part of Ser. No. US 1995-477354, filed on 7 Jun 1995, ABANDONED
DT Utility
FS APPLICATION
LREP GREENLEE WINNER AND SULLIVAN P C, 5370 MANHATTAN CIRCLE, SUITE 201, BOULDER, CO, 80303
CLMN Number of Claims: 77
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 4805
AB The present invention provides compositions useful for transfecting ***eukaryotic*** cells comprising nucleic acid complexes with peptides, wherein the peptide is optionally covalently coupled to a nucleic acid-binding group, and cationic lipids or dendrimers as transfection agents. The invention also provides transfection compositions in which a peptide is covalently linked to the transfection agent (lipid, cationic lipid or dendrimer). Inclusion of peptides or modified-peptides in transfection compositions or covalent attachment of peptides to transfection agents results in enhanced transfection efficiency. Methods for the preparation of transfection compositions and methods of using these transfection compositions as intracellular delivery agents and extracellular targeting agents are also disclosed.

L8 ANSWER 5 OF 132 USPATFULL on STN
AN 2003:207194 USPATFULL
TI Novel compositions and methods for the identification, assessment, prevention and therapy of human cancers
IN Clark, Edwin, Ashland, MA, UNITED STATES
Grenfell-Lee, Tallessyn, Cambridge, MA, UNITED STATES
Lu, Karen, Houston, TX, UNITED STATES
Hartmann, Lynn, Rochester, MN, UNITED STATES
Brown, Jeffrey L., Arlington, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02139 (U.S. corporation)
PI US 2003143552 A1 20030731
AI US 2002-71510 A1 20020208 (10)
PRAI US 2001-267276P 20010208 (60)
DT Utility
FS APPLICATION
LREP LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 69
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4574
AB The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of sensitivity and resistance markers. These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of "resistance markers." These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

L8 ANSWER 6 OF 132 USPATFULL on STN
AN 2003:206860 USPATFULL
TI Compositions containing nucleic acids and ligands for therapeutic treatment
IN Baird, J. Andrew, London, UNITED KINGDOM
Chandler, Lois Ann, Encinitas, CA, UNITED STATES
Sosnowski, Barbara A., Coronado, CA, UNITED STATES
PA Selective Genetics, Inc., San Diego, CA (non-U.S. corporation)
PI US 2003143217 A1 20030731
AI US 2002-189360 A1 20020702 (10)
RLI Continuation of Ser. No. US 1999-449249, filed on 24 Nov 1999, GRANTED, Pat. No. US 6503886 Continuation of Ser. No. US 1996-718904, filed on 24 Sep 1996, GRANTED, Pat. No. US 6037329 Continuation-in-part of Ser. No. US 1995-441979, filed on 16 May 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-213446, filed on 15 Mar 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-213447, filed on 15 Mar 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-305771, filed on 13 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-297961, filed on 29 Aug 1994, ABANDONED
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 7685
AB Preparations of conjugates of a receptor-binding internalized ligand and

a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.

L8 ANSWER 7 OF 132 USPATFULL on STN
AN 2003:206847 USPATFULL
TI Inhibition of RNA function by delivery of inhibitors to animal cells
IN Lewis, David L., Madison, WI, UNITED STATES
Hagstrom, James E., Madison, WI, UNITED STATES
Herweijer, Hans, Madison, WI, UNITED STATES
Loomis, Aaron G., Prairie du Sac, WI, UNITED STATES
Monahan, Sean D., Madison, WI, UNITED STATES
Trubetskoy, Vladimir S., Madison, WI, UNITED STATES
Wolff, Jon A., Madison, WI, UNITED STATES
PI US 2003143204 A1 20030731
AI US 2002-186757 A1 20020701 (10)
RLI Continuation-in-part of Ser. No. US 2001-917154, filed on 27 Jul 2001, PENDING
PRAI US 2001-315394P 20010827 (60)
US 2001-324155P 20010920 (60)
DT Utility
FS APPLICATION
LREP Mark K. Johnson, Mirus, 505 South Rosa Road, Madison, WI, 53719
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2010
AB Described is a process for delivering an inhibitor directed against an expressible nucleic acid sequence in a mammal to inhibit RNA function. An RNA function inhibiting sequence that is specific to the expressible nucleic acid sequence in the mammal is made and inserted into a blood vessel in the mammal. The inhibitor is delivered to a cell wherein expression of the nucleic acid sequence is inhibited.

L8 ANSWER 8 OF 132 USPATFULL on STN
AN 2003:201388 USPATFULL
TI Combined methods for tumor vasculature coagulation and treatment
IN Thorpe, Philip E., Dallas, TX, UNITED STATES
King, Steven W., Rancho Santa Margarita, CA, UNITED STATES
Gottstein, Claudia, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System and Peregrine Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003139374 A1 20030724
AI US 2002-259236 A1 20020927 (10)
PRAI US 2001-325532P 20010927 (60)
DT Utility
FS APPLICATION
LREP Shelley P.M. Fussey, Williams, Morgan & Amerson, P.C., Suite 250, 7676

Hillmont, Houston, TX, 77040
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 10003
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are various defined combinations of agents for use in improved anti-vascular therapies and coagulative tumor treatment. Particularly provided are combined treatment methods, and associated compositions, pharmaceuticals, medicaments, kits and uses, which together function surprisingly effectively in the treatment of vascularized tumors. The invention preferably involves a component or treatment step that enhances the effectiveness of therapy using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.

L8 ANSWER 9 OF 132 USPATFULL on STN
AN 2003:200457 USPATFULL
TI Multimeric proteins and methods of making and using same
IN Fang, Fang, San Diego, CA, UNITED STATES
Luo, Guang-Xiang, San Diego, CA, UNITED STATES
Kohlstaedt, Lori Allison, La Jolla, CA, UNITED STATES
Charles, Catherine Helen, Encinitas, CA, UNITED STATES
PI US 2003138440 A1 20030724
AI US 2002-199957 A1 20020719 (10)
PRAI US 2001-306746P 20010719 (60)
US 2001-335425P 20011130 (60)
DT Utility
FS APPLICATION
LREP Pillsbury Winthrop LLP, Intellectual Property Group, P.O. Box 10500, McLean, VA, 22102
CLMN Number of Claims: 112
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 3098
AB The invention provides multimerization polypeptides capable of conferring formation of multimers when the multimerization polypeptide is linked to a molecule, such as a heterologous polypeptide sequence.

L8 ANSWER 10 OF 132 USPATFULL on STN
AN 2003:194161 USPATFULL
TI Senescent cell-derived inhibitors of DNA synthesis
IN Smith, James R., Houston, TX, UNITED STATES
Noda, Asao, Kita-ku, JAPAN
Adami, Guy, Chicago, IL, UNITED STATES
PI US 2003133971 A1 20030717
AI US 2001-8960 A1 20011207 (10)
RLI Continuation of Ser. No. US 1994-327874, filed on 24 Oct 1994, GRANTED, Pat. No. US 6372249 Continuation-in-part of Ser. No. WO 1994-US9700, filed on 26 Aug 1994, PENDING Continuation-in-part of Ser. No. US 1994-274535, filed on 13 Jul 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-229420, filed on 15 Apr 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-203535, filed on 25 Feb 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-153564, filed on 17 Nov 1993, ABANDONED Continuation-in-part of Ser. No. US 1993-113372, filed on 30 Aug 1993, ABANDONED Continuation-in-part of Ser. No. US

1992-970462, filed on 2 Nov 1992, GRANTED, Pat. No. US 5302706 Continuation-in-part of Ser. No. US 1994-160814, filed on 3 Jan 1994, GRANTED, Pat. No. US 5424400 Continuation-in-part of Ser. No. US 1994-268439, filed on 30 Jun 1994, ABANDONED Continuation-in-part of Ser. No. US 1991-808523, filed on 16 Dec 1991, ABANDONED
DT Utility
FS APPLICATION
LREP CLIFFORD CHANCE US LLP, 200 PARK AVENUE, NEW YORK, NY, 10166
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 5449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening untranslated regions.

L8 ANSWER 11 OF 132 USPATFULL on STN
AN 2003:187407 USPATFULL
TI Combined methods for tumor vasculature coaguligand treatment
IN Thorpe, Philip E., Dallas, TX, UNITED STATES
King, Steven W., Rancho Santa Margarita, CA, UNITED STATES
Gottstein, Claudia, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System and Peregrine Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003129193 A1 20030710
AI US 2002-259227 A1 20020927 (10)
PRAI US 2001-325532P 20010927 (60)
DT Utility
FS APPLICATION
LREP Shelley P.M. Fussey, Williams, Morgan & Amerson, P.C., Suite 250, 7676 Hillmont, Houston, TX, 77040
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 10012
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are various defined combinations of agents for use in improved anti-vascular therapies and coagulative tumor treatment. Particularly provided are combined treatment methods, and associated compositions, pharmaceuticals, medicaments, kits and uses, which together function surprisingly effectively in the treatment of vascularized tumors. The invention preferably involves a component or treatment step that enhances the effectiveness of therapy using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.

L8 ANSWER 12 OF 132 USPATFULL on STN
AN 2003:180797 USPATFULL
TI Diagnostic and therapeutic compositions and methods related to chemokine (C motif) XC receptor 1 (CCXCR1), a G protein-coupled receptor (GPCR)
IN Burmer, Glenna C., Seattle, WA, UNITED STATES
Woodward, Madeline L., Mercer Island, WA, UNITED STATES
Roush, Christine L., Seattle, WA, UNITED STATES

Brown, Joseph P., Seattle, WA, UNITED STATES
PI US 2003124627 A1 20030703
AI US 2002-206401 A1 20020726 (10)
PRAI WO 2001-US45218 20011129
DT Utility
FS APPLICATION
LREP Joshua King, GRAYBEAL JACKSON HALEY LLP, Suite 350, 155-108th Avenue N.E., Bellevue, WA, 98004-5901
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4499
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Systems, methods, compositions, and the like, such as diagnostics, medicaments, and therapeutics relating to CCXCR1 and allergic rhinitis, rheumatoid arthritis, cancers including ovarian, colonic, pancreatic, and prostatic carcinoma, and wound healing. Such diagnostics and therapeutics include peptide, protein, antibody, and nucleic acid based compositions, including agonists, antagonists, probes, antisense, and gene therapy compositions.

L8 ANSWER 13 OF 132 USPATFULL on STN
AN 2003:180711 USPATFULL
TI Interventions to mimic the effects of calorie restriction
IN Spindler, Stephen R., Riverside, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 2003124540 A1 20030703
AI US 2002-56749 A1 20020122 (10)
RLI Continuation of Ser. No. US 2000-648642, filed on 25 Aug 2000, GRANTED, Pat. No. US 6406853
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Long term calorie restriction has the benefit of increasing life span. Methods to screen interventions that mimic the effects of calorie restriction are disclosed. Extensive analysis of genes for which expression is statistically different between control and calorie restricted animals has demonstrated that specific genes are preferentially expressed during calorie restriction. Screening for interventions which produce the same expression profile will provide interventions that increase life span. In a further aspect, it has been discovered that test animals on a calorie restricted diet for a relatively short time have a similar gene expression profile to test animals which have been on a long term calorie restricted diet.

L8 ANSWER 14 OF 132 USPATFULL on STN
AN 2003:180701 USPATFULL
TI Sequence-directed DNA-binding molecules compositons and methods
IN Edwards, Cynthia A., Menlo Park, CA, UNITED STATES

Cantor, Charles R., Del Mar, CA, UNITED STATES
Andrews, Beth M., Maynard, MA, UNITED STATES
Turin, Lisa M., Redwood City, CA, UNITED STATES
Fry, Kirk E., Palo Alto, CA, UNITED STATES
PA Genelabs Technologies, Inc. (U.S. corporation)
PI US 2003124530 A1 20030703
AI US 2001-993346 A1 20011113 (9)
RLI Division of Ser. No. US 1999-354947, filed on 15 Jul 1999, GRANTED, Pat. No. US 6384208 Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, GRANTED, Pat. No. US 6010849 Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, GRANTED, Pat. No. US 5578444 Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, GRANTED, Pat. No. US 5726014 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, GRANTED, Pat. No. US 5693463 Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, ABANDONED
DT Utility
FS APPLICATION
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 47 Drawing Page(s)
LN.CNT 10851
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L8 ANSWER 15 OF 132 USPATFULL on STN
AN 2003:180305 USPATFULL
TI Combined compositions for tumor vasculature coaguligand treatment
IN Thorpe, Philip E., Dallas, TX, UNITED STATES
King, Steven W., Rancho Santa Margarita, CA, UNITED STATES
Gottstein, Claudia, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2003124132 A1 20030703
AI US 2002-259223 A1 20020927 (10)
PRAI US 2001-325532P 20010927 (60)
DT Utility
FS APPLICATION
LREP Shelley P.M. Fussey, Ph.D., WILLIAMS, MORGAN & AMERSON, P.C., Suite 1100, 10333 Richmond Avenue, Houston, TX, 77042
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 10025

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are various defined combinations of agents for use in improved anti-vascular therapies and coagulative tumor treatment. Particularly provided are combined treatment methods, and associated compositions, pharmaceuticals, medicaments, kits and uses, which together function surprisingly effectively in the treatment of vascularized tumors. The invention preferably involves a component or treatment step that enhances the effectiveness of therapy using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.

L8 ANSWER 16 OF 132 USPATFULL on STN
AN 2003:180284 USPATFULL
TI ***Antimicrobial*** agent
IN Rothman, Ulf, St. Peter Port, UNITED KINGDOM
PI US 2003124111 A1 20030703
AI US 2002-231400 A1 20020829 (10)
PRAI SE 2001-2864 20010829
DT Utility
FS APPLICATION
LREP JAMES RAY & ASSOCIATES, 2640 Pitcairn Road, Monroeville, PA, 15146
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 692
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of a proteineous component isolated from plant chromatin, after dissociation of the same, as an ***antimicrobial*** agent, the proteineous component having an apparent molecular weight between 10 and 20 kD. The proteineous plant component is produced by means of a method comprising the steps of homogenizing a plant material in order to expose its plant chromatin, dissociating the plant chromatin with a dissociating agent under hydrophobic conditions, and separating the dissociated plant chromatin into individual fractions, one comprising the proteineous plant component, by means of a hydrophobic interaction separation procedure.

L8 ANSWER 17 OF 132 USPATFULL on STN
AN 2003:172748 USPATFULL
TI Binding domain-immunoglobulin fusion proteins
IN Ledbetter, Jeffrey A., Shoreline, WA, UNITED STATES
Hayden-Ledbetter, Martha S., Shoreline, WA, UNITED STATES
Thompson, Peter A., Danville, CA, UNITED STATES
PA Genecraft, Inc., Shoreline, WA (U.S. corporation)
PI US 2003118592 A1 20030626
AI US 2002-207655 A1 20020725 (10)
RLI Continuation-in-part of Ser. No. US 2002-53530, filed on 17 Jan 2002, PENDING
PRAI US 2001-367358P 20010117 (60)
US 2002-385691P 20020603 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 61
ECL Exemplary Claim: 1

DRWN 53 Drawing Page(s)
LN.CNT 7939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

L8 ANSWER 18 OF 132 USPATFULL on STN
AN 2003:169096 USPATFULL
TI Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
IN Doucette-Stamm, Lynn A., Framingham, MA, United States
Bush, David, Somerville, MA, United States
PA Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)
PI US 6583275 B1 20030624
AI US 1998-107532 19980630 (9)
PRAI US 1998-85598P 19980514 (60)
US 1997-51571P 19970702 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Marschel, Ardin H.
LREP Genome Therapeutics Corporation
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 15265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated polypeptide and nucleic acid sequences derived Enterococcus faecium that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

L8 ANSWER 19 OF 132 USPATFULL on STN
AN 2003:159828 USPATFULL
TI Diagnosing, treating, and preventing cancer using cables
IN Rueda, Bo R., Windham, NH, UNITED STATES
Zukerberg, Lawrence R., Newton, MA, UNITED STATES
Wu, Chin-Lee, Newton, MA, UNITED STATES
PI US 2003109443 A1 20030612
AI US 2002-262480 A1 20021001 (10)
PRAI US 2001-326465P 20011001 (60)
US 2002-356685P 20020214 (60)
DT Utility

FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 2685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein is are methods of diagnosing, methods for determining the prognosis for treatment of, and methods for identifying candidate compounds for treating, stabilizing, or preventing cancer, for example, endometrial cancer. These methods utilize the novel tumor suppressor protein, Cables.

L8 ANSWER 20 OF 132 USPATFULL on STN
AN 2003:159819 USPATFULL
TI Compositions and methods for the therapy and diagnosis of kidney cancer
IN Algate, Paul A., Issaquah, WA, UNITED STATES
Mannion, Jane, Edmonds, WA, UNITED STATES
Gaiger, Alexander, Seattle, WA, UNITED STATES
Gordon, Brian, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003109434 A1 20030612
AI US 2002-102524 A1 20020319 (10)
PRAI US 2001-343340P 20011221 (60)
US 2001-277245P 20010319 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly kidney cancer, are disclosed. Illustrative compositions comprise one or more kidney tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly kidney cancer.

L8 ANSWER 21 OF 132 USPATFULL on STN
AN 2003:152954 USPATFULL
TI NON-NATIVE POLYMERASE ENCODING NUCLEIC ACID CONSTRUCT
IN RABBBANI, ELAZAR, NEW YORK, NY, UNITED STATES
STAVRIANOPOULOS, JANNIS G., BAY SHORE, NY, UNITED STATES
DONEGAN, JAMES J., LONG BEACH, NY, UNITED STATES
LIU, DAKAI, BETHPAGE, NY, UNITED STATES
KELKER, NORMAN E., NEW YORK, NY, UNITED STATES
ENGELHARDT, DEAN L., NEW YORK, NY, UNITED STATES
PI US 2003104620 A1 20030605
AI US 1997-978636 A1 19971125 (8)

RLI Division of Ser. No. US 1995-574443, filed on 15 Dec 1995, ABANDONED
DT Utility
FS APPLICATION
LREP ENZO DIAGNOSTICS, INC., C/O ENZO BIOCHEM INC., 527 MADISON AVENUE 9TH FLOOR, NEW YORK, NY, 10022
CLMN Number of Claims: 244
ECL Exemplary Claim: 1
DRWN 51 Drawing Page(s)
LN.CNT 5162
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an array of compositions useful for effecting and/or exhibiting changes in biological functioning and processing within cells and in biological systems containing such cells. In effect, these compositions combine chemical modifications and/or ligand additions with biological functions. The chemical modifications and/or ligand additions provide additional characteristics to the compositions without interfering substantially with their biological function. Such additional characteristics include nuclease resistance, targeting specific cells or specific cell receptors localizing to specific sites within cells and augmenting interactions between the compositions and target cells of interest as well as decreasing such interactions when desired. Also provided by the present invention are processes and kits.

L8 ANSWER 22 OF 132 USPATFULL on STN
AN 2003:152696 USPATFULL
TI CELL-CYCLE REGULATORY PROTEINS FROM HUMAN PATHOGENS, AND USES RELATED THERETO
IN COTTAREL, GUILLAUME, ARLINGTON, MA, UNITED STATES
DAMAGNEZ, VERONIQUE, CAMBRIDGE, MA, UNITED STATES
DRAETTA, GIULIO, OPERA, ITALY
PI US 2003104362 A1 20030605
AI US 1998-72994 A1 19980505 (9)
RLI Continuation-in-part of Ser. No. US 1995-463090, filed on 5 Jun 1995, GRANTED, Pat. No. US 5801015
DT Utility
FS APPLICATION
LREP ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the discovery of novel cell cycle regulatory proteins from the human pathogen Candida.

L8 ANSWER 23 OF 132 USPATFULL on STN
AN 2003:146199 USPATFULL
TI Combination therapy involving drugs which target cellular proteins and drugs which target pathogen-encoded proteins
IN Schaffer, Priscilla A., Boston, MA, UNITED STATES
Schang, Luis M., Edmonton, CANADA
PI US 2003099944 A1 20030529
AI US 2000-905687 A1 20001206 (9)
RLI Continuation-in-part of Ser. No. US 2000-951058, filed on 12 Sep 2000,

PENDING Continuation-in-part of Ser. No. US 2000-656592, filed on 7 Sep 2000, PENDING Continuation of Ser. No. WO 1999-US16252, filed on 16 Jul 1999, PENDING
PRAI US 1998-94805P 19980731 (60)
US 1999-131264P 19990427 (60)
US 1999-140926P 19990624 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 38 Drawing Page(s)
LN.CNT 4046
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the identification of cdk inhibitors as inhibitors of pathogen gene expression, replication and reactivation. The invention also relates to the identification of a combination therapy to inhibit pathogen replication in which a drug that inhibits pathogen replication by targeting a specific pathogen-encoded protein is administered in combination with a drug that inhibits pathogen replication by targeting host-encoded cdk proteins. Compositions and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors

L8 ANSWER 24 OF 132 USPATFULL on STN
AN 2003:140406 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003096247 A1 20030522
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L8 ANSWER 25 OF 132 USPATFULL on STN
AN 2003:133926 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003092011 A1 20030515
AI US 2001-489 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L8 ANSWER 26 OF 132 USPATFULL on STN
AN 2003:130010 USPATFULL
TI Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
IN Breton, Gary, Marlborough, MA, United States
Bush, David, Somerville, MA, United States
PA Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)
PI US 6562958 B1 20030513
AI US 1999-328352 19990604 (9)
PRAI US 1998-88701P 19980609 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Borin, Michael
LREP Genome Therapeutics Corporation
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 16618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated polypeptide and nucleic acid sequences derived from Acinetobacter mirabilis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides;

and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

L8 ANSWER 27 OF 132 USPATFULL on STN
AN 2003:127221 USPATFULL
TI PROCESS FOR SELECTIVE EXPRESSION OF NUCLEIC ACID PRODUCTS
IN RABBANI, ELAZAR, NEW YORK, NY, UNITED STATES
STAVRIANOPOULOS, JANNIS G., BAY SHORE, NY, UNITED STATES
DONEGAN, JAMES J., LONG BEACH, NY, UNITED STATES
LIU, DAKAI, BETHPAGE, NY, UNITED STATES
KELKER, NORMAM E., NEW YORK, NY, UNITED STATES
ENGELHARDT, DEAN L., NEW YORK, NY, UNITED STATES
PI US 2003087434 A1 20030508
AI US 1997-978635 A1 19971125 (8)
RLI Division of Ser. No. US 1995-574443, filed on 15 Dec 1995, ABANDONED
DT Utility
FS APPLICATION
LREP ENZO THERAPETICS, C/O ENZO BIOCHEM INC, 527 MADISON AVENUE 9TH FLOOR, NEW YORK, NY, 10022
CLMN Number of Claims: 244
ECL Exemplary Claim: 1
DRWN 50 Drawing Page(s)
LN.CNT 4844
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an array of compositions useful for effecting and/or exhibiting changes in biological functioning and processing within cells and in biological systems containing such cells. In effect, these compositions combine chemical modifications and/or ligand additions with biological functions. The chemical modifications and/or ligand additions provide additional characteristics to the compositions without interfering substantially with their biological function. Such additional characteristics include nuclease resistance, targeting specific cells or specific cell receptors localizing to specific sites within cells and augmenting interactions between the compositions and target cells of interest as well as decreasing such interactions when desired. Also provided by the present invention are processes and kits.

L8 ANSWER 28 OF 132 USPATFULL on STN
AN 2003:113463 USPATFULL
TI Recombinant production of human ***histone*** 1 subtypes and their use for therapeutic purposes
IN Pohlmeyer, Kai, Fitzbek, GERMANY, FEDERAL REPUBLIC OF
Behnke, Bert, Ahrensburg, GERMANY, FEDERAL REPUBLIC OF
Wick, Ralf Zabiensky geb., Hamburg, GERMANY, FEDERAL REPUBLIC OF
Mayer, Gerd, Hamburg, GERMANY, FEDERAL REPUBLIC OF
PI US 2003078204 A1 20030424
AI US 2002-194405 A1 20020712 (10)
RLI Continuation of Ser. No. WO 2001-EP290, filed on 11 Jan 2001, UNKNOWN
PRAI DE 2000-10001113 20000113
DT Utility
FS APPLICATION
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402

CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to recombinantly produced human ***histone***
-1 subtypes and to their use for therapeutic purposes.

L8 ANSWER 29 OF 132 USPATFULL on STN
AN 2003:113075 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2003077808 A1 20030424
AI US 2001-764891 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 59131
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel reproductive system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "reproductive system related antigens," and the use of such reproductive system related antigens for detecting disorders of the reproductive system, particularly the presence of cancers and cancer metastases. More specifically, isolated reproductive system associated nucleic acid molecules are provided encoding novel reproductive system associated polypeptides. Novel reproductive system related polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human reproductive system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the reproductive system, including reproductive system cancers, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

L8 ANSWER 30 OF 132 USPATFULL on STN
AN 2003:108972 USPATFULL
TI Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
IN Rubenfield, Marc J., Framingham, MA, United States
Nolling, Jork, Ouincy, MA, United States
Deloughery, Craig, Medford, MA, United States
Bush, David, Somerville, MA, United States
PA Genome Therapeutics Corporation, Waltham, MA, United States (U.S.

corporation)
PI US 6551795 B1 20030422
AI US 1999-252991 19990218 (9)
PRAI US 1998-74788P 19980218 (60)
US 1998-94190P 19980727 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Allen, Marianne P.
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 21431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated polypeptide and nucleic acid sequences derived from Pseudomonas aeruginosa that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

L8 ANSWER 31 OF 132 USPATFULL on STN
AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

L8 ANSWER 32 OF 132 USPATFULL on STN
AN 2003:105883 USPATFULL

TI Encapsulation of plasmid DNA (lipogenes.TM.) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
IN Boulikas, Teni, Mountain View, CA, UNITED STATES
PI US 2003072794 A1 20030417
AI US 2001-876904 A1 20010608 (9)
PRAI US 2000-210925P 20000609 (60)
DT Utility
FS APPLICATION
LREP Antoinette F. Konski, Baker & McKenzie, 660 Hansen Way, Palo Alto, CA, 94304
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4201
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of encapsulated the plasmids, oligonucleotides or negatively-charged drugs with HSV-tk plus encapsulated ganciclovir.

L8 ANSWER 33 OF 132 USPATFULL on STN
AN 2003:100063 USPATFULL
TI Peptide-enhanced transfections
IN Hawley-Nelson, Pamela, Silver Spring, MD, UNITED STATES
Lan, Jianqing, Germantown, MD, UNITED STATES
Shih, PoJen, Columbia, MD, UNITED STATES
Jessee, Joel A., Mt. Airy, MD, UNITED STATES
Schifferli, Kevin P., Germantown, MD, UNITED STATES
Gebeyehu, Gulilat, Silver Spring, MD, UNITED STATES
Ciccarone, Valentina C., Gaithersburg, MD, UNITED STATES
Evans, Krista L., Germantown, MD, UNITED STATES
PA Life Technologies, Inc. (U.S. corporation)
PI US 2003069173 A1 20030410
AI US 2001-911569 A1 20010723 (9)
RLI Continuation of Ser. No. US 1998-39780, filed on 16 Mar 1998, PENDING
DT Utility
FS APPLICATION
LREP GREENLEE WINNER and SULLIVAN, P.C., Suite 201, 5370 Manhattan Circle, Boulder, CO, 80303
CLMN Number of Claims: 77
ECL Exemplary Claim: 1

DRWN 12 Drawing Page(s)
LN.CNT 4787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions useful for transfecting ***eukaryotic*** cells comprising nucleic acid complexes with peptides, wherein the peptide is optionally covalently coupled to a nucleic acid-binding group, and cationic lipids or dendrimers as transfection agents. The invention also provides transfection compositions in which a peptide is covalently linked to the transfection agent (lipid, cationic lipid or dendrimer). Inclusion of peptides or modified-peptides in transfection compositions or covalent attachment of peptides to transfection agents results in enhanced transfection efficiency. Methods for the preparation of transfection compositions and methods of using these transfection compositions as intracellular delivery agents and extracellular targeting agents are also disclosed.

L8 ANSWER 34 OF 132 USPATFULL on STN
AN 2003:86849 USPATFULL
TI Cellular proteins as targets for the treatment of pathogens resistant to drugs that target pathogen-encoded proteins
IN Schaffer, Priscilla A., Boston, MA, UNITED STATES
Schang, Luis M., Edmonton, CANADA
PI US 2003060457 A1 20030327
AI US 2000-905695 A1 20001206 (9)
RLI Continuation-in-part of Ser. No. US 2000-951058, filed on 12 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-656592, filed on 7 Sep 2000, PENDING Continuation of Ser. No. WO 1999-US16252, filed on 16 Jul 1999, PENDING
PRAI US 1998-94805P 19980731 (60)
US 1999-131264P 19990427 (60)
US 1999-140926P 19990624 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 38 Drawing Page(s)
LN.CNT 3979
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the identification of cdk inhibitors as inhibitors of gene expression, replication and reactivation in pathogenic agents. Compositions and assays for the identification and use of such inhibitors are provided, as are methods of use of the inhibitors

L8 ANSWER 35 OF 132 USPATFULL on STN
AN 2003:81623 USPATFULL
TI BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth
IN Arlinghaus, Ralph B., Bellaire, TX, United States
Liu, Jiaxin, Bellaire, TX, United States
Lopez-Berestein, Gabriel, Bellaire, TX, United States
Lu, Dai, Pearland, TX, United States
Wu, Yun, Houston, TX, United States

PA Board of Regents, The University of Texas Systems, Austin, TX, United States (U.S. corporation)
PI US 6537804 B1 20030325
WO 9625520 19960822
AI US 1999-101059 19990621 (9)
WO 1996-US2091 19960216
RLI Continuation-in-part of Ser. No. US 1995-390353, filed on 16 Feb 1995, now patented, Pat. No. US 6107457
DT Utility
FS GRANTED
EXNAM Primary Examiner: McGarry, Sean
LREP Fulbright & Jaworski
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 3281
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for detecting and quantitating BCR-ABL gene products and other abnormal ABL gene products of Ph.sup.1-positive leukemic cells. The invention further provides methods for determining the relative number of leukemic cells compared with normal ABL cells to assess the tumor burden of a patient. In another aspect, the methods of the present invention can be used to determine a specific phase of leukemia, particularly chronic-phase CML.

L8 ANSWER 36 OF 132 USPATFULL on STN
AN 2003:78469 USPATFULL
TI Methods for identifying agents that induce a cellular phenotype, and compositions thereof
IN Kamb, Carl Alexander, Salt Lake City, UT, UNITED STATES
PI US 2003054389 A1 20030320
AI US 2002-196408 A1 20020716 (10)
PRAI US 2001-309088P 20010731 (60)
US 2001-305711P 20010716 (60)
US 2001-305712P 20010716 (60)
DT Utility
FS APPLICATION
LREP MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 4473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to methods for performing negative selection assays leading to the identification of cytostatic or cytotoxic agents that cause a lethal phenotype. The invention is useful also for evaluation of conditional cytotoxicity and cell-specific cytotoxicity.

L8 ANSWER 37 OF 132 USPATFULL on STN
AN 2003:78457 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2003054377 A1 20030320
AI US 2002-102627 A1 20020322 (10)
RLI Continuation of Ser. No. US 2001-764856, filed on 17 Jan 2001, PENDING
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 18653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

L8 ANSWER 38 OF 132 USPATFULL on STN
AN 2003:71365 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2003049650 A1 20030313
AI US 2002-91483 A1 20020307 (10)
RLI Continuation of Ser. No. US 2001-764846, filed on 17 Jan 2001, ABANDONED
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 22593
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for

identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

L8 ANSWER 39 OF 132 USPATFULL on STN
AN 2003:71317 USPATFULL
TI Inhibitors of microbial gene expression replication and pathogenesis
IN Schaffer, Priscilla A., Boston, MA, UNITED STATES
Schang, Luis M., Edmonton, CANADA
Jordan, Robert, Erdenheim, PA, UNITED STATES
PI US 2003049602 A1 20030313
AI US 2000-905689 A1 20001206 (9)
RLI Continuation-in-part of Ser. No. US 2000-951058, filed on 12 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-656592, filed on 7 Sep 2000, PENDING Continuation of Ser. No. WO 1999-US16252, filed on 16 Jul 1999, PENDING
PRAI US 1998-94805P 19980731 (60)
US 1999-131264P 19990427 (60)
US 1999-140926P 19990624 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 73
ECL Exemplary Claim: 1
DRWN 37 Drawing Page(s)
LN.CNT 4213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the identification of cdk inhibitors as inhibitors of microbial gene expression, replication and reactivation. Compositions and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors

L8 ANSWER 40 OF 132 USPATFULL on STN
AN 2003:57930 USPATFULL
TI Methods for halting unwanted cell growth, such as using ligand-directed nucleic acid delivery vehicles
IN Chandler, Lois Ann, Encinitas, CA, UNITED STATES
Sosnowski, Barbara A., Coronado, CA, UNITED STATES
Baird, Andrew, San Diego, CA, UNITED STATES
Pierce, Glenn, Rancho Sante Fe, CA, UNITED STATES
PI US 2003040496 A1 20030227
AI US 2001-861257 A1 20010517 (9)
RLI Continuation of Ser. No. US 1997-805383, filed on 24 Feb 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-718904, filed on 24 Sep 1996, PATENTED Continuation-in-part of Ser. No. US 1995-441979, filed on 16 May 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-213446, filed on 15 Mar 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-213447, filed on 15 Mar 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-297961, filed on 29 Aug 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-305771, filed on 13 Sep 1994, ABANDONED
DT Utility
FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 6321
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of treating tumors with preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as FGF2, or other ligand coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin or a prodrug-encoding agent. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.

L8 ANSWER 41 OF 132 USPATFULL on STN
AN 2003:53521 USPATFULL
TI Antibody methods for selectively inhibiting VEGF
IN Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6524583 B1 20030225
AI US 2000-561499 20000428 (9)
PRAI US 1999-131432P 19990428 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chan, Christina; Assistant Examiner: Huynh, Phuong N
LREP Williams, Morgan and Amerson
CLMN Number of Claims: 40
ECL Exemplary Claim: 1,4
DRWN 7 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 10431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

L8 ANSWER 42 OF 132 USPATFULL on STN
AN 2003:47760 USPATFULL
TI Anti-neoplastic compositions and uses thereof
IN Patel, Salil, Cupertino, CA, United States
McArthur, James, San Carlos, CA, United States
Gyuris, Jeno, Winchester, MA, United States
Mendez, Michael J., El Granada, CA, United States
Finer, Mitchell H., Woodside, CA, United States

PA GPC Biotech Inc., Waltham, MA, United States (U.S. corporation)
Cell Genesys, Inc., Foster City, CA, United States (U.S. corporation)
PI US 6521602 B1 20030218
AI US 2000-516065 20000301 (9)
PRAI US 1999-122974P 19990301 (60)
US 1999-128271P 19990408 (60)
US 1999-128515P 19990409 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Priebe, Scott D.
LREP Roylance, Abrams et al.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1,10
DRWN 30 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 3164
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a nucleic acid composition consisting essentially of a first nucleic acid sequence encoding a chimeric CDKi protein and a second nudeic acid sequence encoding an adenovirus E4 protein, wherein the first and second nucleic acid sequences are operably linked to at least one regulatory sequence.

L8 ANSWER 43 OF 132 USPATFULL on STN
AN 2003:40533 USPATFULL
TI Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
IN Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PA Trimeris, Inc., Durham, NC, United States (U.S. corporation)
PI US 6518013 B1 20030211
AI US 1995-485546 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994, now patented, Pat. No. US 6017536 Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DT Utility
FS GRANTED
EXNAM Primary Examiner: Scheiner, Laurie; Assistant Examiner: Parkin, Jeffrey S.
LREP Pennie & Edmonds LLP, Nelson, M. Bud
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 84 Drawing Figure(s); 83 Drawing Page(s)
LN.CNT 24700
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1(HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI 5, 107.times.178.times.4, and PLZIP) in other viral proteins was employed to identify similar regions

in the Epstein-Barr virus (EBV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the EBV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of EBV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-178, these peptides should provide a novel approach to the development of targeted therapies for the treatment of EBV infections.

L8 ANSWER 44 OF 132 USPATFULL on STN
AN 2003:37603 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027248 A1 20030206
AI US 2001-924340 A1 20010806 (9)
PRAI US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP GENSET, JOHN LUCAS, PHD, J.D., 10665 SORRENTO VALLEY RD, SAN DIEGO, CA, 92121
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L8 ANSWER 45 OF 132 USPATFULL on STN
AN 2003:37516 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027161 A1 20030206
AI US 2001-992600 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13

ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L8 ANSWER 46 OF 132 USPATFULL on STN
AN 2003:30251 USPATFULL
TI Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
IN Kaelin, William G., JR., Boston, MA, UNITED STATES
Livingston, David M., Brookline, MA, UNITED STATES
Kim, Tae-You, Seoul, KOREA, REPUBLIC OF
PI US 2003022198 A1 20030130
AI US 2002-101662 A1 20020319 (10)
PRAI US 2001-277425P 20010320 (60)
DT Utility
FS APPLICATION
LREP Ivor R. Elrifi, Ph.D., MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY and POPEO, P.C., One Financial Center, Boston, MA, 02111
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 3094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is "turned on" only under such conditions.

L8 ANSWER 47 OF 132 USPATFULL on STN
AN 2003:29854 USPATFULL
TI Method of enhancing T cell immunity by selection of antigen specific T cells
IN Ignatowicz, Leszek, Evans, GA, UNITED STATES
Kraj, Piotr, Augusta, GA, UNITED STATES
PI US 2003021796 A1 20030130
AI US 2002-137745 A1 20020502 (10)
PRAI US 2001-288867P 20010504 (60)
DT Utility
FS APPLICATION
LREP Charles P. Landrum, FULBRIGHT & JAWORSKI L.L.P., SUITE 2400, 600 CONGRESS AVENUE, AUSTIN, TX, 78701-3271
CLMN Number of Claims: 38

ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 3185
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is an in vivo system for the development of CD4.sup.+ T cells bearing class II MHC restricted TCR. The cells are induced by the administration of a positively selecting, soluble peptide. Following peptide delivery, double-positive CD4.sup.+CD8.sup.+ cells expressing this TCR differentiate into CD4.sup.+ cells in vivo, or in vitro in thymic organ cultures. This system facilitates the development of antigen-specific functional CD4.sup.+ T cells in a controlled manner, after administration of the peptide. The positively selected CD4.sup.+ T cells remain in the periphery for a prolonged time and respond to the appropriate antigenic challenge.

L8 ANSWER 48 OF 132 USPATFULL on STN
AN 2003:23331 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003017167 A1 20030123
AI US 2001-904456 A1 20010711 (9)
RLI Continuation-in-part of Ser. No. US 2001-878722, filed on 8 Jun 2001, PENDING
PRAI US 2001-290240P 20010510 (60)
US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L8 ANSWER 49 OF 132 USPATFULL on STN
AN 2003:6894 USPATFULL
TI Compositions containing nucleic acids and ligands for therapeutic treatment
IN Baird, J. Andrew, San Diego, CA, United States
Chandler, Lois Ann, Encinitas, CA, United States
Sosnowski, Barbara A., Coronado, CA, United States
PA Selective Genetics, Inc., San Diego, CA, United States (U.S.

corporation)
PI US 6503886 B1 20030107
AI US 1999-449249 19991124 (9)
RLI Continuation of Ser. No. US 1996-718904, filed on 24 Sep 1996, now patented, Pat. No. US 6037329, issued on 14 Mar 2000 Continuation-in-part of Ser. No. US 1995-441979, filed on 16 May 1995, now abandoned Continuation-in-part of Ser. No. US 1994-213446, filed on 15 Mar 1994, now abandoned Continuation-in-part of Ser. No. US 1994-213447, filed on 15 Mar 1994, now abandoned Continuation-in-part of Ser. No. US 1994-297961, filed on 29 Aug 1994, now abandoned Continuation-in-part of Ser. No. US 1994-305771, filed on 13 Sep 1994, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nguyen, Dave T.
LREP Seed Intellectual Property Law Group PLLC
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 41 Drawing Figure(s); 25 Drawing Page(s)
LN.CNT 7526
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.

L8 ANSWER 50 OF 132 USPATFULL on STN
AN 2002:344628 USPATFULL
TI Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
IN Gaiger, Alexander, Seattle, WA, UNITED STATES
Algate, Paul A., Issaquah, WA, UNITED STATES
Mannion, Jane, Seattle, WA, UNITED STATES
PI US 2002198362 A1 20021226
AI US 2001-796692 A1 20010301 (9)
PRAI US 2000-223378P 20000807 (60)
US 2000-223416P 20000804 (60)
US 2000-222903P 20000803 (60)
US 2000-218950P 20000714 (60)
US 2000-206201P 20000522 (60)
US 2000-202084P 20000504 (60)
US 2000-200999P 20000501 (60)
US 2000-200303P 20000428 (60)
US 2000-200779P 20000428 (60)
US 2000-200545P 20000427 (60)
US 2000-190479P 20000317 (60)
US 2000-186126P 20000301 (60)
DT Utility

FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 100
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 19014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, human leukemias and lymphomas of the follicular, Hodgkin's and B cell and T cll non-Hodgkin's types. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of a variety of leukemias and lymphomas.

L8 ANSWER 51 OF 132 USPATFULL on STN
AN 2002:337379 USPATFULL
TI Pharmaceuticals and methods for treating hypoxia and screening methods therefor
IN Kaelin, William G., JR., Boston, MA, UNITED STATES
Ivan, Mircea, Cambridge, MA, UNITED STATES
PI US 2002192737 A1 20021219
AI US 2002-101812 A1 20020319 (10)
PRAI US 2001-277425P 20010320 (60)
US 2001-277431P 20010320 (60)
US 2001-277440P 20010320 (60)
US 2001-332493P 20011109 (60)
US 2001-332334P 20011109 (60)
US 2001-345200P 20011109 (60)
US 2001-345131P 20011220 (60)
US 2001-342598P 20011220 (60)
US 2001-345132P 20011220 (60)
DT Utility
FS APPLICATION
LREP Ivor R. Elrifi, MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY and POPEO, P.C., One Financial Center, Boston, MA, 02111
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 3858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. Tie ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a

hypoxic state, such that the light-generating fusion protein is "turned on" only under such conditions.

L8 ANSWER 52 OF 132 USPATFULL on STN
AN 2002:330253 USPATFULL
TI Methods of treating liver disease and liver damage with growth hormone and foxM1B
IN Costa, Robert H., Oak Park, IL, UNITED STATES
Wang, Xinhe, Chicago, IL, UNITED STATES
Adami, Guy, Brookfield, IL, UNITED STATES
Tan, Yongjun, Arlington Heights, IL, UNITED STATES
Krupczak-Hollis, Katherine, Chicago, IL, UNITED STATES
PA Board of Trustees for the University of Illinois (U.S. corporation)
PI US 2002187936 A1 20021212
AI US 2002-151587 A1 20020517 (10)
PRAI US 2001-291789P 20010517 (60)
US 2001-305821P 20010716 (60)
US 2001-315484P 20010828 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
CLMN Number of Claims: 144
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 2973
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method of treating liver damage or disease in a patient by stimulating liver regeneration. Specifically, the invention provides a method of inducing liver cell proliferation comprising contacting liver cells that express FoxM1B protein with growth hormone. The invention also provides methods of screening for compounds that induce FoxM1B protein expression, nuclear localization, or both expression and nuclear localization. The invention further provides pharmaceutical compositions comprising selected compounds and methods of using such compositions.

L8 ANSWER 53 OF 132 USPATFULL on STN
AN 2002:329447 USPATFULL
TI Methods for viral oncoapoptosis in cancer therapy
IN Blaho, John A., New York, NY, UNITED STATES
Aubert, Martine, New York, NY, UNITED STATES
PA Mount Sinai School of Medicine (U.S. corporation)
PI US 2002187126 A1 20021212
AI US 2002-118655 A1 20020408 (10)
PRAI US 2001-282214P 20010406 (60)
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an effective approach to inducing

apoptosis of cancer cells, for anti-cancer therapy, using modified herpes viruses (HSV). The modification, deletion of an immediate early gene, results in a replication defective HSV (rdHSV). As a result of deletion of the immediate early gene, specifically ICP27 or ICP4, or both, the modified HSV is unable to complete its replication cycle while inducing apoptosis of the infected tumor cell. A particular advantage of this approach is that induction of apoptosis is specific for tumor cells, but not for normal cells. Moreover, the modified HSV can be engineered to contain a cancer therapeutic gene, i.e., it can act as a cancer therapeutic gene therapy vector, although it has potent anti-tumor activity on its own.

L8 ANSWER 54 OF 132 USPATFULL on STN
AN 2002:314649 USPATFULL
TI Human rhinovirus assays, and compositions therefrom
IN Kamb, Carl Alexander, Salt Lake City, UT, UNITED STATES
Poritz, Mark Aaron, Salt Lake City, UT, UNITED STATES
Teng, David Heng-Fai, Salt Lake City, UT, UNITED STATES
PI US 2002177125 A1 20021128
AI US 2001-991003 A1 20011116 (9)
RLI Continuation-in-part of Ser. No. US 1997-812994, filed on 4 Mar 1997, GRANTED, Pat. No. US 5955275 Continuation-in-part of Ser. No. US 1999-259155, filed on 26 Feb 1999, ABANDONED
PRAI US 2000-253333P 20001127 (60)
US 2001-272026P 20010228 (60)
DT Utility
FS APPLICATION
LREP Joseph A. Williams, Jr. Ph.D., Marshall, Gerstein, & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL, 60606-6402
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 3734
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for assaying for viral-related activity are disclosed. The assays of the invention provide for the identification of biologically active phenotypic probes and cellular targets and fragments, variants and mimetics thereof.

L8 ANSWER 55 OF 132 USPATFULL on STN
AN 2002:310941 USPATFULL
TI Suppression of cyclin kinase 2 activity for prevention and treatment of DNA viral infections
IN Albrecht, Thomas, Galveston, TX, United States
Thompson, Aubrey E., Dickinson, TX, United States
Bresnahan, Wade, Plainsboro, NJ, United States
Meijer, Laurent, Roscoff, FRANCE
PA Board of Regents, The University of Texas, Austin, TX, United States (U.S. corporation)
PI US 6486166 B1 20021126
AI US 1999-389830 19990903 (9)
RLI Continuation of Ser. No. WO 1998-US4154, filed on 2 Mar 1998
PRAI US 1997-38126P 19970303 (60)
DT Utility
FS GRANTED

EXNAM Primary Examiner: Webman, Edward J.
LREP Fulbright & Jaworski
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 30 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 1990
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An important aspect of the present invention is a method for inhibiting proliferation of a DNA virus dependent upon events associated with cell proliferation for replication. The DNA virus includes any of the herpesvirus family, and most particularly human cytomegalovirus. The method involves administering prophylactically or therapeutically effective amount of a cyclin-dependent kinase inhibitor to a patient or animal.

L8 ANSWER 56 OF 132 USPATFULL on STN
AN 2002:303980 USPATFULL
TI Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
IN Roth, Jack A., Houston, TX, United States
Cai, De Wei, Cheltenham, PA, United States
Mukhopadhyay, Tapas, Houston, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6482803 B1 20021119
AI US 1995-523030 19950901 (8)
DT Utility
FS GRANTED
EXNAM Primary Examiner: LeGuyader, John L.
LREP Fulbright & Jaworski
CLMN Number of Claims: 25
ECL Exemplary Claim: 1,4
DRWN 12 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 2784
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses expression constructs and methods for employing them that result in the modulation of abnormal oncogene and tumor suppressor genes in a novel approach to cancer prevention and therapy. In one embodiment, an expression construct expresses a ribozyme that inactivates mutant p53 and also expresses the functional p53.

L8 ANSWER 57 OF 132 USPATFULL on STN
AN 2002:297296 USPATFULL
TI Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
IN Bolognesi, Dani Paul, Durham, NC, United States
Matthews, Thomas James, Durham, NC, United States
Wild, Carl T., Durham, NC, United States
Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
Langlois, Alphonse J., Durham, NC, United States
PA Trimeris, Inc., Durham, NC, United States (U.S. corporation)
PI US 6479055 B1 20021112
AI US 1995-470896 19950606 (8)

RLI Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994, now patented, Pat. No. US 6017536 Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DT Utility
FS GRANTED
EXNAM Primary Examiner: Stucker, Jeffrey
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 84 Drawing Figure(s); 83 Drawing Page(s)
LN.CNT 26553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-viral activity. In particular, the invention relates to methods of using such peptides as inhibitory of respiratory syncytial virus ("RSV") transmission to uninfected cells. The peptides used in the methods of the invention are homologs of the DP-178 and DP-107 peptides, peptides corresponding to amino acid residues 638 to 673, and to amino acid residues 558 to 595, respectively, of the HIV-1.sub.LAI transmembrane protein (TM) gp41.

L8 ANSWER 58 OF 132 USPATFULL on STN
AN 2002:296074 USPATFULL
TI System for regulating in vivo the expression of a transgene by conditional inhibition
IN Scherman, Daniel, Paris, FRANCE
Bettan, Michael, Paris, FRANCE
Bigey, Pascal, Paris, FRANCE
PI US 2002166132 A1 20021107
AI US 2001-931007 A1 20010817 (9)
PRAI FR 2000-110730 20000818
US 2000-239246P 20001011 (60)
DT Utility
FS APPLICATION
LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N. W., Washington, DC, 20005-3315
CLMN Number of Claims: 112
ECL Exemplary Claim: 1
DRWN 31 Drawing Page(s)
LN.CNT 2992
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel constructs and compositions and to a novel method for regulating the expression of a transgene of interest in vivo by conditional inhibition, and to the uses thereof in experimental, clinical and therapeutic domains or for the production of animals or plants.

For example, the novel regulation method is based on the coexpression of a transgene of interest encoding a transcript of interest and of an inhibitory transgene encoding an inhibitory transcript specific for the transcript of interest, so as to obtain constitutive inhibition of the activity of the transcript of interest, and to be able to ensure effective regulation of the transcript of interest, either by inhibiting its inhibitory transcript, or by activating the transcript of interest,

or alternatively by activating the transcript of interest and concomitantly inhibiting its inhibitory transcript.

L8 ANSWER 59 OF 132 USPATFULL on STN
AN 2002:294709 USPATFULL
TI 47508, a novel human ***histone*** deacetylase family member and uses thereof
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002164752 A1 20021107
AI US 2001-911150 A1 20010723 (9)
PRAI US 2000-220008P 20000721 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 47508 nucleic acid molecules, which encode novel human ***histone*** deacetylase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47508 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47508 gene has been introduced or disrupted. The invention still further provides isolated 47508 proteins, fusion proteins, antigenic peptides and anti-47508 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

L8 ANSWER 60 OF 132 USPATFULL on STN
AN 2002:294599 USPATFULL
TI Method to screen phage display libraries with different ligands
IN Tomlinson, Ian, Cambridge, UNITED KINGDOM
Winter, Greg, London, UNITED KINGDOM
PI US 2002164642 A1 20021107
AI US 2001-968561 A1 20011001 (9)
RLI Division of Ser. No. US 2000-511939, filed on 24 Feb 2000, PENDING
PRAI GB 1997-22131 19971020
WO 1998-GB3135 19981020
US 1997-65428P 19971113 (60)
US 1997-66729P 19971121 (60)
DT Utility
FS APPLICATION
LREP PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods for selecting repertoires of polypeptides using generic and target ligands. In particular, the invention relates to a library comprising a repertoire of polypeptides

of the immunoglobulin superfamily, wherein the members of the repertoire have a known main chain conformation.

L8 ANSWER 61 OF 132 USPATFULL on STN
AN 2002:273550 USPATFULL
TI Nucleic acids, proteins and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002151681 A1 20021017
AI US 2001-925300 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US5988, filed on 8 Mar 2000, UNKNOWN
PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 29771
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to newly identified prostate or prostate cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "prostate cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, and to antibodies that immunospecifically bind these polypeptides, as well as the use of such prostate cancer polynucleotides, antigens, and antibodies for detection, prevention, prognosis, and treatment of disorders of the reproductive system, particularly disorders of the prostate, including, but not limited to, the presence of prostate cancer and prostate cancer metastases. More specifically, isolated prostate cancer nucleic acid molecules are provided encoding novel prostate cancer polypeptides. Novel prostate cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human prostate cancer polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the prostate, including prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

L8 ANSWER 62 OF 132 USPATFULL on STN
AN 2002:272801 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002150922 A1 20021017

AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L8 ANSWER 63 OF 132 USPATFULL on STN
AN 2002:246789 USPATFULL
TI Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
IN Grimley, Philip M., Potoma, MD, United States
Mehta, Sunil, Rumford, RI, United States
PA The Henry Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)
PI US 6455593 B1 20020924
AI US 2001-778892 20010208 (9)
RLI Division of Ser. No. US 1998-168106, filed on 8 Oct 1998, now patented, Pat. No. US 6274576 Continuation of Ser. No. US 1996-667543, filed on 21 Jun 1996, now abandoned
PRAI US 1995-546P 19950627 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chang, Ceila
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 56 Drawing Figure(s); 40 Drawing Page(s)
LN.CNT 4358
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of potentiating cell damage in a target cell population by administering a "restraining agent" and concomitantly or subsequently applying a "targeted cytotoxic insult." The restraining agent is administered at a concentration and under conditions sufficient to retard, but not to arrest, the progress of the target cell population through the cell cycle, a concept termed "dynamic retardation." With such a mechanism, all the cells intended for damage by the targeted cytotoxic insult are likely to cycle into the relevant interval of vulnerability (target interval) within the cell cycle,

resulting in a larger number of susceptible cells, and the time period during which those cells are vulnerable to the action of a given targeted cytotoxic insult is increased, resulting in a higher probability and percentage of cell killing.

L8 ANSWER 64 OF 132 USPATFULL on STN
AN 2002:243796 USPATFULL
TI Bioengineered vehicles for targeted nucleic acid delivery
IN Huston, James S., Chestnut Hill, MA, UNITED STATES
Wils, Pierre, Paris, FRANCE
Zhu, Quan, Needham, MA, UNITED STATES
Laurent, Oliver, Berkley, CA, UNITED STATES
Marasco, Wayne A., Oakland, CA, UNITED STATES
Scherman, Daniel, Paris, FRANCE
PI US 2002132990 A1 20020919
AI US 2001-888721 A1 20010625 (9)
PRAI US 2000-213653P 20000623 (60)
DT Utility
FS APPLICATION
LREP Patrick J. Kelly, Synnestvedt & Lechner LLP, 2600 Aramark Tower, 1101 Market Street, Philadelphia, PA, 19107
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 2019
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There is disclosed a gene-delivery compound comprising: (A) a single-chain binding polypeptide having at least one effector segment which includes at least one cysteinyl residue; and (B) a nucleic acid-binding moiety which is coupled to the polypeptide via the cysteinyl residue. There is disclosed also a gene-delivery compound comprising: (A) a single-chain, binding polypeptide having at least one effector segment which includes at least one cysteinyl residue; (B) a lipid-associating moiety which is coupled to the polypeptide via the cysteinyl residue. Additionally disclosed are compositions comprising the above-mentioned compounds and a nucleic acid.

L8 ANSWER 65 OF 132 USPATFULL on STN
AN 2002:235495 USPATFULL
TI Novel cark protein and nucleic acid molecules and uses therefor
IN Raju, Jeyaseelan, Acton, MA, UNITED STATES
PI US 2002127684 A1 20020912
AI US 2001-947199 A1 20010905 (9)
RLI Continuation-in-part of Ser. No. US 1999-458457, filed on 10 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-291839, filed on 14 Apr 1999, PATENTED
PRAI US 1998-111938P 19981211 (60)
DT Utility
FS APPLICATION
LREP LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 35 Drawing Page(s)
LN.CNT 5319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated CARK nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CARK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CARK gene has been introduced or disrupted. The invention still further provides isolated CARK proteins, fusion proteins, antigenic peptides and anti-CARK antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

L8 ANSWER 66 OF 132 USPATFULL on STN
AN 2002:221018 USPATFULL
TI Antibody conjugate formulations for selectively inhibiting VEGF
IN Thorpe, Philip E., Dallas, TX, UNITED STATES
Brekken, Rolf A., Seattle, WA, UNITED STATES
PA Board of Regents,The University of Texas System (U.S. corporation)
PI US 2002119153 A1 20020829
AI US 2001-998831 A1 20011130 (9)
RLI Continuation of Ser. No. US 2000-561108, filed on 28 Apr 2000, PATENTED
PRAI US 1999-131432P 19990428 (60)
DT Utility
FS APPLICATION
LREP Shelley P.M. Fussey, WILLIAMS, MORGAN & AMERSON, P.C., Suite 250, 7676 Hillmont, Houston, TX, 77040
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 10502
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

L8 ANSWER 67 OF 132 USPATFULL on STN
AN 2002:206193 USPATFULL
TI Isolated p27 protein and methods for its production and use
IN Massague, Joan, New York, NY, UNITED STATES
Roberts, James M., Seattle, WA, UNITED STATES
Koff, Andrew, New York, NY, UNITED STATES
Polyak, Kornelia, Baltimore, MD, UNITED STATES
PI US 2002110886 A1 20020815
AI US 2001-865018 A1 20010524 (9)
RLI Continuation of Ser. No. US 1997-854039, filed on 9 May 1997, PENDING Continuation of Ser. No. US 1997-765702, filed on 28 Apr 1997, PENDING A 371 of International Ser. No. WO 1995-US7361, filed on 7 Jun 1995, UNKNOWN
DT Utility
FS APPLICATION
LREP ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
CLMN Number of Claims: 35

ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 2446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An isolated protein designated p27 is disclosed. The p27 protein has an apparent molecular weight of about 27 kD, and is capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. A nucleic acid sequence encoding p27 protein is disclosed, as well as a method for producing p27 in cultured cells. In vitro assays for discovering agents which affect the activity of p27 are also provided. Methods of diagnosing and treating hypoproliferative disorders are provided.

L8 ANSWER 68 OF 132 USPATFULL on STN
AN 2002:191573 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002102638 A1 20020801
AI US 2001-764846 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 22814
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

L8 ANSWER 69 OF 132 USPATFULL on STN
AN 2002:191539 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2002102604 A1 20020801
AI US 2000-731872 A1 20001207 (9)
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)
DT Utility
FS APPLICATION

LREP John Lucas, Ph.D., J.D., Genset Corporation, 10665 Srrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 28061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L8 ANSWER 70 OF 132 USPATFULL on STN
AN 2002:188220 USPATFULL
TI Detection of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients
IN Deretic, Vojo, San Antonio, TX, United States
Martin, Daniel W., Palo Alto, CA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6426187 B1 20020730
AI US 2000-609151 20000630 (9)
RLI Continuation of Ser. No. US 1995-505307, filed on 24 Nov 1995, now patented, Pat. No. US 6083691, issued on 4 Jul 2000 Continuation-in-part of Ser. No. US 1994-260202, filed on 15 Jun 1994, now patented, Pat. No. US 5573910 Continuation-in-part of Ser. No. US 1993-17114, filed on 12 Feb 1993, now patented, Pat. No. US 5591838
PRAI WO 1994-US2034 19940214
DT Utility
FS GRANTED
EXNAM Primary Examiner: Myers, Carla J.; Assistant Examiner: Johannsen, Diana
LREP Fulbright & Jaworski L.L.P.
CLMN Number of Claims: 33
ECL Exemplary Claim: 28
DRWN 22 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 3294
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for detecting the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. Chronic respiratory infections with mucoid Pseudomonas aeruginosa are the leading cause of high mortality and morbidity in cystic fibrosis. The initially colonizing strains are nonmucoid but in the cystic fibrosis lung they invariably convert into the mucoid form causing further disease deterioration and poor prognosis. Mucoidy is a critical P. aeruginosa virulence factor in cystic fibrosis that has been associated with biofilm develoment and resistance to phagocytosis. The molecular basis of this conversion to mucoidy is also disclosed. The present invention provides for detecting the switch from nonmucoid to mucoid state as caused by either frameshift deletions and duplications or nonsense changes in the second gene of the cluster, mucA. Inactivation of mucA results in constitutive expression of genes, such as algD, dependent on algU for transcription. Also disclosed is a novel alginate biosynthesis heterologous expression

system for use in screening candidate substances that inhibit conversion to mucoidy.

L8 ANSWER 71 OF 132 USPATFULL on STN
AN 2002:167884 USPATFULL
TI Antibody conjugate kits for selectively inhibiting VEGF
IN Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PA Board of Regents, The University of Texax System, Austin, TX, United States (U.S. corporation)
PI US 6416758 B1 20020709
AI US 2000-561526 20000428 (9)
PRAI US 1999-131432P 19990428 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Huynh, Phuong
LREP Williams, Morgan and Amerson
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 10439
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions.

L8 ANSWER 72 OF 132 USPATFULL on STN
AN 2002:166381 USPATFULL
TI Adenosine deaminase deficient transgenic mice and methods for the use thereof
IN Kellems, Rodney E., Houston, TX, UNITED STATES
Datta, Surjit K., Houston, TX, UNITED STATES
Blackburn, Michael R., Pearland, TX, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2002088017 A1 20020704
AI US 2001-761198 A1 20010116 (9)
RLI Continuation of Ser. No. US 1999-301665, filed on 28 Apr 1999, UNKNOWN
DT Utility
FS APPLICATION
LREP Stephen M. Hash, Ph.D., FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 7243
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the production of adenosine deaminase (ADA) deficient mice and the use of such mice as an animal model for dysfunctions associated with elevated adenosine levels. Also, provided by the present invention are methods of treating dysfunctions associated with elevated adenosine levels and methods of screening compounds for

pharmaceutical activity in the treatment of dysfunctions associated with elevated adenosine levels.

L8 ANSWER 73 OF 132 USPATFULL on STN
AN 2002:164768 USPATFULL
TI B-catenin assays, and compositions therefrom
IN Kamb, Carl Alexander, Salt Lake City, UT, UNITED STATES
Yoo, Sanghee, Salt Lake City, UT, UNITED STATES
Garcia-Guzman, Miguel, Salt Lake City, UT, UNITED STATES
Pierce, Michael Leslie, Salt Lake City, UT, UNITED STATES
PI US 2002086386 A1 20020704
AI US 2001-990912 A1 20011116 (9)
RLI Continuation-in-part of Ser. No. US 1997-812994, filed on 4 Mar 1997, GRANTED, Pat. No. US 5955275
PRAI US 2000-253325P 20001127 (60)
DT Utility
FS APPLICATION
LREP Joseph A. Williams, Jr., MARSHALL, GERSTEIN, MURRAY & BORUN, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL, 60606-6402
CLMN Number of Claims: 92
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 4004
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for assaying a cellular pathway, and more particularly a .beta.-catenin-related pathway, are disclosed. The assays of the invention utilize particular host cells with desired .beta.-catenin pathway elements, and results in the identification of biologically active phenotypic probes and cellular targets and fragments, variants and mimetics thereof.

L8 ANSWER 74 OF 132 USPATFULL on STN
AN 2002:164735 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002086353 A1 20020704
AI US 2001-764856 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 23314
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating,

preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

L8 ANSWER 75 OF 132 USPATFULL on STN
AN 2002:157600 USPATFULL
TI Treatment of inflammation with p20
IN Brigham, Kenneth L., Nashville, TN, UNITED STATES
Stecenko, Arlene A., Nashville, TN, UNITED STATES
Sealy, Linda, Brentwood, TN, UNITED STATES
PI US 2002082204 A1 20020627
AI US 2001-789836 A1 20010220 (9)
PRAI US 2000-183584P 20000218 (60)
DT Utility
FS APPLICATION
LREP WADDEY & PATTERSON, 414 UNION STREET, SUITE 2020, BANK OF AMERICA PLAZA, NASHVILLE, TN, 37219
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 4639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions, methods, and kits for treating inflammation and regulating inflammatory responses including cytokine, prostanoid, prostaglandin, and growth factor expression.

L8 ANSWER 76 OF 132 USPATFULL on STN
AN 2002:157089 USPATFULL
TI Retinoid pathway assays, and compositions therefrom
IN Kamb, Carl Alexander, Salt Lake City, UT, UNITED STATES
Richards, Burt Timothy, Midway, UT, UNITED STATES
Karpilow, Jon, Boulder, CO, UNITED STATES
PI US 2002081688 A1 20020627
AI US 2001-990747 A1 20011116 (9)
RLI Continuation-in-part of Ser. No. US 1997-812994, filed on 4 Mar 1997, GRANTED, Pat. No. US 5955275
PRAI US 2000-249468P 20001117 (60)
DT Utility
FS APPLICATION
LREP Joseph A. Williams, Jr., MARSHALL, GERSTEIN, MURRAY & BORUN, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL, 60606-6402
CLMN Number of Claims: 110
ECL Exemplary Claim: 1
DRWN 33 Drawing Page(s)
LN.CNT 3714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for assaying a cellular pathway, and more particularly a retinoic acid-related pathway, are disclosed. The assays of the invention utilize particular host cells with desired retinoic acid pathway elements, and results in the identification of biologically active phenotypic probes and cellular targets and fragments, variants and mimetics thereof.

L8 ANSWER 77 OF 132 USPATFULL on STN
AN 2002:157060 USPATFULL
TI Nucleic acids, proteins and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002081659 A1 20020627
AI US 2001-925297 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US5989, filed on 8 Mar 2000, UNKNOWN
PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 20326
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel pancreatic related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "pancreatic antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such pancreatic polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the pancreas, including, but not limited to, the presence of pancreatic cancer and pancreatic cancer metastases. More specifically, isolated pancreatic nucleic acid molecules are provided encoding novel pancreatic polypeptides. Novel pancreatic polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human pancreatic polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the pancreas, including pancreatic cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

L8 ANSWER 78 OF 132 USPATFULL on STN
AN 2002:144075 USPATFULL
TI Interventions to mimic the effects of calorie restriction
IN Spindler, Stephen R., Riverside, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6406853 B1 20020618
AI US 2000-648642 20000825 (9)
RLI Continuation-in-part of Ser. No. US 1999-471225, filed on 23 Dec 1999
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Taylor, Janell E.
LREP Townsend & Townsend & Crew LLP
CLMN Number of Claims: 26

ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Long term calorie restriction has the benefit of increasing life span. Methods to screen interventions that mimic the effects of calorie restriction are disclosed. Extensive analysis of genes for which expression is statistically different between control and calorie restricted animals has demonstrated that specific genes are preferentially expressed during calorie restriction. Screening for interventions which produce the same expression profile will provide interventions that increase life span. In a further aspect, it has been discovered that test animals on a calorie restricted diet for a relatively short time have a similar gene expression profile to test animals which have been on a long term calorie restricted diet.

L8 ANSWER 79 OF 132 USPATFULL on STN
AN 2002:133425 USPATFULL
TI METHODS FOR SELECTING FUNCTIONAL POLYPEPTIDES
IN WINTER, GREG, CAMBRIDGE, UNITED KINGDOM
TOMLINSON, IAN, CAMBRIDGE, UNITED KINGDOM
PI US 2002068276 A1 20020606
AI US 1998-192854 A1 19981117 (9)
PRAI GB 1997-22131 19971020
US 1997-65428P 19971113 (60)
US 1997-66729P 19971121 (60)
DT Utility
FS APPLICATION
LREP KATHLEEN M. WILLIAMS, PH.D., PALMER & DODGE, LLP, 111 HUNTINGTON AVENUE AT THE PRUDENTIAL CENTER, BOSTON, MA, 02199-7613
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 2342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method for selecting, from a repertoire of polypeptides, a population of functional polypeptides which bind a target ligand in a first binding site and a generic ligand in a second binding site, which generic ligand is capable of binding functional members of the repertoire regardless of target ligand specificity, comprising the steps of: a) contacting the repertoire with the generic ligand and selecting functional polypeptides bound thereto; and b) contacting the selected functional polypeptides with the target ligand and selecting a population of polypeptides which bind to the target ligand. The invention accordingly provides a method by which a polypeptide repertoire is preselected, according to functionality as determined by the ability to bind the generic ligand, and the subset of polypeptides obtained as a result of such preselection is then employed for further selection according to the ability to bind the target ligand.

L8 ANSWER 80 OF 132 USPATFULL on STN
AN 2002:122614 USPATFULL
TI Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy
IN Hung, Mien-Chie, Houston, TX, United States

Ueno, Naoto T., Houston, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6395712 B1 20020528
WO 9735012 19970925
AI US 1997-809021 19970319 (8)
WO 1997-US3830 19970319
19970319 PCT 371 date
PRAI US 1996-13750P 19960320 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Crouch, Deborah
LREP Fulbright & Jaworski LLP
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 84 Drawing Figure(s); 45 Drawing Page(s)
LN.CNT 5197
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods for the inhibition, of the gene product of the neu oncogene, p185neu tyrosine kinase. Over-expression of the neu oncogene leads to chemoresistance. The methods disclosed involve the novel use of E1A and/or LT in combination with chemotherapeutic drugs to treat carcinoma. Furthermore, E1A surprisingly potentiates the antineoplastic effects of the chemotherapeutic agents. The inventors propose that E1A sensitizes cancer cells such that they become amenable to treatment by chemotherapeutic drugs.

L8 ANSWER 81 OF 132 USPATFULL on STN
AN 2002:119616 USPATFULL
TI Method of identifying ligands of biological target molecules
IN Elling, Christian E., Copenhagen, DENMARK
Holst Lange, Birgitte, Copenhagen, DENMARK
Schwartz, Thue W., Frederiksburg, DENMARK
Gerlach, Lars Ole, Copenhagen, DENMARK
Pedersen, Jan Torleif, Bronshoj, DENMARK
PI US 2002061599 A1 20020523
AI US 2000-752102 A1 20001229 (9)
PRAI DK 1999-1879 19991230
DK 1999-1880 19991230
DK 2000-705 20000428
US 2000-175664P 20000112 (60)
US 2000-175401P 20000111 (60)
US 2000-202990P 20000509 (60)
DT Utility
FS APPLICATION
LREP Dike, Bronstein, Roberty & Cushman, Intellectual Property Practice Group, EDWARDS & ANGELL, LLP, 130 Water Street, Boston, MA, 02109-4280
CLMN Number of Claims: 79
ECL Exemplary Claim: 1
DRWN 29 Drawing Page(s)
LN.CNT 3495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a molecular approach for rapidly and selectively identifying small organic molecule ligands, i.e. compounds, that are capable of interacting with and binding to specific sites on

biological target molecules. The methods of the present invention are applicable to any biological target molecule that has or can be manipulated to have a metal-ion binding site. Biological target molecules are e.g. proteins, polypeptides, oligopeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids, lipoproteins and derivatives thereof. More specifically, the biological target molecules include membrane receptors, signal transduction proteins, scaffolding proteins, nuclear receptors, steroid receptors, intracellular receptors, transcription factors, enzymes, allosteric enzyme regulatory proteins, growth factors, hormones, neuropeptides and immonoglobulins. A very interesting group of biological target molecules are membrane proteins such as, e.g., transmembrane protein (e.g. 7 TMs).

The methods described herein make it possible to construct and screen libraries of compounds specifically directed against predetermined epitopes on the biological target molecules. The compounds are initially constructed to be bi-functional, i.e. having both a metal-ion binding moiety, which conveys them with the ability to bind to either a natural or an artificially constructed metal-ion binding site as well as a variable moiety, which is varied chemically to probe for interactions with specific parts of the biological target molecule located spatially adjacent to the metal-ion binding site. Compounds may subsequently be further modified to bind to the unmodified biological target molecule without help of the bridging metal-ion. The methods according to the invention may be performed easily and quickly and lead to unambiguous results. The compounds identified by the methods described herein may themselves be employed for various applications or may be further derivatised or modified to provide novel compounds.

L8 ANSWER 82 OF 132 USPATFULL on STN
AN 2002:108815 USPATFULL
TI Telomerase compositions and methods
IN Gottschling, Daniel E., Chicago, IL, United States
Singer, Miriam S., Chicago, IL, United States
PA Arch Development, Chicago, IL, United States (U.S. corporation)
PI US 6387619 B1 20020514
AI US 1999-345294 19990630 (9)
RLI Division of Ser. No. US 1997-938534, filed on 26 Sep 1997, now patented, Pat. No. US 5916752 Division of Ser. No. US 1995-431080, filed on 28 Apr 1995, now patented, Pat. No. US 5698686 Division of Ser. No. US 345294 Continuation-in-part of Ser. No. US 1994-326781, filed on 20 Oct 1994, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Fredman, Jeffrey
LREP Fulbright & Jaworski, LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 6648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are various methods, compositions and screening assays connected with telomerase, including genes encoding the template RNA of S. cerevisiae telomerase and various telomerase-associated polypeptides.

L8 ANSWER 83 OF 132 USPATFULL on STN
AN 2002:102627 USPATFULL
TI Sequence directed DNA binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 6384208 B1 20020507
AI US 1999-354947 19990715 (9)
RLI Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, now patented, Pat. No. US 6010849, issued on 4 Jan 2000 Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444, issued on 26 Nov 1996 Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014, issued on 10 Mar 1998 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463, issued on 2 Dec 1997 Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Schwartzman, Robert A.; Assistant Examiner: Davis, Katharine F.
LREP Fabian, Gary, Thrower, Larry W., Perkins Coie LLP
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 71 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 5215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L8 ANSWER 84 OF 132 USPATFULL on STN
AN 2002:88268 USPATFULL
TI Peptide-enhanced transfections
IN Hawley-Nelson, Pamela, Silver Spring, MD, United States
Lan, Jianqing, Germantown, MD, United States
Shih, PoJen, Columbia, MD, United States
Jessee, Joel A., Mt. Airy, MD, United States
Schifferli, Kevin P., Germantown, MD, United States
Gebeyehu, Gulilat, Silver Spring, MD, United States
Ciccarone, Valentina C., Gaithersburg, MD, United States

Evans, Krista L., Germantown, MD, United States
PA Life Technologies, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6376248 B1 20020423
AI US 1998-39780 19980316 (9)
RLI Continuation-in-part of Ser. No. US 1997-818200, filed on 14 Mar 1997, now patented, Pat. No. US 6051429, issued on 8 Apr 2000
DT Utility
FS GRANTED
EXNAM Primary Examiner: Brusca, John S.
LREP Greenlee, Winner and Sullivan, P.C.
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 4698
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compositions useful for transfecting ***eukaryotic*** cells comprising nucleic acid complexes with peptides, wherein the peptide is optionally covalently coupled to a nucleic acid-binding group, and cationic lipids or dendrimers as transfection agents. The invention also provides transfection compositions in which a peptide is covalently linked to the transfection agent (lipid, cationic lipid or dendrimer). Inclusion of peptides or modified-peptides in transfection compositions or covalent attachment of peptides to transfection agents results in enhanced transfection efficiency. Methods for the preparation of transfection compositions and methods of using these transfection compositions as intracellular delivery agents and extracellular targeting agents are also disclosed.

L8 ANSWER 85 OF 132 USPATFULL on STN
AN 2002:81054 USPATFULL
TI Senscent cell-derived inhibitors of DNA synthesis
IN Smith, James R., Houston, TX, United States
Drutz, David J., Houston, TX, United States
Wilson, Deborah R., Houston, TX, United States
Zumstein, Louis A., Houston, TX, United States
PA Baylor College of Medicine, Houston, TX, United States (U.S. corporation)
PI US 6372249 B1 20020416
AI US 1994-327874 19941024 (8)
RLI Continuation-in-part of Ser. No. WO 1994-US9700, filed on 26 Aug 1994 Continuation-in-part of Ser. No. US 1994-274535, filed on 13 Jul 1994, now abandoned Continuation-in-part of Ser. No. US 1994-229420, filed on 15 Apr 1994, now abandoned Continuation-in-part of Ser. No. US 1994-203535, filed on 25 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-153564, filed on 17 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1993-113372, filed on 30 Aug 1993, now abandoned Continuation-in-part of Ser. No. US 1992-970462, filed on 2 Nov 1992, now patented, Pat. No. US 5302706, issued on 12 Apr 1994 Continuation-in-part of Ser. No. US 327874 Division of Ser. No. US 1994-268439, filed on 30 Jun 1994, now abandoned Division of Ser. No. US 1994-160814, filed on 3 Jan 1994, now patented, Pat. No. US 5424400 Continuation-in-part of Ser. No. US 1991-808523, filed on 16 Dec 1991, now abandoned
DT Utility
FS GRANTED

EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Gucker, Stephen
LREP Norton, Esq., Gerard P., Clifford Chance Rogers & Wells LLP
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 5347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening untranslated regions.

L8 ANSWER 86 OF 132 USPATFULL on STN
AN 2002:72987 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Clapper, Jonathan D., Seattle, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
PI US 2002040127 A1 20020404
AI US 2001-878722 A1 20010608 (9)
PRAI US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)
US 2001-290240P 20010510 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8110
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L8 ANSWER 87 OF 132 USPATFULL on STN
AN 2002:72627 USPATFULL
TI Nucleic, acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002039764 A1 20020404
AI US 2001-925298 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US5881, filed on 8 Mar 2000, UNKNOWN

PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 20087
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel ovarian cancer and/or breast cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian and/or breast antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian and/or breast polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian and/or breast nucleic acid molecules are provided encoding novel ovarian and/or breast polypeptides. Novel ovarian and/or breast polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian and/or breast polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

L8 ANSWER 88 OF 132 USPATFULL on STN
AN 2002:66885 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
IN Trepicchio, William L., Andover, MA, UNITED STATES
Oestreicher, Judith L., Portsmouth, NH, UNITED STATES
Dorner, Andrew J., Lexington, MA, UNITED STATES
Krueger, James G., New York, NY, UNITED STATES
PI US 2002037538 A1 20020328
AI US 2001-852400 A1 20010509 (9)
PRAI US 2000-203087P 20000509 (60)
DT Utility
FS APPLICATION
LREP LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 6087
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating psoriasis. A variety of markers

are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of psoriasis.

L8 ANSWER 89 OF 132 USPATFULL on STN
AN 2002:51093 USPATFULL
TI Isolated p27 protein
IN Massague, Joan, New York, NY, United States
Roberts, James M., Seattle, WA, United States
Koff, Andrew, New York, NY, United States
Polyak, Kornelia, Baltimore, MD, United States
PA Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S. corporation)
Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 6355774 B1 20020312
AI US 1997-854039 19970509 (8)
RLI Continuation of Ser. No. US 765702 Continuation-in-part of Ser. No. US 1994-275983, filed on 15 Jul 1994, now patented, Pat. No. US 5688665 Continuation-in-part of Ser. No. US 1994-179045, filed on 7 Jan 1994, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Hayes, Robert C.
LREP Ropes & Gray, Vincent, Matthew P., Halstead, David P.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 41 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 2691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An isolated protein designated p27 is disclosed. The p27 protein has an apparent molecular weight of about 27 kD, and is capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. A nucleic acid sequence encoding p27 protein is disclosed, as well as a method for producing p27 in cultured cells. In vitro assays for discovering agents which affect the activity of p27 are also provided. Methods of diagnosing and treating hypoproliferative disorders are provided.

L8 ANSWER 90 OF 132 USPATFULL on STN
AN 2002:48623 USPATFULL
TI Novel multicyclic compounds and the use thereof
IN Ator, Mark A., Paoli, PA, UNITED STATES
Bihovsky, Ron, Wynnewood, PA, UNITED STATES
Chatterjee, Sankar, Wynnewood, PA, UNITED STATES
Dunn, Derek, Thorndale, PA, UNITED STATES
Hudkins, Robert L., Chester Springs, PA, UNITED STATES
PI US 2002028815 A1 20020307
AI US 2001-850858 A1 20010508 (9)
PRAI US 2000-202947P 20000509 (60)
DT Utility
FS APPLICATION
LREP Robert T. Hrubiec, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA, 19380
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)

LN.CNT 6638
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.

L8 ANSWER 91 OF 132 USPATFULL on STN
AN 2002:37305 USPATFULL
TI Method of regulating transcription in a cell
IN Emerson, Beverly M., San Diego, CA, UNITED STATES
PA Salk Institute for Biological Studies (U.S. corporation)
PI US 2002022021 A1 20020221
AI US 2001-781592 A1 20010212 (9)
PRAI US 2000-181864P 20000211 (60)
DT Utility
FS APPLICATION
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. Box 2938, Minneapolis, MN, 55402
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods and compounds for altering remodeling of chromatin in a cell.

L8 ANSWER 92 OF 132 USPATFULL on STN
AN 2002:19060 USPATFULL
TI Antibody conjugate compositions for selectively inhibiting VEGF
IN Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6342221 B1 20020129
AI US 2000-561108 20000428 (9)
PRAI US 1999-131432P 19990428 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Huynh, Phuong N.
LREP Williams, Morgan and Amerson
CLMN Number of Claims: 68
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 10492
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies

are also provided.

L8 ANSWER 93 OF 132 USPATFULL on STN
AN 2002:19058 USPATFULL
TI Antibody compositions for selectively inhibiting VEGF
IN Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6342219 B1 20020129
AI US 2000-561500 20000428 (9)
PRAI US 1999-131432P 19990428 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Huynh, Phuong N.
LREP Williams, Morgan and Amerson
CLMN Number of Claims: 50
ECL Exemplary Claim: 20
DRWN 7 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 10403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

L8 ANSWER 94 OF 132 USPATFULL on STN
AN 2001:218486 USPATFULL
TI ***ANTIMICROBIAL*** ***HISTONE*** ***H1*** COMPOSITIONS, KITS, AND METHODS OF USE THEREOF
IN CLASS, REINER J. W., DREXEL HILL, PA, United States
HAND, CHRISTOPHER M., WAYNE, PA, United States
PI US 2001046976 A1 20011129
US 6565854 B2 20030520
AI US 1999-372500 A1 19990811 (9)
PRAI US 1998-96382P 19980813 (60)
DT Utility
FS APPLICATION
LREP AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes antibiotic pharmaceutical compositions comprising ***eukaryotic*** ***histone*** ***H1*** protein and methods of using ***eukaryotic*** ***histone*** ***H1*** protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a

eukaryotic ***histone*** ***H1*** -containing animal feed and methods of improving growth of an animal by supplying the feed to the animal. The invention still further includes a kit comprising a ***eukaryotic*** ***histone*** ***H1*** -containing antibiotic pharmaceutical composition and an instructional material which describes the use of the composition. In addition, the invention includes a vaccine comprising a ***eukaryotic*** ***histone*** ***H1*** protein and a method of vaccinating an animal using the vaccine.

L8 ANSWER 95 OF 132 USPATFULL on STN
AN 2001:202398 USPATFULL
TI Methods for determining isolated p27 protein levels and uses thereof
IN Roberts, James M., Seattle, WA, United States
Porter, Peggy L., Seattle, WA, United States
Polyak, Kornelia, Roslindale, MA, United States
Massague, Joan, New York, NY, United States
Koff, Andrew, Westbury, NY, United States
PA Memorial Sloan-Kettering Cancer Center, New York, United States (U.S. corporation)
Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S. corporation)
PI US 6316208 B1 20011113
AI US 1997-794002 19970203 (8)
RLI Continuation-in-part of Ser. No. WO 1995-US7361, filed on 7 Jun 1995 Continuation-in-part of Ser. No. US 1994-275983, filed on 15 Jul 1994, now patented, Pat. No. US 5688665 Continuation-in-part of Ser. No. US 1994-179045, filed on 7 Jan 1994, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Hayes, Robert C.
LREP Foley, Hoag & Eliot, LLP, Vincent, Matthew P., Halstead, David P.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 32 Drawing Page(s)
LN.CNT 2961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention is directed to the discovery of a protein involved in regulation of cell-cycle progression, and includes reagents and methods related thereto.

L8 ANSWER 96 OF 132 USPATFULL on STN
AN 2001:131291 USPATFULL
TI Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
IN Grimley, Philip M., Potomac, MD, United States
Mehta, Sunil, Rumford, RI, United States
PA The Henry Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)
PI US 6274576 B1 20010814
AI US 1998-168106 19981008 (9)
RLI Continuation of Ser. No. US 1996-667543, filed on 21 Jun 1996, now abandoned
PRAI US 1995-546P 19950627 (60)
DT Utility

FS GRANTED
EXNAM Primary Examiner: Chang, Ceila
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 56 Drawing Figure(s); 40 Drawing Page(s)
LN.CNT 4031
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of potentiating cell damage in a target cell population by administering a "restraining agent" and concomitantly or subsequently applying a "targeted cytotoxic insult." The restraining agent is administered at a concentration and under conditions sufficient to retard, but not to arrest, the progress of the target cell population through the cell cycle, a concept termed "dynamic retardation." With such a mechanism, all the cells intended for damage by the targeted cytotoxic insult are likely to cycle into the relevant interval of vulnerability (target interval) within the cell cycle, resulting in a larger number of susceptible cells, and the time period during which those cells are vulnerable to the action of a given targeted cytotoxic insult is increased, resulting in a higher probability and percentage of cell killing.

L8 ANSWER 97 OF 132 USPATFULL on STN
AN 2001:123570 USPATFULL
TI DNA fragmentation factor involved in apoptosis
IN Wang, Xiaodong, Dallas, TX, United States
Liu, Xueson, Dallas, TX, United States
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2001011078 A1 20010802
AI US 2000-748451 A1 20001222 (9)
RLI Division of Ser. No. US 1998-61702, filed on 16 Apr 1998, GRANTED, Pat. No. US 6165737
DT Utility
FS APPLICATION
LREP Gina N. Shishima, Esq., FULBRIGHT & JAWORSKI, 600 Congress Avenue, Suite 1900, Austin, TX, 78701
CLMN Number of Claims: 100
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5190
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and compositions relating to DNA Fragmentation Factor (DFF) polypeptides and related nucleic acids. More particularly, the present invention provides the sequence for the active subunit of DFF. The polypeptides may be produced recombinantly from host cells transformed from the disclosed DFF encoding nucleic acids or purified from human cells. The invention provides isolated DFF hybridization probes and primers capable of specifically hybridization with the disclosed DFF genes, DFF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions.

L8 ANSWER 98 OF 132 USPATFULL on STN
AN 2001:109885 USPATFULL
TI NOVEL PROPERTY EFFECTING AND/OR PROPERTY EXHIBITING COMPOSITIONS FOR

THERAPEUTIC AND DIAGNOSTIC USES
IN RABBANI, ELAZAR, NEW YORK, NY, United States
STAVRIANOPOULOS, JANNIS G., BAY SHORE, NY, United States
DONEGAN, JAMES J., LONG BEACH, NY, United States
LIU, DAKAI, BETHPAGE, NY, United States
KELKER, NORMAN E., NEW YORK, NY, United States
ENGLEHARDT, DEAN L., NEW YORK, NY, United States
PI US 2001007767 A1 20010712
AI US 1997-978632 A1 19971125 (8)
RLI Continuation of Ser. No. US 1995-574443, filed on 15 Dec 1995, ABANDONED
DT Utility
FS APPLICATION
LREP RONALD C FEDUS, ENZO BIOCHEMICAL INC., 527 MADISON AVENUE, 9TH FLOOR, NEW YORK, NY, 10022
CLMN Number of Claims: 244
ECL Exemplary Claim: 1
DRWN 51 Drawing Page(s)
LN.CNT 4848
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an array of compositions useful for effecting and/or exhibiting changes in biological functioning and processing within cells and in biological systems containing such cells. In effect, these compositions combine chemical modifications and/or ligand additions with biological functions. The chemical modifications and/or ligand additions provide additional characteristics to the compositions without interfering substantially with their biological function. Such additional characteristics include nuclease resistance, targeting specific cells or specific cell receptors localizing to specific sites within cells and augmenting interactions between the compositions and target cells of interest as well as decreasing such interactions when desired. Also provided by the present invention are processes and kits.

L8 ANSWER 99 OF 132 USPATFULL on STN
AN 2001:105197 USPATFULL
TI NOVEL PROPERTY EFFECTING AND/OR PROPERTY EXHIBITING COMPOSITIONS FOR THERAPEUTIC AND DIAGNOSTIC USES
IN RABBANI, ELAZAR, NEW YORK, NY, United States
STAVRIANOPOULOS, JANNIS G., BAY SHORE, NY, United States
DONEGAN, JAMES J., LONG BEACH, NY, United States
LIU, DAKAI, BETHPAGE, NY, United States
KELKER, NORMAN E., NEW YORK, NY, United States
ENGELHARDT, DEAN L., NEW YORK, NY, United States
PI US 2001006816 A1 20010705
AI US 1997-978637 A1 19971125 (8)
RLI Division of Ser. No. US 1995-574443, filed on 15 Dec 1995, ABANDONED
DT Utility
FS APPLICATION
LREP RONALD C FEDUS, ENZO DIAGNOSTICS INC, ENZO BIOCHEM INC, 527 MADISON AVENUE 9TH FLOOR, NEW YORK, NY, 10022
CLMN Number of Claims: 244
ECL Exemplary Claim: 1
DRWN 51 Drawing Page(s)
LN.CNT 4831
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an array of compositions useful for effecting and/or exhibiting changes in biological functioning and processing within cells and in biological systems containing such cells. In effect, these compositions combine chemical modifications and/or ligand additions with biological functions. The chemical modifications and/or ligand additions provide additional characteristics to the compositions without interfering substantially with their biological function. Such additional characteristics include nuclease resistance, targeting specific cells or specific cell receptors localizing to specific sites within cells and augmenting interactions between the compositions and target cells of interest as well as decreasing such interactions when desired. Also provided by the present invention are processes and kits.

L8 ANSWER 100 OF 132 USPATFULL on STN
AN 2001:105196 USPATFULL
TI NOVEL PROPERTY EFFECTING AND/OR PROPERTY EXHIBITING COMPOSITIONS FOR THERAPEUTIC AND DIAGNOSTIC USES
IN RABBANI, ELAZAR, NEW YORK, NY, United States
STAVRIANOPOULOS, JANNIS G., BAY SHORE, NY, United States
DONEGAN, JAMES J., LONG BEACH, NY, United States
LIU, DAKAI, BETHPAGE, NY, United States
KELKER, NORMAN E., NEW YORK, NY, United States
ENGELHARDT, DEAN L., NEW YORK, NY, United States
PI US 2001006815 A1 20010705
AI US 1997-978634 A1 19971125 (8)
RLI Continuation of Ser. No. US 1995-574443, filed on 15 Dec 1995, ABANDONED
DT Utility
FS APPLICATION
LREP RONALD C FEDUS, ENZO DIAGNOSTICS INC, 527 MADISON AVENUE, 9TH FLOOR, NEW YORK, NY, 10022
CLMN Number of Claims: 244
ECL Exemplary Claim: 1
DRWN 51 Drawing Page(s)
LN.CNT 4845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an array of compositions useful for effecting and/or exhibiting changes in biological functioning and processing within cells and in biological systems containing such cells. In effect, these compositions combine chemical modifications and/or ligand additions with biological functions. The chemical modifications and/or ligand additions provide additional characteristics to the compositions without interfering substantially with their biological function. Such additional characteristics include nuclease resistance, targeting specific cells or specific cell receptors localizing to specific sites within cells and augmenting interactions between the compositions and target cells of interest as well as decreasing such interactions when desired. Also provided by the present invention are processes and kits.

L8 ANSWER 101 OF 132 USPATFULL on STN
AN 2001:105195 USPATFULL
TI NOVEL PROPERTY EFFECTING AND/ OR PROPERTY EXHIBITING COMPOSITIONS FOR THERAPEUTIC AND DIAGNOSTIC USES
IN RABBANI, ELAZAR, NEW YORK, NY, United States

STAVRIANOPOULOS, JANNIS G., BAY SHORE, NY, United States
DONEGAN, JAMES J., LONG BEACH, NY, United States
LIU, DAKAI, BETHPAGE, NY, United States
KELKER, NORMAN E., NEW YORK, NY, United States
ENGELHARDT, DEAN L., NEW YORK, NY, United States
PI US 2001006814 A1 20010705
AI US 1997-978633 A1 19971125 (8)
RLI Division of Ser. No. US 1995-574443, filed on 15 Dec 1995, ABANDONED
DT Utility
FS APPLICATION
LREP RONALD C. FEDUS, ENZO DIAGNOSTICS, INC, C/O ENZO BIOCHEM, INC, 527 MADISON AVENUE (9TH FLOOR), NEW YORK, NY, 10022
CLMN Number of Claims: 244
ECL Exemplary Claim: 1
DRWN 51 Drawing Page(s)
LN.CNT 4847
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an array of compositions useful for effecting and/or exhibiting changes in biological functioning and processing within cells and in biological systems containing such cells. In effect, these compositions combine chemical modifications and/or ligand additions with biological functions. The chemical modifications and/or ligand additions provide additional characteristics to the compositions without interfering substantially with their biological function. Such additional characteristics include nuclease resistance, targeting specific cells or specific cell receptors localizing to specific sites within cells and augmenting interactions between the compositions and target cells of interest as well as decreasing such interactions when desired. Also provided by the present invention are processes and kits.

L8 ANSWER 102 OF 132 USPATFULL on STN
AN 2001:82900 USPATFULL
TI Antibodies for detecting p27 protein
IN Massague, Joan, New York, NY, United States
Roberts, James M., Seattle, WA, United States
Koff, Andrew, New York, NY, United States
Polyak, Kornelia, Baltimore, MD, United States
PA Fred Hutchinson Institute for Cancer Research, Seattle, WA, United States (U.S. corporation)
Sloan-Kettering Institute for Cancer Research, New Yotk, NY, United States (U.S. corporation)
PI US 6242575 B1 20010605
AI US 1997-822936 19970221 (8)
RLI Division of Ser. No. US 765702 Continuation-in-part of Ser. No. US 1994-275983, filed on 15 Jul 1994, now patented, Pat. No. US 5688665 Continuation-in-part of Ser. No. US 1994-179045, filed on 7 Jan 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Johnson, Nancy A
LREP Foley Hoag & Eliot
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 41 Drawing Figure(s); 30 Drawing Page(s)

LN.CNT 2437
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention provides an isolated protein having an apparent molecular weight of about 27 kD and capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. The subject invention further provides an isolated antibody and a purified preparation of polyclonal and monoclonal antibodies which are specifically immunoreactive with a p27 protein. The subject invention further provides a kit for detecting a p27 protein.

L8 ANSWER 103 OF 132 USPATFULL on STN
AN 2001:67794 USPATFULL
TI Human respiratory syncytial virus peptides with antifusogenic and antiviral activities
IN Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PA Trimeris, Inc., Durham, NC, United States (U.S. corporation)
PI US 6228983 B1 20010508
AI US 1995-485264 19950607 (8)
RLI Division of Ser. No. US 1995-470896, filed on 6 Jun 1995
Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994
Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994
Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DT Utility
FS Granted
EXNAM Primary Examiner: Scheiner, Laurie; Assistant Examiner: Parkin, Jeffrey S.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 84 Drawing Figure(s); 83 Drawing Page(s)
LN.CNT 32166
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.

L8 ANSWER 104 OF 132 USPATFULL on STN
AN 2001:44433 USPATFULL
TI Adenosine deaminase deficient transgenic mice and methods for the use thereof
IN Kellems, Rodney E., Houston, TX, United States
Datta, Surjit K., Houston, TX, United States
Blackburn, Michael R., Pearland, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6207876 B1 20010327
AI US 1999-301665 19990428 (9)
PRAI US 1998-83408P 19980429 (60)

US 1998-83370P 19980428 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: LeGuyader, John L.; Assistant Examiner: Kaushal, Sumesh
LREP Fulbright Jaworski, LLP
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 6595
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the production of adenosine deaminase (ADA) deficient mice and the use of such mice as an animal model for dysfunctions associated with elevated adenosine levels. Also, provided by the present invention are methods of treating dysfunctions associated with elevated adenosine levels and methods of screening compounds for pharmaceutical activity in the treatment of dysfunctions associated with elevated adenosine levels.

L8 ANSWER 105 OF 132 USPATFULL on STN
AN 2001:29329 USPATFULL
TI Recombinant expression of proteins from secretory cell lines
IN Newgard, Christopher B., Dallas, TX, United States
Halban, Philippe, Geneva, Switzerland
Normington, Karl D., Dallas, TX, United States
Clark, Samuel A., Rockwell, TX, United States
Thigpen, Anice E., Dallas, TX, United States
Quaade, Christian, Dallas, TX, United States
Kruse, Fred, Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Betagene, Inc., Dallas, TX, United States (U.S. corporation)
PI US 6194176 B1 20010227
AI US 1997-785271 19970117 (8)
RLI Continuation-in-part of Ser. No. US 1996-589028, filed on 19 Jan 1996
DT Utility
FS Granted
EXNAM Primary Examiner: Campbell, Eggerton A.
LREP Arnold, White & Durkee
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 7541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.

L8 ANSWER 106 OF 132 USPATFULL on STN

AN 2000:174366 USPATFULL
TI DNA fragmentation factor involved in apoptosis
IN Wang, Xiaodong, Dallas, TX, United States
Liu, Xuesong, Dallas, TX, United States
PA The University of Texas System Board of Regents, Austin, TX, United States (U.S. corporation)
PI US 6165737 20001226
AI US 1998-61702 19980416 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Moore, William W.
LREP Fulbright & Jaworski L.L.P.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 5176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and compositions relating to DNA Fragmentation Factor (DFF) polypeptides and related nucleic acids. More particularly, the present invention provides the sequence for the active subunit of DFF. The polylpeptides may be produced recombinantly from host cells transformed from the disclosed DFF encoding nucleic acids or purified from human cells. The invention provides isolated DFF hybridization probes and primers capable of specifically hybridization with the disclosed DFF genes, DFF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions.

L8 ANSWER 107 OF 132 USPATFULL on STN
AN 2000:113735 USPATFULL
TI Recombinant expression of proteins from secretory cell lines
IN Newgard, Christopher B., Dallas, TX, United States
Halban, Philippe, Geneva, Switzerland
Normington, Karl D., Dallas, TX, United States
Clark, Samuel A., Rockwall, TX, United States
Thigpen, Anice E., Dallas, TX, United States
Quaade, Christian, Dallas, TX, United States
Kruse, Fred, Dallas, TX, United States
McGarry, Dennis, Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Betagene, Inc., Dallas, TX, United States (U.S. corporation)
PI US 6110707 20000829
AI US 1997-784582 19970117 (8)
RLI Continuation-in-part of Ser. No. US 1996-589028, filed on 19 Jan 1996
PRAI US 1996-28279P 19961011 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Campbell, Eggerton A.
LREP Arnold, White & Durkee
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 39 Drawing Figure(s); 31 Drawing Page(s)
LN.CNT 10089

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention a provides methods for production of heterologous polypeptides, for example amylin, using recombinantly engineered cell lines. Also described are methods engineering cells for high level expression, methods of large scale heterologous protein production, methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines, and methods for isolating novel amylin receptors.

L8 ANSWER 108 OF 132 USPATFULL on STN

AN 2000:87959 USPATFULL

TI Recombinant expression of proteins from secretory cell lines

IN Newgard, Christopher B., Dallas, TX, United States
Normington, Karl D., Dallas, TX, United States
Clark, Samuel A., Rockwall, TX, United States
Thigpen, Anice E., Dallas, TX, United States
Quaade, Christian, Dallas, TX, United States
Kruse, Fred, Dallas, TX, United States

PA Betagene, Inc., Dallas, TX, United States (U.S. corporation)
Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

PI US 6087129 20000711

AI US 1996-589028 19960119 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Campbell, Eggerton A.

LREP Arnold, White & Durkee

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN 16 Drawing Figure(s); 17 Drawing Page(s)

LN.CNT 6238

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.

L8 ANSWER 109 OF 132 USPATFULL on STN

AN 2000:84032 USPATFULL

TI Detection of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients

IN Deretic, Vojo, San Antonio, TX, United States
Martin, Daniel W., Palo Alto, CA, United States

PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

PI US 6083691 20000704

AI US 1995-505307 19951124 (8)

RLI Continuation-in-part of Ser. No. US 1993-17114, filed on 12 Feb 1993, now patented, Pat. No. US 5591838

DT Utility

FS Granted
EXNAM Primary Examiner: Houtteman, Scott W.
LREP Arnold, White & Durkee
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 22 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 3355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for detecting the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. Chronic respiratory infections with mucoid Pseudomonas aeruginosa are the leading cause of high mortality and morbidity in cystic fibrosis. The initially colonizing strains are nonmucoid but in the cystic fibrosis lung they invariably convert into the mucoid form causing further disease deterioration and poor prognosis. Mucoidy is a critical P. aeruginosa virulence factor in cystic fibrosis that has been associated with biofilm development and resistance to phagocytosis. The molecular basis of this conversion to mucoidy is also disclosed. The present invention provides for detecting the switch from nonmucoid to mucoid state as caused by either frameshift deletions and duplications or nonsense changes in the second gene of the cluster, mucA. Inactivation of mucA results in constitutive expression of genes, such as algD, dependent on algU for transcription. Also disclosed is a novel alginate biosynthesis heterologous expression system for use in screening candidate substances that inhibit conversion to mucoidy.

L8 ANSWER 110 OF 132 USPATFULL on STN
AN 2000:31403 USPATFULL
TI Compositions containing nucleic acids and ligands for therapeutic treatment
IN Baird, J. Andrew, San Diego, CA, United States
Chandler, Lois Ann, Encinitas, CA, United States
Sosnowski, Barbara A., Coronado, CA, United States
PA Selective Genetics, Inc., La Jolla, CA, United States (U.S. corporation)
PI US 6037329 20000314
AI US 1996-718904 19960924 (8)
RLI Continuation-in-part of Ser. No. US 1995-441979, filed on 16 May 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-213446, filed on 15 Mar 1994, now abandoned Ser. No. Ser. No. US 1994-213447, filed on 15 Mar 1994, now abandoned Ser. No. Ser. No. US 1994-297961, filed on 29 Aug 1994, now abandoned And Ser. No. US 1994-305771, filed on 13 Sep 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Priebe, Scott D.; Assistant Examiner: Nguyen, Dave Trong
LREP Seed and Berry LLP
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 34 Drawing Figure(s); 25 Drawing Page(s)
LN.CNT 7163
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with

an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.

L8 ANSWER 111 OF 132 USPATFULL on STN
AN 2000:18565 USPATFULL
TI Isolated nucleic acid molecules encoding P57KIP2
IN Massague, Joan, New York, NY, United States
Lee, Mong-Hong, New York, NY, United States
PA Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 6025480 20000215
AI US 1995-415655 19950403 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Fredman, Jeffrey
LREP White, John P.Cooper & Dunham LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 3
DRWN 25 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2164
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides an isolated nucleic acid molecule encoding a mammalian p57.sup.KIP2. This invention also provides vectors comprising the isolated nucleic acid molecule encoding a mammalian p57.sup.KIP2. This invention further provides a host vector system for the production of a mammalian p57.sup.KIP2. This invention also provides probes for the isolated nucleic acid molecule encoding a mammalian p57.sup.KIP2. This invention provides antibodies directed against a mammalian p57.sup.KIP2. This invention also provides transgenic animals comprising isolated nucleic acid molecules encoding a mammalian p57.sup.KIP2. Finally, this invention provides different uses of the mammalian p57.sup.KIP2.

L8 ANSWER 112 OF 132 USPATFULL on STN
AN 2000:1692 USPATFULL
TI Sequence-directed DNA binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood, CA, United States (U.S. corporation)
PI US 6010849 20000104
AI US 1995-482080 19950607 (8)
RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a

continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Schwartzman, Robert
LREP Fabin, Gary R.Dehlinger & Associates
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 10022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L8 ANSWER 113 OF 132 USPATFULL on STN
AN 1999:72446 USPATFULL
TI Telomerase screening methods
IN Gottschling, Daniel E., Chicago, IL, United States
Singer, Miriam S., Chicago, IL, United States
PA Arch Development Corporation, Chicago, IL, United States (U.S. corporation)
PI US 5916752 19990629
AI US 1997-938534 19970926 (8)
RLI Division of Ser. No. US 1995-431080, filed on 28 Apr 1995, now patented, Pat. No. US 5698686 which is a continuation-in-part of Ser. No. US 1994-326781, filed on 20 Oct 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Fredman, Jeffrey
LREP Arnold, White & Durkee
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 7780
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are various methods, compositions and screening assays connected with telomerase, including genes encoding the template RNA of S. cerevisiae telomerase and various telomerase-associated polypeptides.

L8 ANSWER 114 OF 132 USPATFULL on STN
AN 1999:18912 USPATFULL
TI Method of determining DNA sequence preference of a DNA-binding molecule
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States

Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5869241 19990209
AI US 1995-475228 19950607 (8)
RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stepanie W.; Assistant Examiner: Whisenant, Ethan
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 72 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 9840
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L8 ANSWER 115 OF 132 USPATFULL on STN
AN 1998:154291 USPATFULL
TI Use of ciclopirox or a pharmaceutically acceptable salt thereof for inhibiting neuronal cell damage or neuronal cell death
IN Greene, Lloyd A., Larchmont, NY, United States
Farinelli, Stephen E., New York, NY, United States
PA The Trustees of Columbia University in the City of New York, New York, NY, United States (U.S. corporation)
PI US 5846984 19981208
AI US 1996-588764 19960119 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Criares, Theodore J.
LREP White, John P.Cooper & Dunham LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 28 Drawing Page(s)

LN.CNT 1212
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone, also known as ciclopirox, and its salts such as ciclopirox olamine are used to inhibit neuronal cell damage or neuronal cell death.

L8 ANSWER 116 OF 132 USPATFULL on STN
AN 1998:44877 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5744131 19980428
AI US 1995-476876 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 5113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L8 ANSWER 117 OF 132 USPATFULL on STN
AN 1998:39383 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5738990 19980414
AI US 1995-475221 19950607 (8)

RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Guzo, David; Assistant Examiner: Brusca, John S.
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 5040
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L8 ANSWER 118 OF 132 USPATFULL on STN
AN 1998:33942 USPATFULL
TI Inhibitors of cyclin dependent kinases
IN Mansuri, Muzammil M., Lexington, MA, United States
Murthi, Krishna K., Waltham, MA, United States
Pal, Kollol, Needham, MA, United States
PA Mitotix, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5733920 19980331
AI US 1995-551031 19951031 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Dahlen, Garth M.
LREP Foley, Hoag & Eliot, LLP
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel inhibitors of cyclin-dependent kinases, in particular inhibitors of the CDK/cyclin complexes such as CDK4/cyclin D1. The novel compounds are analogs of chromones. These compounds can be used for inhibiting excessive or abnormal cell proliferation. Thus, the novel compounds are useful for treating a subject with a disorder associated with excessive cell proliferation, such as cancer.

L8 ANSWER 119 OF 132 USPATFULL on STN
AN 1998:28088 USPATFULL
TI Pharmacologically active pyridine derivatives and processes for the

preparation thereof
IN Zimmermann, Jurg, Wallbach, Switzerland
PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)
PI US 5728708 19980317
WO 9509853 19930413
AI US 1995-446743 19950531 (8)
WO 1994-EP3151 19940921
19950531 PCT 371 date
19950531 PCT 102(e) date
PRAI CH 1993-2969 19931001
CH 1994-2281 19940718
DT Utility
FS Granted
EXNAM Primary Examiner: Ford, John M.
LREP Ferraro, Gregory D.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2107
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB N-phenyl-2-pyrimidineamine derivatives of formula I ##STR1## wherein the substituents are as defined in claim 1 and the derivatives of formula I can be used, for example, in the treatment of tumour diseases.

L8 ANSWER 120 OF 132 USPATFULL on STN
AN 1998:25075 USPATFULL
TI Screening assay for the detection of DNA-binding molecules
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
Turin, Lisa M., Berkeley, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5726014 19980310
AI US 1993-123936 19930917 (8)
RLI Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 72 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 5659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein

complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L8 ANSWER 121 OF 132 USPATFULL on STN
AN 1998:14634 USPATFULL
TI Method of constructing sequence-specific DNA-binding molecules
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5716780 19980210
AI US 1995-484499 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 4929
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L8 ANSWER 122 OF 132 USPATFULL on STN
AN 1998:1785 USPATFULL
TI Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
IN Zimmermann, Jurg, Wallbach, Switzerland
PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)
PI US 5705502 19980106
WO 9509851 19950413
AI US 1995-446742 19950531 (8)
WO 1994-EP3148 19940921
19950531 PCT 371 date

19950531 PCT 102(e) date
PRAI CH 1993-2968 19931001
CH 1994-2280 19940718
DT Utility
FS Granted
EXNAM Primary Examiner: Ford, John M.
LREP Ferraro, Gregory D.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1283
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described are N-phenyl-2-pyrimidineamine derivatives of formula I ##STR1## wherein R.sub.1 is a substituted cyclic radical, the cyclic radical being bonded at a ring carbon atom in each case and being selected from phenyl, pyridyl, pyrazinyl, thiazolyl, pyrimidinyl, pyridazinyl and imidazolyl, and the substituents of the above-mentioned cyclic radical being selected from one or more of the groups halogen, cyano, carbamoyl, --C(.dbd.O)--OR.sub.3, --C(.dbd.O)--R.sub.4, --SO.sub.2 --N(R.sub.5)--R.sub.6, --N(R.sub.7)--R.sub.8, --OR.sub.9 and fluorine-substituted lower alkyl, wherein

R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are each independently of the others hydrogen or lower alkyl that is unsubstituted or substituted by mono- or di-lower alkylamino; and

R.sub.2 is selected from halogen, cyano, carbamoyl, --C(.dbd.O)--OR.sub.10, --C(.dbd.O)--R.sub.11, --SO.sub.2 --N(R.sub.12)--R.sub.13, --N(R.sub.14)--R.sub.15, --OR.sub.16 and fluorine-substituted lower alkyl, wherein

R.sub.10, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15 and R.sub.16 are each independently of the others hydrogen or lower alkyl that is unsubstituted or substituted by mono- or di-lower alkylamino. Those compounds can be used, for example, in the treatment of tumour diseases.

L8 ANSWER 123 OF 132 USPATFULL on STN
AN 97:118172 USPATFULL
TI Yeast telomerase compositions
IN Gottschling, Daniel E., Chicago, IL, United States
Singer, Miriam S., Chicago, IL, United States
PA Arch Development Corporation, Chicago, IL, United States (U.S. corporation)
PI US 5698686 19971216
AI US 1995-431080 19950428 (8)
RLI Continuation-in-part of Ser. No. US 1994-326781, filed on 20 Oct 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Fredman, Jeffrey
LREP Arnold, White & Durkee
CLMN Number of Claims: 71
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 7319

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are various methods, compositions and screening assays connected with telomerase, including genes encoding the template RNA of S. cerevisiae telomerase and various telomerase-associated polypeptides.

L8 ANSWER 124 OF 132 USPATFULL on STN

AN 97:112300 USPATFULL

TI Method of ordering sequence binding preferences of a DNA-binding molecule

IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States4)

PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

PI US 5693463 19971202

AI US 1992-996783 19921223 (7)

DCD 20110426

RLI Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy

LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN 48 Drawing Figure(s); 33 Drawing Page(s)

LN.CNT 4908

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L8 ANSWER 125 OF 132 USPATFULL on STN

AN 97:106954 USPATFULL

TI Isolated nucleic acid molecules encoding the p27 KIP-1 protein

IN Massague, Joan, New York, NY, United States
Roberts, James M., Seattle, WA, United States
Koff, Andrew, New York, NY, United States
Polyak, Kornelia, New York, NY, United States

PA Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S. corporation)
Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)

PI US 5688665 19971118
AI US 1994-275983 19940715 (8)
RLI Continuation-in-part of Ser. No. US 1994-179045, filed on 7 Jan 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Allen, Marianne P.; Assistant Examiner: Hayes, Robert C.
LREP Vincent, Matthew P., Arnold, Beth E.Foley, Hoag & Eliot LLP
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 2486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention provides an isolated protein having an apparent molecular weight of about 27 kD and capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. The subject invention further provides a recombinant nucleic acid molecule which encodes the p27 protein of the subject invention, and related vectors and host vector systems. The subject invention further provides a method for producing the p27 protein of the subject invention using the host vector system. The subject invention further provides methods of determining whether an agent is capable of specifically inhibiting or enhancing the ability of p27 protein to inhibit the activation of cyclin E-Cdk2 complex. Finally, this subject invention provides different uses of the isolated protein, the recombinant nucleic acid molecule encoding the isolated protein and the agent capable of inhibiting or enchancing the ability of p27 protein to inhibit the activation of cyclin E-Cdk2 complex.

L8 ANSWER 126 OF 132 USPATFULL on STN
AN 97:1557 USPATFULL
TI Detection of conversion to mucoidy in pseudomonas aeruginosa infecting cystic fibrosis patients
IN Deretic, Vojo, San Antonio, TX, United States
Martin, Daniel W., San Antonio, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5591838 19970107
AI US 1993-17114 19930212 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Parr, Margaret; Assistant Examiner: Houttem, Scott
LREP Arnold, White & Durkee
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 25 Drawing Page(s)
LN.CNT 2225
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for detecting the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. Chronic respiratory infections with mucoid Pseudomonas aeruginosa are the leading cause of high mortality and morbidity in cystic fibrosis. The initially colonizing strains are nonmucoid but in the cystic fibrosis lung they invariably convert into the mucoid form causing further disease deterioration and poor prognosis. The molecular basis of this conversion to mucoidy is

also disclosed. The algU gene encodes a protein homologous to an alternative sigma factor regulating sporulation and other developmental processes in Bacillus, and along with the negative regulators mucA and mucB comprises the gene cluster controlling conversion to mucoidy. The switch from nonmucoid to mucoid state is caused by frameshift deletions and duplications in the second gene of the cluster, mucA. Inactivation of mucA results in constitutive expression of genes, such as algD, dependent on algU for transcription. Insertional inactivation of mucB on the chromosome of the standard genetic strain PAO also resulted in mucoid phenotype, and in a strong transcriptional activation of algD. Activation of algD results in increased synthesis of the exopolysaccharide alginate rendering P. aeruginosaa mucoid.

L8 ANSWER 127 OF 132 USPATFULL on STN
AN 96:108816 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5578444 19961126
AI US 1993-171389 19931220 (8)
RLI Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Brookes, Allen A., Stratford, Carol A.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 71 Drawing Figure(s); 48 Drawing Page(s)
LN.CNT 5845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L8 ANSWER 128 OF 132 USPATFULL on STN
AN 96:103875 USPATFULL
TI Detection of conversion to mucoidy in Pseudomonas aeruginosa infecting

cystic fibrosis patients involving the algu gene
IN Deretic, Vojo, San Antonio, TX, United States
Martin, Daniel W., San Antonio, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5573910 19961112
AI US 1994-260202 19940615 (8)
RLI Continuation-in-part of Ser. No. US 1993-17114, filed on 12 Feb 1993
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Rees, Dianne
LREP Arnold White & Durkee
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 22 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 3374
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for detecting the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. Mucoidy is a critical P. aeruginosa virulence factor in cystic fibrosis that has been associated with biofilm develoment and resistance to phagocytosis. The present invention provides for detecting the switch from nonmucoid to mucoid state as caused by the interaction of the algU gene product, algU, with RNA polymerase. Inactivation of algU results in a loss of expression of genes, such as algD, dependent on algU for transcription. Also disclosed is a novel alginate biosynthesis heterologous expression system for use in screening candidate substances that inhibit conversion to mucoidy by inhibiting the interaction of algU with the RNA polymerase holoenzyme.

L8 ANSWER 129 OF 132 USPATFULL on STN
AN 96:87509 USPATFULL
TI Protein serine kinase, SRPK1
IN Gui, Jian-Fang, San Diego, CA, United States
Fu, Xiang-Dong, San Diego, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5559019 19960924
AI US 1994-264002 19940622 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Patterson, Jr., Charles L.; Assistant Examiner: Bugaisky, G. E.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 44 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 1952
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel serine protein kinase, SRPK1, having a molecular weight of about 92 kD and phosphorylating the SR family of splicing factors in a cell-cycle regulated manner is described. Polynucleotide and polypeptide sequences for SRPK1 are provided as well as methods for modulating splicing and alternative splicing of precursor mRNAs.

L8 ANSWER 130 OF 132 USPATFULL on STN
AN 96:70558 USPATFULL
TI Pyrimidine derivatives
IN Zimmermann, J urg, Wallbach, Switzerland
PA Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)
PI US 5543520 19960806
AI US 1994-306333 19940915 (8)
PRAI CH 1993-2966 19931001
CH 1994-2278 19940718
DT Utility
FS Granted
EXNAM Primary Examiner: Ford, John M.
LREP Mathias, Marla J., Kaiser, Karen G., Fishman, Irving M.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 602
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are disclosed N-(fluoroalkoxyphenyl)-2-pyrimidine-amine derivatives of formula I ##STR1## wherein R.sub.1 is isoquinolinyl, thienyl or 1H-pyrrolyl, and R.sub.2 is fluoro-substituted alkoxy containing up to 2 carbon atoms. These compounds can be used, inter alia, for the therapy of tumoral diseases.

L8 ANSWER 131 OF 132 USPATFULL on STN
AN 88:26041 USPATFULL
TI Biologically functional molecular chimeras
IN Cohen, Stanley N., Menlo Park, CA, United States
Boyer, Herbert W., Mill Valley, CA, United States
PA The Board of Trustees of the Leland Stanford, Jr. University, Stanford, CA, United States (U.S. corporation)
PI US 4740470 19880426
AI US 1984-602294 19840420 (6)
DCD 19971202
RLI Continuation of Ser. No. US 1978-959288, filed on 9 Nov 1978, now patented, Pat. No. US 4468464 which is a continuation of Ser. No. US 1976-687430, filed on 17 May 1976, now abandoned which is a continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tanenholtz, Alvin E.
LREP Rowland, Bertram I.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 982
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions are provided for replication and expression of exogenous genes in microorganisms. Plasmids or virus DNA are cleaved to provide linear DNA having ligatable termini, which are bound to a gene having complementary termini, to provide a biologically functional replicon with a desired phenotypical property. The replicon is inserted into a microorganism cell by transformation. Isolation of the transformants provides cells for replication and expression of the DNA

molecules present in the modified plasmid. The method provides a convenient and efficient way to introduce genetic capability into microorganisms for the production of nucleic acids and proteins, such as medically or commercially useful enzymes, which may have direct usefulness, or may find expression in the production of drugs, such as hormones, antibiotics, or the like, fixation of nitrogen, fermentation, utilization of specific feedstocks, or the like.

The invention was supported by generous grants of NIH, NSF and the American Cancer Society.

L8 ANSWER 132 OF 132 USPATFULL on STN
AN 80:60508 USPATFULL
TI Process for producing biologically functional molecular chimeras
IN Cohen, Stanley N., Portola Valley, CA, United States
Boyer, Herbert W., Mill Valley, CA, United States
PA Board of Trustees of the Leland Stanford Jr. University, Stanford, CA, United States (U.S. corporation)
PI US 4237224 19801202
AI US 1979-1021 19790104 (6)
RLI Continuation-in-part of Ser. No. US 1978-959288, filed on 9 Nov 1978, now Defensive Publication No. which is a continuation-in-part of Ser. No. US 1976-687430, filed on 17 May 1976, now abandoned which is a continuation-in-part of Ser. No. US 1974-520691, filed on 4 Nov 1974, now Defensive Publication No.
DT Utility
FS Granted
EXNAM Primary Examiner: Tanenholtz, Alvin E.
LREP Rowland, Bertram I.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 983
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method and compositions are provided for replication and expression of exogenous genes in microorganisms. Plasmids or virus DNA are cleaved to provide linear DNA having ligatable termini to which is inserted a gene having complementary termini, to provide a biologically functional replicon with a desired phenotypical property. The replicon is inserted into a microorganism cell by transformation. Isolation of the transformants provides cells for replication and expression of the DNA molecules present in the modified plasmid. The method provides a convenient and efficient way to introduce genetic capability into microorganisms for the production of nucleic acids and proteins, such as medically or commercially useful enzymes, which may have direct usefulness, or may find expression in the production of drugs, such as hormones, antibiotics, or the like, fixation of nitrogen, fermentation, utilization of specific feedstocks, or the like.

=> s l8 and (animal feed)
L9 3 L8 AND (ANIMAL FEED)
=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:115183 CAPLUS
DN 134:168376
TI ***Antimicrobial*** ***histone*** ***H1*** compositions, kits, and methods of use thereof
IN Class, Reiner; Zeppezauer, Michael
PA Symbiotec Gm.b.H., Germany; Philadelphia Health and Education Corp.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001010901	A2	20010215	WO 2000-US21747	20000809
WO 2001010901	A3	20010809		
WO 2001010901	C2	20020912		
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 2001046976	A1	20011129	US 1999-372500	19990811
US 6565854	B2	20030520		
EP 1200463	A2	20020502	EP 2000-957347	20000809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

PRAI US 1999-372500 A 19990811
US 1998-96382P P 19980813
WO 2000-US21747 W 20000809
AB The invention includes antibiotic pharmaceutical compns. comprising ***eukaryotic*** ***histone*** ***H1*** protein and methods of using ***eukaryotic*** ***histone*** ***H1*** protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a ***eukaryotic*** ***histone*** ***H1*** -contg. ***animal*** ***feed*** and methods of improving growth of an animal by supplying the feed to the animal. The invention still further includes a kit comprising a ***eukaryotic*** ***histone*** ***H1*** -contg. antibiotic pharmaceutical compn. and an instructional material which describes the use of the compn. In addn., the invention includes a vaccine comprising a ***eukaryotic*** ***histone*** ***H1*** protein and a method of vaccinating an animal using the vaccine.

L9 ANSWER 2 OF 3 USPATFULL on STN
AN 2003:180284 USPATFULL
TI ***Antimicrobial*** agent
IN Rothman, Ulf, St. Peter Port, UNITED KINGDOM
PI US 2003124111 A1 20030703
AI US 2002-231400 A1 20020829 (10)
PRAI SE 2001-2864 20010829
DT Utility

FS APPLICATION
LREP JAMES RAY & ASSOCIATES, 2640 Pitcairn Road, Monroeville, PA, 15146
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 692
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of a proteineous component isolated from plant chromatin, after dissociation of the same, as an ***antimicrobial*** agent, the proteineous component having an apparent molecular weight between 10 and 20 kD. The proteineous plant component is produced by means of a method comprising the steps of homogenizing a plant material in order to expose its plant chromatin, dissociating the plant chromatin with a dissociating agent under hydrophobic conditions, and separating the dissociated plant chromatin into individual fractions, one comprising the proteineous plant component, by means of a hydrophobic interaction separation procedure.

L9 ANSWER 3 OF 3 USPATFULL on STN
AN 2001:218486 USPATFULL
TI ***ANTIMICROBIAL*** ***HISTONE*** ***H1*** COMPOSITIONS, KITS, AND METHODS OF USE THEREOF
IN CLASS, REINER J. W., DREXEL HILL, PA, United States
HAND, CHRISTOPHER M., WAYNE, PA, United States
PI US 2001046976 A1 20011129
US 6565854 B2 20030520
AI US 1999-372500 A1 19990811 (9)
PRAI US 1998-96382P 19980813 (60)
DT Utility
FS APPLICATION
LREP AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes antibiotic pharmaceutical compositions comprising ***eukaryotic*** ***histone*** ***H1*** protein and methods of using ***eukaryotic*** ***histone*** ***H1*** protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a ***eukaryotic*** ***histone*** ***H1*** -containing ***animal*** ***feed*** and methods of improving growth of an animal by supplying the feed to the animal. The invention still further includes a kit comprising a ***eukaryotic*** ***histone*** ***H1*** -containing antibiotic pharmaceutical composition and an instructional material which describes the use of the composition. In addition, the invention includes a vaccine comprising a ***eukaryotic*** ***histone*** ***H1*** protein and a method of vaccinating an animal using the vaccine.

=> s l8 and (food?)
L10 48 L8 AND (FOOD?)

=> s l8 and (foodstuff)
L11 3 L8 AND (FOODSTUFF)

=> d l10 bib ab 1-
YOU HAVE REQUESTED DATA FROM 48 ANSWERS - CONTINUE? Y/(N):y

L10 ANSWER 1 OF 48 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:115183 CAPLUS
DN 134:168376
TI ***Antimicrobial*** ***histone*** ***H1*** compositions, kits, and methods of use thereof
IN Class, Reiner; Zeppezauer, Michael
PA Symbiotec Gm.b.H., Germany; Philadelphia Health and Education Corp.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001010901	A2	20010215	WO 2000-US21747	20000809
WO 2001010901	A3	20010809		
WO 2001010901	C2	20020912		
US 2001046976	A1	20011129	US 1999-372500	19990811
US 6565854	B2	20030520		
EP 1200463	A2	20020502	EP 2000-957347	20000809

W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

PRAI US 1999-372500 A 19990811
US 1998-96382P P 19980813
WO 2000-US21747 W 20000809
AB The invention includes antibiotic pharmaceutical compns. comprising ***eukaryotic*** ***histone*** ***H1*** protein and methods of using ***eukaryotic*** ***histone*** ***H1*** protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a ***eukaryotic*** ***histone*** ***H1*** -contg. animal feed and methods of improving growth of an animal by supplying the feed to the animal. The invention still further includes a kit comprising a ***eukaryotic*** ***histone*** ***H1*** -contg. antibiotic pharmaceutical compn. and an instructional material which describes the use of the compn. In addn., the invention includes a vaccine comprising a ***eukaryotic*** ***histone*** ***H1*** protein and a method of vaccinating an animal using the vaccine.

L10 ANSWER 2 OF 48 USPATFULL on STN
AN 2003:200457 USPATFULL
TI Multimeric proteins and methods of making and using same
IN Fang, Fang, San Diego, CA, UNITED STATES

Luo, Guang-Xiang, San Diego, CA, UNITED STATES
Kohlstaedt, Lori Allison, La Jolla, CA, UNITED STATES
Charles, Catherine Helen, Encinitas, CA, UNITED STATES
PI US 2003138440 A1 20030724
AI US 2002-199957 A1 20020719 (10)
PRAI US 2001-306746P 20010719 (60)
US 2001-335425P 20011130 (60)
DT Utility
FS APPLICATION
LREP Pillsbury Winthrop LLP, Intellectual Property Group, P.O. Box 10500, McLean, VA, 22102
CLMN Number of Claims: 112
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 3098
AB The invention provides multimerization polypeptides capable of conferring formation of multimers when the multimerization polypeptide is linked to a molecule, such as a heterologous polypeptide sequence.

L10 ANSWER 3 OF 48 USPATFULL on STN
AN 2003:180711 USPATFULL
TI Interventions to mimic the effects of calorie restriction
IN Spindler, Stephen R., Riverside, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 2003124540 A1 20030703
AI US 2002-56749 A1 20020122 (10)
RLI Continuation of Ser. No. US 2000-648642, filed on 25 Aug 2000, GRANTED, Pat. No. US 6406853
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Long term calorie restriction has the benefit of increasing life span. Methods to screen interventions that mimic the effects of calorie restriction are disclosed. Extensive analysis of genes for which expression is statistically different between control and calorie restricted animals has demonstrated that specific genes are preferentially expressed during calorie restriction. Screening for interventions which produce the same expression profile will provide interventions that increase life span. In a further aspect, it has been discovered that test animals on a calorie restricted diet for a relatively short time have a similar gene expression profile to test animals which have been on a long term calorie restricted diet.

L10 ANSWER 4 OF 48 USPATFULL on STN
AN 2003:180701 USPATFULL
TI Sequence-directed DNA-binding molecules compositons and methods
IN Edwards, Cynthia A., Menlo Park, CA, UNITED STATES
Cantor, Charles R., Del Mar, CA, UNITED STATES
Andrews, Beth M., Maynard, MA, UNITED STATES

Turin, Lisa M., Redwood City, CA, UNITED STATES
Fry, Kirk E., Palo Alto, CA, UNITED STATES
PA Genelabs Technologies, Inc. (U.S. corporation)
PI US 2003124530 A1 20030703
AI US 2001-993346 A1 20011113 (9)
RLI Division of Ser. No. US 1999-354947, filed on 15 Jul 1999, GRANTED, Pat. No. US 6384208 Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, GRANTED, Pat. No. US 6010849 Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, GRANTED, Pat. No. US 5578444 Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, GRANTED, Pat. No. US 5726014 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, GRANTED, Pat. No. US 5693463 Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, ABANDONED
DT Utility
FS APPLICATION
LREP PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 47 Drawing Page(s)
LN.CNT 10851
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 5 OF 48 USPATFULL on STN
AN 2003:180284 USPATFULL
TI ***Antimicrobial*** agent
IN Rothman, Ulf, St. Peter Port, UNITED KINGDOM
PI US 2003124111 A1 20030703
AI US 2002-231400 A1 20020829 (10)
PRAI SE 2001-2864 20010829
DT Utility
FS APPLICATION
LREP JAMES RAY & ASSOCIATES, 2640 Pitcairn Road, Monroeville, PA, 15146
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 692
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of a proteineous component isolated from plant chromatin, after dissociation of the same, as an ***antimicrobial*** agent, the proteineous component having an apparent molecular weight between 10 and 20 kD. The proteineous plant component is produced by means of a method comprising the steps of

homogenizing a plant material in order to expose its plant chromatin, dissociating the plant chromatin with a dissociating agent under hydrophobic conditions, and separating the dissociated plant chromatin into individual fractions, one comprising the proteineous plant component, by means of a hydrophobic interaction separation procedure.

L10 ANSWER 6 OF 48 USPATFULL on STN
AN 2003:172748 USPATFULL
TI Binding domain-immunoglobulin fusion proteins
IN Ledbetter, Jeffrey A., Shoreline, WA, UNITED STATES
Hayden-Ledbetter, Martha S., Shoreline, WA, UNITED STATES
Thompson, Peter A., Danville, CA, UNITED STATES
PA Genecraft, Inc., Shoreline, WA (U.S. corporation)
PI US 2003118592 A1 20030626
AI US 2002-207655 A1 20020725 (10)
RLI Continuation-in-part of Ser. No. US 2002-53530, filed on 17 Jan 2002, PENDING
PRAI US 2001-367358P 20010117 (60)
US 2002-385691P 20020603 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 61
ECL Exemplary Claim: 1
DRWN 53 Drawing Page(s)
LN.CNT 7939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

L10 ANSWER 7 OF 48 USPATFULL on STN
AN 2003:159819 USPATFULL
TI Compositions and methods for the therapy and diagnosis of kidney cancer
IN Algate, Paul A., Issaquah, WA, UNITED STATES
Mannion, Jane, Edmonds, WA, UNITED STATES
Gaiger, Alexander, Seattle, WA, UNITED STATES
Gordon, Brian, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003109434 A1 20030612
AI US 2002-102524 A1 20020319 (10)
PRAI US 2001-343340P 20011221 (60)
US 2001-277245P 20010319 (60)
DT Utility

FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly kidney cancer, are disclosed. Illustrative compositions comprise one or more kidney tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly kidney cancer.

L10 ANSWER 8 OF 48 USPATFULL on STN
AN 2003:152696 USPATFULL
TI CELL-CYCLE REGULATORY PROTEINS FROM HUMAN PATHOGENS, AND USES RELATED THERETO
IN COTTAREL, GUILLAUME, ARLINGTON, MA, UNITED STATES
DAMAGNEZ, VERONIQUE, CAMBRIDGE, MA, UNITED STATES
DRAETTA, GIULIO, OPERA, ITALY
PI US 2003104362 A1 20030605
AI US 1998-72994 A1 19980505 (9)
RLI Continuation-in-part of Ser. No. US 1995-463090, filed on 5 Jun 1995, GRANTED, Pat. No. US 5801015
DT Utility
FS APPLICATION
LREP ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the discovery of novel cell cycle regulatory proteins from the human pathogen Candida.

L10 ANSWER 9 OF 48 USPATFULL on STN
AN 2003:140406 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003096247 A1 20030522
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION

LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L10 ANSWER 10 OF 48 USPATFULL on STN
AN 2003:133926 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003092011 A1 20030515
AI US 2001-489 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L10 ANSWER 11 OF 48 USPATFULL on STN
AN 2003:113075 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2003077808 A1 20030424
AI US 2001-764891 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)

DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 59131
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel reproductive system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "reproductive system related antigens," and the use of such reproductive system related antigens for detecting disorders of the reproductive system, particularly the presence of cancers and cancer metastases. More specifically, isolated reproductive system associated nucleic acid molecules are provided encoding novel reproductive system associated polypeptides. Novel reproductive system related polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human reproductive system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the reproductive system, including reproductive system cancers, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

L10 ANSWER 12 OF 48 USPATFULL on STN
AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions

thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

L10 ANSWER 13 OF 48 USPATFULL on STN
AN 2003:81623 USPATFULL
TI BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth
IN Arlinghaus, Ralph B., Bellaire, TX, United States
Liu, Jiaxin, Bellaire, TX, United States
Lopez-Berestein, Gabriel, Bellaire, TX, United States
Lu, Dai, Pearland, TX, United States
Wu, Yun, Houston, TX, United States
PA Board of Regents, The University of Texas Systems, Austin, TX, United States (U.S. corporation)
PI US 6537804 B1 20030325
WO 9625520 19960822
AI US 1999-101059 19990621 (9)
WO 1996-US2091 19960216
RLI Continuation-in-part of Ser. No. US 1995-390353, filed on 16 Feb 1995, now patented, Pat. No. US 6107457
DT Utility
FS GRANTED
EXNAM Primary Examiner: McGarry, Sean
LREP Fulbright & Jaworski
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 3281
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for detecting and quantitating BCR-ABL gene products and other abnormal ABL gene products of Ph.sup.1-positive leukemic cells. The invention further provides methods for determining the relative number of leukemic cells compared with normal ABL cells to assess the tumor burden of a patient. In another aspect, the methods of the present invention can be used to determine a specific phase of leukemia, particularly chronic-phase CML.

L10 ANSWER 14 OF 48 USPATFULL on STN
AN 2003:78457 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2003054377 A1 20030320
AI US 2002-102627 A1 20020322 (10)
RLI Continuation of Ser. No. US 2001-764856, filed on 17 Jan 2001, PENDING
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 18653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

L10 ANSWER 15 OF 48 USPATFULL on STN
AN 2003:71365 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2003049650 A1 20030313
AI US 2002-91483 A1 20020307 (10)
RLI Continuation of Ser. No. US 2001-764846, filed on 17 Jan 2001, ABANDONED
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 22593
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

L10 ANSWER 16 OF 48 USPATFULL on STN
AN 2003:37603 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE

PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027248 A1 20030206
AI US 2001-924340 A1 20010806 (9)
PRAI US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP GENSET, JOHN LUCAS, PHD, J.D., 10665 SORRENTO VALLEY RD, SAN DIEGO, CA, 92121
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L10 ANSWER 17 OF 48 USPATFULL on STN
AN 2003:37516 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027161 A1 20030206
AI US 2001-992600 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L10 ANSWER 18 OF 48 USPATFULL on STN
AN 2003:23331 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003017167 A1 20030123
AI US 2001-904456 A1 20010711 (9)
RLI Continuation-in-part of Ser. No. US 2001-878722, filed on 8 Jun 2001, PENDING
PRAI US 2001-290240P 20010510 (60)
US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L10 ANSWER 19 OF 48 USPATFULL on STN
AN 2002:344628 USPATFULL
TI Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
IN Gaiger, Alexander, Seattle, WA, UNITED STATES
Algate, Paul A., Issaquah, WA, UNITED STATES
Mannion, Jane, Seattle, WA, UNITED STATES
PI US 2002198362 A1 20021226
AI US 2001-796692 A1 20010301 (9)
PRAI US 2000-223378P 20000807 (60)
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 100
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 19014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, human leukemias and lymphomas of the follicular, Hodgkin's and B cell and T cll non-Hodgkin's types. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific

malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of a variety of leukemias and lymphomas.

L10 ANSWER 20 OF 48 USPATFULL on STN
AN 2002:310941 USPATFULL
TI Suppression of cyclin kinase 2 activity for prevention and treatment of DNA viral infections
IN Albrecht, Thomas, Galveston, TX, United States
Thompson, Aubrey E., Dickinson, TX, United States
Bresnahan, Wade, Plainsboro, NJ, United States
Meijer, Laurent, Roscoff, FRANCE
PA Board of Regents, The University of Texas, Austin, TX, United States (U.S. corporation)
PI US 6486166 B1 20021126
AI US 1999-389830 19990903 (9)
RLI Continuation of Ser. No. WO 1998-US4154, filed on 2 Mar 1998
PRAI US 1997-38126P 19970303 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Webman, Edward J.
LREP Fulbright & Jaworski
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 30 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 1990
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An important aspect of the present invention is a method for inhibiting proliferation of a DNA virus dependent upon events associated with cell proliferation for replication. The DNA virus includes any of the herpesvirus family, and most particularly human cytomegalovirus. The method involves administering prophylactically or therapeutically effective amount of a cyclin-dependent kinase inhibitor to a patient or animal.

L10 ANSWER 21 OF 48 USPATFULL on STN
AN 2002:303980 USPATFULL
TI Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
IN Roth, Jack A., Houston, TX, United States
Cai, De Wei, Cheltenham, PA, United States
Mukhopadhyay, Tapas, Houston, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6482803 B1 20021119
AI US 1995-523030 19950901 (8)
DT Utility
FS GRANTED
EXNAM Primary Examiner: LeGuyader, John L.
LREP Fulbright & Jaworski

CLMN Number of Claims: 25
ECL Exemplary Claim: 1,4
DRWN 12 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 2784
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses expression constructs and methods for employing them that result in the modulation of abnormal oncogene and tumor suppressor genes in a novel approach to cancer prevention and therapy. In one embodiment, an expression construct expresses a ribozyme that inactivates mutant p53 and also expresses the functional p53.

L10 ANSWER 22 OF 48 USPATFULL on STN
AN 2002:273550 USPATFULL
TI Nucleic acids, proteins and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002151681 A1 20021017
AI US 2001-925300 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US5988, filed on 8 Mar 2000, UNKNOWN
PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 29771
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to newly identified prostate or prostate cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "prostate cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, and to antibodies that immunospecifically bind these polypeptides, as well as the use of such prostate cancer polynucleotides, antigens, and antibodies for detection, prevention, prognosis, and treatment of disorders of the reproductive system, particularly disorders of the prostate, including, but not limited to, the presence of prostate cancer and prostate cancer metastases. More specifically, isolated prostate cancer nucleic acid molecules are provided encoding novel prostate cancer polypeptides. Novel prostate cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human prostate cancer polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the prostate, including prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

L10 ANSWER 23 OF 48 USPATFULL on STN

AN 2002:272801 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002150922 A1 20021017
AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

L10 ANSWER 24 OF 48 USPATFULL on STN
AN 2002:191573 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002102638 A1 20020801
AI US 2001-764846 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 22814
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating,

preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

L10 ANSWER 25 OF 48 USPATFULL on STN
AN 2002:191539 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2002102604 A1 20020801
AI US 2000-731872 A1 20001207 (9)
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., Genset Corporation, 10665 Srrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 28061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L10 ANSWER 26 OF 48 USPATFULL on STN
AN 2002:166381 USPATFULL
TI Adenosine deaminase deficient transgenic mice and methods for the use thereof
IN Kellems, Rodney E., Houston, TX, UNITED STATES
Datta, Surjit K., Houston, TX, UNITED STATES
Blackburn, Michael R., Pearland, TX, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2002088017 A1 20020704
AI US 2001-761198 A1 20010116 (9)
RLI Continuation of Ser. No. US 1999-301665, filed on 28 Apr 1999, UNKNOWN
DT Utility
FS APPLICATION
LREP Stephen M. Hash, Ph.D., FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 7243
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the production of adenosine deaminase

(ADA) deficient mice and the use of such mice as an animal model for dysfunctions associated with elevated adenosine levels. Also, provided by the present invention are methods of treating dysfunctions associated with elevated adenosine levels and methods of screening compounds for pharmaceutical activity in the treatment of dysfunctions associated with elevated adenosine levels.

L10 ANSWER 27 OF 48 USPATFULL on STN
AN 2002:164735 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002086353 A1 20020704
AI US 2001-764856 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 23314
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

L10 ANSWER 28 OF 48 USPATFULL on STN
AN 2002:157060 USPATFULL
TI Nucleic acids, proteins and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002081659 A1 20020627
AI US 2001-925297 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US5989, filed on 8 Mar 2000, UNKNOWN
PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 20326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pancreatic related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "pancreatic antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such pancreatic polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the pancreas, including, but not limited to, the presence of pancreatic cancer and pancreatic cancer metastases. More specifically, isolated pancreatic nucleic acid molecules are provided encoding novel pancreatic polypeptides. Novel pancreatic polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human pancreatic polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the pancreas, including pancreatic cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

L10 ANSWER 29 OF 48 USPATFULL on STN
AN 2002:144075 USPATFULL
TI Interventions to mimic the effects of calorie restriction
IN Spindler, Stephen R., Riverside, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6406853 B1 20020618
AI US 2000-648642 20000825 (9)
RLI Continuation-in-part of Ser. No. US 1999-471225, filed on 23 Dec 1999
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Taylor, Janell E.
LREP Townsend & Townsend & Crew LLP
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Long term calorie restriction has the benefit of increasing life span. Methods to screen interventions that mimic the effects of calorie restriction are disclosed. Extensive analysis of genes for which expression is statistically different between control and calorie restricted animals has demonstrated that specific genes are preferentially expressed during calorie restriction. Screening for interventions which produce the same expression profile will provide interventions that increase life span. In a further aspect, it has been discovered that test animals on a calorie restricted diet for a relatively short time have a similar gene expression profile to test animals which have been on a long term calorie restricted diet.

L10 ANSWER 30 OF 48 USPATFULL on STN
AN 2002:102627 USPATFULL

TI Sequence directed DNA binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 6384208 B1 20020507
AI US 1999-354947 19990715 (9)
RLI Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, now patented, Pat. No. US 6010849, issued on 4 Jan 2000 Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444, issued on 26 Nov 1996 Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014, issued on 10 Mar 1998 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463, issued on 2 Dec 1997 Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Schwartzman, Robert A.; Assistant Examiner: Davis, Katharine F.
LREP Fabian, Gary, Thrower, Larry W., Perkins Coie LLP
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 71 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 5215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 31 OF 48 USPATFULL on STN
AN 2002:72987 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Clapper, Jonathan D., Seattle, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
PI US 2002040127 A1 20020404
AI US 2001-878722 A1 20010608 (9)
PRAI US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)

US 2001-290240P 20010510 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8110
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

L10 ANSWER 32 OF 48 USPATFULL on STN
AN 2002:72627 USPATFULL
TI Nucleic, acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002039764 A1 20020404
AI US 2001-925298 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US5881, filed on 8 Mar 2000, UNKNOWN
PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 20087
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel ovarian cancer and/or breast cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian and/or breast antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian and/or breast polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian and/or breast nucleic acid molecules are provided encoding novel ovarian and/or breast polypeptides. Novel ovarian and/or breast polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian and/or breast polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods

useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

L10 ANSWER 33 OF 48 USPATFULL on STN
AN 2002:37305 USPATFULL
TI Method of regulating transcription in a cell
IN Emerson, Beverly M., San Diego, CA, UNITED STATES
PA Salk Institute for Biological Studies (U.S. corporation)
PI US 2002022021 A1 20020221
AI US 2001-781592 A1 20010212 (9)
PRAI US 2000-181864P 20000211 (60)
DT Utility
FS APPLICATION
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. Box 2938, Minneapolis, MN, 55402
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods and compounds for altering remodeling of chromatin in a cell.

L10 ANSWER 34 OF 48 USPATFULL on STN
AN 2001:218486 USPATFULL
TI ***ANTIMICROBIAL*** ***HISTONE*** ***H1*** COMPOSITIONS, KITS, AND METHODS OF USE THEREOF
IN CLASS, REINER J. W., DREXEL HILL, PA, United States
HAND, CHRISTOPHER M., WAYNE, PA, United States
PI US 2001046976 A1 20011129
US 6565854 B2 20030520
AI US 1999-372500 A1 19990811 (9)
PRAI US 1998-96382P 19980813 (60)
DT Utility
FS APPLICATION
LREP AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes antibiotic pharmaceutical compositions comprising ***eukaryotic*** ***histone*** ***H1*** protein and methods of using ***eukaryotic*** ***histone*** ***H1*** protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a ***eukaryotic*** ***histone*** ***H1*** -containing animal feed and methods of improving growth of an animal by supplying the feed to

the animal. The invention still further includes a kit comprising a ***eukaryotic*** ***histone*** ***H1*** -containing antibiotic pharmaceutical composition and an instructional material which describes the use of the composition. In addition, the invention includes a vaccine comprising a ***eukaryotic*** ***histone*** ***H1*** protein and a method of vaccinating an animal using the vaccine.

L10 ANSWER 35 OF 48 USPATFULL on STN
AN 2001:123570 USPATFULL
TI DNA fragmentation factor involved in apoptosis
IN Wang, Xiaodong, Dallas, TX, United States
Liu, Xueson, Dallas, TX, United States
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2001011078 A1 20010802
AI US 2000-748451 A1 20001222 (9)
RLI Division of Ser. No. US 1998-61702, filed on 16 Apr 1998, GRANTED, Pat. No. US 6165737
DT Utility
FS APPLICATION
LREP Gina N. Shishima, Esq., FULBRIGHT & JAWORSKI, 600 Congress Avenue, Suite 1900, Austin, TX, 78701
CLMN Number of Claims: 100
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5190
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and compositions relating to DNA Fragmentation Factor (DFF) polypeptides and related nucleic acids. More particularly, the present invention provides the sequence for the active subunit of DFF. The polypeptides may be produced recombinantly from host cells transformed from the disclosed DFF encoding nucleic acids or purified from human cells. The invention provides isolated DFF hybridization probes and primers capable of specifically hybridization with the disclosed DFF genes, DFF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions.

L10 ANSWER 36 OF 48 USPATFULL on STN
AN 2001:44433 USPATFULL
TI Adenosine deaminase deficient transgenic mice and methods for the use thereof
IN Kellems, Rodney E., Houston, TX, United States
Datta, Surjit K., Houston, TX, United States
Blackburn, Michael R., Pearland, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6207876 B1 20010327
AI US 1999-301665 19990428 (9)
PRAI US 1998-83408P 19980429 (60)
US 1998-83370P 19980428 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: LeGuyader, John L.; Assistant Examiner: Kaushal, Sumesh
LREP Fulbright Jaworski, LLP

CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 6595
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the production of adenosine deaminase (ADA) deficient mice and the use of such mice as an animal model for dysfunctions associated with elevated adenosine levels. Also, provided by the present invention are methods of treating dysfunctions associated with elevated adenosine levels and methods of screening compounds for pharmaceutical activity in the treatment of dysfunctions associated with elevated adenosine levels.

L10 ANSWER 37 OF 48 USPATFULL on STN
AN 2001:29329 USPATFULL
TI Recombinant expression of proteins from secretory cell lines
IN Newgard, Christopher B., Dallas, TX, United States
Halban, Philippe, Geneva, Switzerland
Normington, Karl D., Dallas, TX, United States
Clark, Samuel A., Rockwell, TX, United States
Thigpen, Anice E., Dallas, TX, United States
Quaade, Christian, Dallas, TX, United States
Kruse, Fred, Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Betagene, Inc., Dallas, TX, United States (U.S. corporation)
PI US 6194176 B1 20010227
AI US 1997-785271 19970117 (8)
RLI Continuation-in-part of Ser. No. US 1996-589028, filed on 19 Jan 1996
DT Utility
FS Granted
EXNAM Primary Examiner: Campbell, Eggerton A.
LREP Arnold, White & Durkee
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 7541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.

L10 ANSWER 38 OF 48 USPATFULL on STN
AN 2000:174366 USPATFULL
TI DNA fragmentation factor involved in apoptosis
IN Wang, Xiaodong, Dallas, TX, United States
Liu, Xuesong, Dallas, TX, United States
PA The University of Texas System Board of Regents, Austin, TX, United States (U.S. corporation)

PI US 6165737 20001226
AI US 1998-61702 19980416 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Moore, William W.
LREP Fulbright & Jaworski L.L.P.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 5176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and compositions relating to DNA Fragmentation Factor (DFF) polypeptides and related nucleic acids. More particularly, the present invention provides the sequence for the active subunit of DFF. The polylpeptides may be produced recombinantly from host cells transformed from the disclosed DFF encoding nucleic acids or purified from human cells. The invention provides isolated DFF hybridization probes and primers capable of specifically hybridization with the disclosed DFF genes, DFF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions.

L10 ANSWER 39 OF 48 USPATFULL on STN
AN 2000:113735 USPATFULL
TI Recombinant expression of proteins from secretory cell lines
IN Newgard, Christopher B., Dallas, TX, United States
Halban, Philippe, Geneva, Switzerland
Normington, Karl D., Dallas, TX, United States
Clark, Samuel A., Rockwall, TX, United States
Thigpen, Anice E., Dallas, TX, United States
Quaade, Christian, Dallas, TX, United States
Kruse, Fred, Dallas, TX, United States
McGarry, Dennis, Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Betagene, Inc., Dallas, TX, United States (U.S. corporation)
PI US 6110707 20000829
AI US 1997-784582 19970117 (8)
RLI Continuation-in-part of Ser. No. US 1996-589028, filed on 19 Jan 1996
PRAI US 1996-28279P 19961011 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Campbell, Eggerton A.
LREP Arnold, White & Durkee
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 39 Drawing Figure(s); 31 Drawing Page(s)
LN.CNT 10089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention a provides methods for production of heterologous polypeptides, for example amylin, using recombinantly engineered cell lines. Also described are methods engineering cells for high level expression, methods of large scale heterologous protein production, methods for treatment of disease in vivo using viral delivery systems

and recombinant cell lines, and methods for isolating novel amylin receptors.

L10 ANSWER 40 OF 48 USPATFULL on STN
AN 2000:1692 USPATFULL
TI Sequence-directed DNA binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood, CA, United States (U.S. corporation)
PI US 6010849 20000104
AI US 1995-482080 19950607 (8)
RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Schwartzman, Robert
LREP Fabin, Gary R.Dehlinger & Associates
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 10022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 41 OF 48 USPATFULL on STN
AN 1999:18912 USPATFULL
TI Method of determining DNA sequence preference of a DNA-binding molecule
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

PI US 5869241 19990209
AI US 1995-475228 19950607 (8)
RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stepanie W.; Assistant Examiner: Whisenant, Ethan
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 72 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 9840
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 42 OF 48 USPATFULL on STN
AN 1998:44877 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5744131 19980428
AI US 1995-476876 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 5113

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 43 OF 48 USPATFULL on STN

AN 1998:39383 USPATFULL

TI Sequence-directed DNA-binding molecules compositions and methods

IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States

PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

PI US 5738990 19980414

AI US 1995-475221 19950607 (8)

RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Guzo, David; Assistant Examiner: Brusca, John S.

LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 48 Drawing Figure(s); 33 Drawing Page(s)

LN.CNT 5040

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 44 OF 48 USPATFULL on STN

AN 1998:33942 USPATFULL
TI Inhibitors of cyclin dependent kinases
IN Mansuri, Muzammil M., Lexington, MA, United States
Murthi, Krishna K., Waltham, MA, United States
Pal, Kollol, Needham, MA, United States
PA Mitotix, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5733920 19980331
AI US 1995-551031 19951031 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Dahlen, Garth M.
LREP Foley, Hoag & Eliot, LLP
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel inhibitors of cyclin-dependent kinases, in particular inhibitors of the CDK/cyclin complexes such as CDK4/cyclin D1. The novel compounds are analogs of chromones. These compounds can be used for inhibiting excessive or abnormal cell proliferation. Thus, the novel compounds are useful for treating a subject with a disorder associated with excessive cell proliferation, such as cancer.

L10 ANSWER 45 OF 48 USPATFULL on STN
AN 1998:25075 USPATFULL
TI Screening assay for the detection of DNA-binding molecules
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
Turin, Lisa M., Berkeley, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5726014 19980310
AI US 1993-123936 19930917 (8)
RLI Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 72 Drawing Figure(s); 47 Drawing Page(s)
LN.CNT 5659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein

complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

L10 ANSWER 46 OF 48 USPATFULL on STN
AN 1998:14634 USPATFULL
TI Method of constructing sequence-specific DNA-binding molecules
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5716780 19980210
AI US 1995-484499 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 4929
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 47 OF 48 USPATFULL on STN
AN 97:112300 USPATFULL
TI Method of ordering sequence binding preferences of a DNA-binding molecule
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States4)
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5693463 19971202

AI US 1992-996783 19921223 (7)
DCD 20110426
RLI Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 4908
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

L10 ANSWER 48 OF 48 USPATFULL on STN
AN 96:108816 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5578444 19961126
AI US 1993-171389 19931220 (8)
RLI Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Atzel, Amy
LREP Fabian, Gary R., Brookes, Allen A., Stratford, Carol A.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 71 Drawing Figure(s); 48 Drawing Page(s)
LN.CNT 5845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their

ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

=> s l8 and (personal care?)
L12 0 L8 AND (PERSONAL CARE?)
=> s l8 and (cream or lotion or deodorant or lipstick or toothpaste or floss or mouthwash or tampon or insole)
L13 36 L8 AND (CREAM OR LOTION OR DEODORANT OR LIPSTICK OR TOOTHPASTE OR FLOSS OR MOUTHWASH OR TAMPON OR INSOLE)
=> d bib 1-
YOU HAVE REQUESTED DATA FROM 36 ANSWERS - CONTINUE? Y/(N):y

L13 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:115183 CAPLUS
DN 134:168376
TI ***Antimicrobial*** ***histone*** ***H1*** compositions, kits, and methods of use thereof
IN Class, Reiner; Zeppezauer, Michael
PA Symbiotec Gm.b.H., Germany; Philadelphia Health and Education Corp.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001010901	A2	20010215	WO 2000-US21747	20000809
WO 2001010901	A3	20010809		
WO 2001010901	C2	20020912		
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 2001046976	A1	20011129	US 1999-372500	19990811
US 6565854	B2	20030520		
EP 1200463	A2	20020502	EP 2000-957347	20000809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

PRAI US 1999-372500 A 19990811
US 1998-96382P P 19980813
WO 2000-US21747 W 20000809

L13 ANSWER 2 OF 36 USPATFULL on STN
AN 2003:215360 USPATFULL
TI Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
IN Kaelin, William G., JR., Boston, MA, UNITED STATES
Livingston, David M., Brookline, MA, UNITED STATES
Kim, Tae-You, Seoul, KOREA, REPUBLIC OF
PI US 2003150005 A1 20030807
AI US 2002-287670 A1 20021104 (10)
RLI Continuation-in-part of Ser. No. US 2002-101662, filed on 19 Mar 2002, PENDING
PRAI US 2001-277425P 20010320 (60)
DT Utility
FS APPLICATION
LREP MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
CLMN Number of Claims: 18
ECL Exemplary Claim: 1

DRWN 30 Drawing Page(s)
LN.CNT 3741

L13 ANSWER 3 OF 36 USPATFULL on STN
AN 2003:207194 USPATFULL
TI Novel compositions and methods for the identification, assessment, prevention and therapy of human cancers
IN Clark, Edwin, Ashland, MA, UNITED STATES
Grenfell-Lee, Tallessyn, Cambridge, MA, UNITED STATES
Lu, Karen, Houston, TX, UNITED STATES
Hartmann, Lynn, Rochester, MN, UNITED STATES
Brown, Jeffrey L., Arlington, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02139 (U.S. corporation)
PI US 2003143552 A1 20030731
AI US 2002-71510 A1 20020208 (10)
PRAI US 2001-267276P 20010208 (60)
DT Utility
FS APPLICATION
LREP LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 69
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4574

L13 ANSWER 4 OF 36 USPATFULL on STN
AN 2003:159828 USPATFULL
TI Diagnosing, treating, and preventing cancer using cables
IN Rueda, Bo R., Windham, NH, UNITED STATES
Zukerberg, Lawrence R., Newton, MA, UNITED STATES
Wu, Chin-Lee, Newton, MA, UNITED STATES
PI US 2003109443 A1 20030612
AI US 2002-262480 A1 20021001 (10)
PRAI US 2001-326465P 20011001 (60)
US 2002-356685P 20020214 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 2685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 36 USPATFULL on STN
AN 2003:159819 USPATFULL
TI Compositions and methods for the therapy and diagnosis of kidney cancer
IN Algate, Paul A., Issaquah, WA, UNITED STATES
Mannion, Jane, Edmonds, WA, UNITED STATES
Gaiger, Alexander, Seattle, WA, UNITED STATES
Gordon, Brian, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003109434 A1 20030612
AI US 2002-102524 A1 20020319 (10)

PRAI US 2001-343340P 20011221 (60)
US 2001-277245P 20010319 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 36 USPATFULL on STN
AN 2003:146199 USPATFULL
TI Combination therapy involving drugs which target cellular proteins and drugs which target pathogen-encoded proteins
IN Schaffer, Priscilla A., Boston, MA, UNITED STATES
Schang, Luis M., Edmonton, CANADA
PI US 2003099944 A1 20030529
AI US 2000-905687 A1 20001206 (9)
RLI Continuation-in-part of Ser. No. US 2000-951058, filed on 12 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-656592, filed on 7 Sep 2000, PENDING Continuation of Ser. No. WO 1999-US16252, filed on 16 Jul 1999, PENDING
PRAI US 1998-94805P 19980731 (60)
US 1999-131264P 19990427 (60)
US 1999-140926P 19990624 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 38 Drawing Page(s)
LN.CNT 4046
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 36 USPATFULL on STN
AN 2003:140406 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003096247 A1 20030522
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609

CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 36 USPATFULL on STN
AN 2003:133926 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003092011 A1 20030515
AI US 2001-489 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 36 USPATFULL on STN
AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 36 USPATFULL on STN
AN 2003:86849 USPATFULL
TI Cellular proteins as targets for the treatment of pathogens resistant to drugs that target pathogen-encoded proteins
IN Schaffer, Priscilla A., Boston, MA, UNITED STATES

Schang, Luis M., Edmonton, CANADA
PI US 2003060457 A1 20030327
AI US 2000-905695 A1 20001206 (9)
RLI Continuation-in-part of Ser. No. US 2000-951058, filed on 12 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-656592, filed on 7 Sep 2000, PENDING Continuation of Ser. No. WO 1999-US16252, filed on 16 Jul 1999, PENDING
PRAI US 1998-94805P 19980731 (60)
US 1999-131264P 19990427 (60)
US 1999-140926P 19990624 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 38 Drawing Page(s)
LN.CNT 3979
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 36 USPATFULL on STN
AN 2003:71317 USPATFULL
TI Inhibitors of microbial gene expression replication and pathogenesis
IN Schaffer, Priscilla A., Boston, MA, UNITED STATES
Schang, Luis M., Edmonton, CANADA
Jordan, Robert, Erdenheim, PA, UNITED STATES
PI US 2003049602 A1 20030313
AI US 2000-905689 A1 20001206 (9)
RLI Continuation-in-part of Ser. No. US 2000-951058, filed on 12 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-656592, filed on 7 Sep 2000, PENDING Continuation of Ser. No. WO 1999-US16252, filed on 16 Jul 1999, PENDING
PRAI US 1998-94805P 19980731 (60)
US 1999-131264P 19990427 (60)
US 1999-140926P 19990624 (60)
DT Utility
FS APPLICATION
LREP MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
CLMN Number of Claims: 73
ECL Exemplary Claim: 1
DRWN 37 Drawing Page(s)
LN.CNT 4213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 12 OF 36 USPATFULL on STN
AN 2003:37603 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027248 A1 20030206
AI US 2001-924340 A1 20010806 (9)
PRAI US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)

US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP GENSET, JOHN LUCAS, PHD, J.D., 10665 SORRENTO VALLEY RD, SAN DIEGO, CA, 92121
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 13 OF 36 USPATFULL on STN
AN 2003:37516 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027161 A1 20030206
AI US 2001-992600 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 14 OF 36 USPATFULL on STN
AN 2003:30251 USPATFULL
TI Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
IN Kaelin, William G., JR., Boston, MA, UNITED STATES
Livingston, David M., Brookline, MA, UNITED STATES
Kim, Tae-You, Seoul, KOREA, REPUBLIC OF
PI US 2003022198 A1 20030130
AI US 2002-101662 A1 20020319 (10)
PRAI US 2001-277425P 20010320 (60)
DT Utility
FS APPLICATION
LREP Ivor R. Elrifi, Ph.D., MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY and POPEO, P.C., One Financial Center, Boston, MA, 02111
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 3094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 15 OF 36 USPATFULL on STN
AN 2003:23331 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003017167 A1 20030123
AI US 2001-904456 A1 20010711 (9)
RLI Continuation-in-part of Ser. No. US 2001-878722, filed on 8 Jun 2001, PENDING
PRAI US 2001-290240P 20010510 (60)
US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 16 OF 36 USPATFULL on STN
AN 2002:344628 USPATFULL
TI Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
IN Gaiger, Alexander, Seattle, WA, UNITED STATES
Algate, Paul A., Issaquah, WA, UNITED STATES
Mannion, Jane, Seattle, WA, UNITED STATES
PI US 2002198362 A1 20021226
AI US 2001-796692 A1 20010301 (9)
PRAI US 2000-223378P 20000807 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 100
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 19014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 36 USPATFULL on STN
AN 2002:337379 USPATFULL
TI Pharmaceuticals and methods for treating hypoxia and screening methods therefor
IN Kaelin, William G., JR., Boston, MA, UNITED STATES
Ivan, Mircea, Cambridge, MA, UNITED STATES
PI US 2002192737 A1 20021219
AI US 2002-101812 A1 20020319 (10)
PRAI US 2001-277425P 20010320 (60)
DT Utility
FS APPLICATION
LREP Ivor R. Elrifi, MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY and POPEO, P.C.,

One Financial Center, Boston, MA, 02111
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 3858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 18 OF 36 USPATFULL on STN
AN 2002:329447 USPATFULL
TI Methods for viral oncoapoptosis in cancer therapy
IN Blaho, John A., New York, NY, UNITED STATES
Aubert, Martine, New York, NY, UNITED STATES
PA Mount Sinai School of Medicine (U.S. corporation)
PI US 2002187126 A1 20021212
AI US 2002-118655 A1 20020408 (10)
PRAI US 2001-282214P 20010406 (60)
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 19 OF 36 USPATFULL on STN
AN 2002:310941 USPATFULL
TI Suppression of cyclin kinase 2 activity for prevention and treatment of DNA viral infections
IN Albrecht, Thomas, Galveston, TX, United States
Thompson, Aubrey E., Dickinson, TX, United States
Bresnahan, Wade, Plainsboro, NJ, United States
Meijer, Laurent, Roscoff, FRANCE
PA Board of Regents, The University of Texas, Austin, TX, United States (U.S. corporation)
PI US 6486166 B1 20021126
AI US 1999-389830 19990903 (9)
RLI Continuation of Ser. No. WO 1998-US4154, filed on 2 Mar 1998
PRAI US 1997-38126P 19970303 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Webman, Edward J.
LREP Fulbright & Jaworski
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 30 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 1990
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 20 OF 36 USPATFULL on STN
AN 2002:294709 USPATFULL
TI 47508, a novel human ***histone*** deacetylase family member and uses thereof
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002164752 A1 20021107

AI US 2001-911150 A1 20010723 (9)
PRAI US 2000-220008P 20000721 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 5104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 21 OF 36 USPATFULL on STN
AN 2002:272801 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002150922 A1 20021017
AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 22 OF 36 USPATFULL on STN
AN 2002:235495 USPATFULL
TI Novel cark protein and nucleic acid molecules and uses therefor
IN Raju, Jeyaseelan, Acton, MA, UNITED STATES
PI US 2002127684 A1 20020912
AI US 2001-947199 A1 20010905 (9)
RLI Continuation-in-part of Ser. No. US 1999-458457, filed on 10 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-291839, filed on 14 Apr 1999, PATENTED
PRAI US 1998-111938P 19981211 (60)
DT Utility
FS APPLICATION
LREP LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 35 Drawing Page(s)
LN.CNT 5319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 23 OF 36 USPATFULL on STN
AN 2002:191539 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2002102604 A1 20020801
AI US 2000-731872 A1 20001207 (9)
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., Genset Corporation, 10665 Srrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 28061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 24 OF 36 USPATFULL on STN
AN 2002:157600 USPATFULL
TI Treatment of inflammation with p20
IN Brigham, Kenneth L., Nashville, TN, UNITED STATES
Stecenko, Arlene A., Nashville, TN, UNITED STATES
Sealy, Linda, Brentwood, TN, UNITED STATES
PI US 2002082204 A1 20020627
AI US 2001-789836 A1 20010220 (9)
PRAI US 2000-183584P 20000218 (60)
DT Utility
FS APPLICATION
LREP WADDEY & PATTERSON, 414 UNION STREET, SUITE 2020, BANK OF AMERICA PLAZA, NASHVILLE, TN, 37219
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 4639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 25 OF 36 USPATFULL on STN
AN 2002:122614 USPATFULL
TI Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy
IN Hung, Mien-Chie, Houston, TX, United States
Ueno, Naoto T., Houston, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6395712 B1 20020528
WO 9735012 19970925
AI US 1997-809021 19970319 (8)
WO 1997-US3830 19970319
19970319 PCT 371 date
PRAI US 1996-13750P 19960320 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Crouch, Deborah

LREP Fulbright & Jaworski LLP
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 84 Drawing Figure(s); 45 Drawing Page(s)
LN.CNT 5197
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 26 OF 36 USPATFULL on STN
AN 2002:72987 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Jiang, Yuqiu, Kent, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Clapper, Jonathan D., Seattle, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
PI US 2002040127 A1 20020404
AI US 2001-878722 A1 20010608 (9)
PRAI US 2000-256571P 20001218 (60)
US 2000-210821P 20000609 (60)
US 2001-290240P 20010510 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8110
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 27 OF 36 USPATFULL on STN
AN 2002:66885 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
IN Trepicchio, William L., Andover, MA, UNITED STATES
Oestreicher, Judith L., Portsmouth, NH, UNITED STATES
Dorner, Andrew J., Lexington, MA, UNITED STATES
Krueger, James G., New York, NY, UNITED STATES
PI US 2002037538 A1 20020328
AI US 2001-852400 A1 20010509 (9)
PRAI US 2000-203087P 20000509 (60)
DT Utility
FS APPLICATION
LREP LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 6087
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 28 OF 36 USPATFULL on STN
AN 2002:37305 USPATFULL
TI Method of regulating transcription in a cell
IN Emerson, Beverly M., San Diego, CA, UNITED STATES
PA Salk Institute for Biological Studies (U.S. corporation)

PI US 2002022021 A1 20020221
AI US 2001-781592 A1 20010212 (9)
PRAI US 2000-181864P 20000211 (60)
DT Utility
FS APPLICATION
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. Box 2938, Minneapolis, MN, 55402
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 29 OF 36 USPATFULL on STN
AN 2001:218486 USPATFULL
TI ***ANTIMICROBIAL*** ***HISTONE*** ***H1*** COMPOSITIONS, KITS, AND METHODS OF USE THEREOF
IN CLASS, REINER J. W., DREXEL HILL, PA, United States
HAND, CHRISTOPHER M., WAYNE, PA, United States
PI US 2001046976 A1 20011129
US 6565854 B2 20030520
AI US 1999-372500 A1 19990811 (9)
PRAI US 1998-96382P 19980813 (60)
DT Utility
FS APPLICATION
LREP AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 30 OF 36 USPATFULL on STN
AN 2001:123570 USPATFULL
TI DNA fragmentation factor involved in apoptosis
IN Wang, Xiaodong, Dallas, TX, United States
Liu, Xueson, Dallas, TX, United States
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2001011078 A1 20010802
AI US 2000-748451 A1 20001222 (9)
RLI Division of Ser. No. US 1998-61702, filed on 16 Apr 1998, GRANTED, Pat. No. US 6165737
DT Utility
FS APPLICATION
LREP Gina N. Shishima, Esq., FULBRIGHT & JAWORSKI, 600 Congress Avenue, Suite 1900, Austin, TX, 78701
CLMN Number of Claims: 100
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 5190
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 31 OF 36 USPATFULL on STN
AN 2001:29329 USPATFULL

TI Recombinant expression of proteins from secretory cell lines
IN Newgard, Christopher B., Dallas, TX, United States
Halban, Philippe, Geneva, Switzerland
Normington, Karl D., Dallas, TX, United States
Clark, Samuel A., Rockwell, TX, United States
Thigpen, Anice E., Dallas, TX, United States
Quaade, Christian, Dallas, TX, United States
Kruse, Fred, Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Betagene, Inc., Dallas, TX, United States (U.S. corporation)
PI US 6194176 B1 20010227
AI US 1997-785271 19970117 (8)
RLI Continuation-in-part of Ser. No. US 1996-589028, filed on 19 Jan 1996
DT Utility
FS Granted
EXNAM Primary Examiner: Campbell, Eggerton A.
LREP Arnold, White & Durkee
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 7541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 32 OF 36 USPATFULL on STN
AN 2000:174366 USPATFULL
TI DNA fragmentation factor involved in apoptosis
IN Wang, Xiaodong, Dallas, TX, United States
Liu, Xuesong, Dallas, TX, United States
PA The University of Texas System Board of Regents, Austin, TX, United States (U.S. corporation)
PI US 6165737 20001226
AI US 1998-61702 19980416 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Moore, William W.
LREP Fulbright & Jaworski L.L.P.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 5176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 33 OF 36 USPATFULL on STN
AN 2000:113735 USPATFULL
TI Recombinant expression of proteins from secretory cell lines
IN Newgard, Christopher B., Dallas, TX, United States
Halban, Philippe, Geneva, Switzerland
Normington, Karl D., Dallas, TX, United States
Clark, Samuel A., Rockwall, TX, United States
Thigpen, Anice E., Dallas, TX, United States
Quaade, Christian, Dallas, TX, United States
Kruse, Fred, Dallas, TX, United States
McGarry, Dennis, Dallas, TX, United States

PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Betagene, Inc., Dallas, TX, United States (U.S. corporation)
PI US 6110707 20000829
AI US 1997-784582 19970117 (8)
RLI Continuation-in-part of Ser. No. US 1996-589028, filed on 19 Jan 1996
PRAI US 1996-28279P 19961011 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Campbell, Eggerton A.
LREP Arnold, White & Durkee
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 39 Drawing Figure(s); 31 Drawing Page(s)
LN.CNT 10089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 34 OF 36 USPATFULL on STN
AN 2000:87959 USPATFULL
TI Recombinant expression of proteins from secretory cell lines
IN Newgard, Christopher B., Dallas, TX, United States
Normington, Karl D., Dallas, TX, United States
Clark, Samuel A., Rockwall, TX, United States
Thigpen, Anice E., Dallas, TX, United States
Quaade, Christian, Dallas, TX, United States
Kruse, Fred, Dallas, TX, United States
PA Betagene, Inc., Dallas, TX, United States (U.S. corporation)
Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6087129 20000711
AI US 1996-589028 19960119 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Campbell, Eggerton A.
LREP Arnold, White & Durkee
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 6238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 35 OF 36 USPATFULL on STN
AN 1998:154291 USPATFULL
TI Use of ciclopirox or a pharmaceutically acceptable salt thereof for inhibiting neuronal cell damage or neuronal cell death
IN Greene, Lloyd A., Larchmont, NY, United States
Farinelli, Stephen E., New York, NY, United States
PA The Trustees of Columbia University in the City of New York, New York, NY, United States (U.S. corporation)
PI US 5846984 19981208
AI US 1996-588764 19960119 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Criares, Theodore J.
LREP White, John P.Cooper & Dunham LLP

CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 1212
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 36 OF 36 USPATFULL on STN
AN 1998:33942 USPATFULL
TI Inhibitors of cyclin dependent kinases
IN Mansuri, Muzammil M., Lexington, MA, United States
Murthi, Krishna K., Waltham, MA, United States
Pal, Kollol, Needham, MA, United States
PA Mitotix, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5733920 19980331
AI US 1995-551031 19951031 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Dahlen, Garth M.
LREP Foley, Hoag & Eliot, LLP
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1951
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l8 and (coating a medical)
L14 0 L8 AND (COATING A MEDICAL)
=> s l8 and ((coat?)(3w)(device?))
L15 1 L8 AND ((COAT?)(3W)(DEVICE?))
=> d bib

L15 ANSWER 1 OF 1 USPATFULL on STN
AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
US 2001-305484P 20010712 (60)
US 2001-265305P 20010130 (60)
US 2001-267568P 20010209 (60)
US 2001-313999P 20010820 (60)
US 2001-291631P 20010516 (60)
US 2001-287112P 20010428 (60)
US 2001-278651P 20010321 (60)
US 2001-265682P 20010131 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic

L15 ANSWER 1 OF 1 USPATFULL on STN
SUMM [2043] SEQ ID ***NO*** :2003 is ***the*** determined cDNA sequence of clone 61496359
DETD . . . chromodomain helicase DNA binding protein 1-
like (CHD1L)
441 PNCM-324 77165 Hu. accessory proteins BAP31/BAP29, 6C6-
Ag, CDM
442 PNCM-326 77167 Hu. ***eukaryotic*** translation initiation factor 2, subunit
2 (beta, 38kD) (EIF2S2)
443 PNCM-329 77169 Hu. uveal autoantigen
444 PNCM-331 77171 Hu. Prosaposin
445 PNCM-332 77172. . .
DETD . . . 4.34 0.163 0.037 8 39 Human Kreisler

maf-related leucine zipper
homolog
4393 p0151r09c08 R0584 B4 4.44 0.393 0.089 107 40
Human ***histone*** acetyltransferase
4394 p0150r16c09 R0581 G5 3.55 0.238 0.067 95 41
Human coronin, actin-binding protein 1C
4395 p0150r14c11 R0581 C6 3.99 0.096 0.024. . . 103
43 Human X-prolyl aminopeptidase-like
4397 p0150r12c23 R0580 G12 4.06 0.14 0.034 75 44
Clone RP4-758N20 on chromosome 1p31.3-32
4398 p0150r16c02 R0581 ***H1*** 3.09 0.093 0.03 98
45 KIAA1228 protein
4399 p0155r10c08 R0600 D4 3.07 0.245 0.08 121 46
cDNA DKFZp586I1419
4400 p0150r02c05 R0578 C3. . . chromosome 19, cosmid F21856
4449 p0150r09c21 R0580 A11 3.49 0.169 0.048 51 96
Human false p73 target protein gene
4450 p0150r12c02 R0580 ***H1*** 3.31 0.173 0.052 76
97 cDNA FLJ12946 fis, clone NT2RP2005254
4451 p0150r03c17 R0578 E9 4.16 0.212 0.051 20 98
cDNA DKFZp434L1715
4453. . .